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Abstract 
In vertebrate DNA, 70% of CpG dinucleotides are modified by the addition of a 
methyl group to cyclic carbon 5 of cytosine. The methylation of cytosine plays a 
fundamental role in mediating transcriptional repression. However, the presence of 
this epigenetic modification also poses a threat to genetic integrity, as 5-
methylcytosine can undergo spontançous hydrolytic deamination to form thymine. If 
the resulting T:G mismatch is replicated prior to being repaired, a C:G to T:A 
transition mutation is fixed in one of the two daughter DNA molecules. 
Methyl-CpG-binding domain protein 4 (MBD4) is a DNA glycosylase that can 
excise thymine from mismatches with guanine, and that acts preferentially on T:G 
mismatches within CpG dinucleotides in vitro. In order to test the hypothesis that 
MBD4 repairs the product of 5-methylcytosine deamination in vivo, Mbd4-deficient 
mice were crossed onto the Big Blue genetic background. This background enables 
the frequency and spectrum of in 'vivo mutations in a bacteriophage X cli transgene to 
be determined. Mbd4 mice were shown to have a significantly increased frequency 
of C:G to T:A transition mutations at CpG dinucleotides, confirming that Mbd4 
repairs the product of 5-methylcytosine deamination in vivo. Another DNA 
glycosylase, T:G mismatch-specific thymine DNA glycosylase (TDG) can also 
excise thymine from T:G mismatches within CpG dinucleotides in vitro. In an 
attempt to determine the relative contributions of MBD4 and TDG to the repair of 5-
methylcytosine deamination-induced T:G mismatches in vivo, the frequencies and 
spectra of mutations in wild type, Mbd4 knockout, Tdg knockout and Mbd4/Tdg 
double knockout cell lines were determined. 
An additional line of research focused on potential mechanisms by which the 
thymine DNA glycosylase activity of MBD4 may be regulated. MBD4 is known to 
interact with ZSWIM3, a previously uncharacterised protein, and this interaction was 
investigated by mapping the protein-protein interaction domains using the yeast two- 
hybrid assay, and by analysing the intracellular localisation of ZSWIM3 by 
immunocytochemistry. Finally, 	the 	potential 	post-translational modification of 
MBD4 by sumoylation was investigated in a series of in vitro and in vivo 
experiments. 
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Chapter 1: Introduction 
Chapter 1 
Introduction 
1.1 Chapter overview 
This chapter begins by introducing the naturally occurring modification of the DNA 
bases cytosine and adenine by methylation, and the biological functions of DNA 
methylation in prokaryotes and eukaiyotes. The deamination of C5-methylcytosine 
and the prokaryotic and eukaryotic DNA repair pathways that counteract this 
potentially mutagenic event are then discussed. Finally, the mammalian DNA repair 
glycosylases MBD4 and TDG are discussed in detail. At the end of the chapter, the 
aims of the research presented in Chapters 3 to 5 are outlined briefly. 
1.2 DNA methylation 
The DNA bases cytosine and adenine can be modified by the addition of a methyl 
group (-CH3) in cellular organisms. The methyl group is added to cyclic carbon 5 or 
exocyclic nitrogen 4 of cytosine to give C5-methylcytosine or N4-methylcytosine 
respectively, or to exocyclic nitrogen 6 of adenine to give N6-methyladenine 
(Hotchkiss, 1948; Janulaitis et al., 1983; Dunn and Smith, 1955), as shown in Figure 
1.1. 
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Figure 1.1: Naturally occurring DNA base modifications. (A) Cytosine can be methylated at 
cyclic carbon 5 or at exocyclic nitrogen 4. (B) Adenine can be methylated at excocyclic 
nitrogen 6. The N-glycosylic bond that links the adenine or cytosine base to cyclic carbon 1 
of deoxyribose is shown, and the methyl groups that can be added to cytosine or adenine 
are highlighted in bold. 
The methyl groups are added post-rcplicatively to a cytosine or adenine base within a 
specific double-stranded DNA sequence by a group of enzymes called DNA 
methyltransferases, which use S-adenosyl-L-methionine (SAM) as the methyl group 
donor. The methylation of cytosine or adenine at these positions does not change the 
base-pairing specificity with DNA or RNA. 
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1.2.1 DNA methylation in prokaryotes 
The DNA of prokaryotes can contain the naturally occurring modified DNA bases 
C5-methylcytosine, N4-methylcytosine and N6-methyladenine (Ehrlich et al., 1985). 
The genome of Escherichia co/i, the most extensively studied prokaryote, contains 
C5-methylcytosine and N6-methyladenine. The E. co/i K-12 laboratory strain has a 
single chromosomally-encoded DNA cytosine C5 methyltransferase, Dcm, which 
methylates the second cytosine base in the sequence 5'-CC(AIT)GG-3' (Marinus and 
Morris, 1973; Boyer et al., 1973). Although Dcm methylation is present in various 
enterobacteria other than E. co/i, the function of this modification is unknown 
(Palmer and Marinus, 1994). The E. coli B laboratory strain is naturally dcm, and 
bacteria that have a mutated and non-functional dcm gene are viable and lack any 
obvious phenotype (Bale et a/., 1979). However, Dcm recognition sequences are 
maintained within Dcm-encoding bacterial genomes by a specific DNA repair 
pathway as described in Section 1.4.1, therefore it is likely that Dcm-methylated 
sequences perform a useful function that has not yet been identified in the laboratory 
environment. 
E. co/i also has two chromosomally-encoded DNA adenine N6 methyltransferases, 
Dam and EcoKl (Palmer. and Marinus, 1994). Dam methylates the adenine base in 
the symmetrical sequence 5 '-GATC-3' to create a fully methylated Dam site (Geier 
and Modrich, 1979). When Dam-methylated DNA is replicated, the two daughter 
DNA molecules contain hemi-methylated Dam sites, where the methylated Dam sites 
are present in the parental DNA strand, and the unmethylated Dam sites are present 
in the nascent DNA strand. This allows the post-replicative mismatch repair (MMR) 
pathway to discriminate between the parental and the nascent DNA strands, and to 
effect the replacement of misincorporated nucleotides in the nascent DNA strand. 
Hemi-methylated Dam sites are converted to the fully methylated state by Dam 
shortly after DNA replication. Dam methylation has also been shown to regulate 
chromosomal replication and gene expression. 
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The EcoKl DNA adenine N6 methyltransferase methylates the second adenine base 
in the asymmetrical and bipartite sequence 5 '-AAC(N)6GTGC-Y. EcoKi is part of a 
type I restriction-modification (R-M) system (Wilson and Murray, 1991). R-M 
systems have two components; a DNA methyltransferase that methylates adenine or 
cytosine bases within a specific double-stranded DNA sequence, and a restriction 
endonuclease that cleaves this DNA sequence when it is unmethylated. In host 
bacteria with an R-M system, host DNA is methylated by the R-M DNA adenine or 
cytosine methyltransferase and is resistant to cleavage by the corresponding R-M 
restriction endonuclease. Non-host DNA, which has not been methylated by the R-M 
DNA methyltransferase, is cleaved by the R-M restriction endonuclease. R-M 
systems are believed to constitute an effective defence mechanism against 
bacteriophage infection (Wilson and Murray, 1991). E. co/i can also host a large 
number of episomally-encoded R-M systems such as the EcoRI type II R-M system, 
in which the EcoRI DNA adenine N6 methyltransferase methylates the second 
adenine base in the symmetrical sequence 5'-GAATTC-3' to create a fully 
methylated EcoPJ site that is resistant to cleavage by the EcoPJ restriction 
endonuclease. 
1.2.2 DNA methylation in eukaryotes 
The DNA of lower eukaryotes and plants can contain C5-methylcytosine and N6-
methyladenine, whereas the only naturally occurring modified DNA base to be 
directly identified in the DNA of higher eukaryotes is C5-methylcyto sine (C5-
methylcytosine is referred to as 5-methylcytosine or 5meC hereafter). 
In prokaryotic genomes, the majority of DNA methyltransferase recognition 
sequences are methylated, but in eukaryotic genomes the proportion of modified 
DNA methyltransferase recognition sequences,' and the location of these methylated 
sequences within the genome, varies widely. Some lower eukaryote genomes, e.g. 
those of the yeasts Saccharomyces cerevisiae and Schizosacchüromyces pombe, and 
the worm Caenorhabditis elegans, do not contain 5meC. It was previously thought 
that the genome of the fruit fly Drosophila melanogaster also lacked 5meC, but a 
4 
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low level of 5meC has recently been detected in the D. melanogaster genome 
(Gowher et al., 2000; Lyko et al., 2000). A small number of invertebrates ináluchng 
the sea squirt Ciona intestinalis have genomes with a mosaic pattern of DNA 
methylation (Tweedie et al., 1997). Approximately 50% of the C. intestinalis 
genome is methylated, and many housekeeping genes are present in the methylated 
regions of the genome (Miho Suzuki, University of Edinburgh, personal 
communication). In contrast, vertebrate genomes (including those of fish, 
amphibians, reptiles, birds and mammals) are globally methylated with the exception 
of relatively short regions of DNA called CpG islands. 
CpG islands are C and G-rich regions of DNA that have a high frequency of CpG 
dinucleotides (Antequera and Bird, 1993). CpG islands are 1kb in length and are 
present at the promoters of approximately 60% of human RNA polymerase II-
transcribed genes (Bird, 1986). Although CpG islands are generally unmethylated, 
they can become methylated, and this generally results in the transcriptional 
repression of the associated gene. CpG island methylation and transcriptional 
repression has been shown to occur in several situations e.g. X chromosome 
inactivation (Riggs and Pfeifer, 1992), the repression of the maternal or paternal 
allele of a gene by genomic imprinting (Razin and Cedar, 1994), and the repression 
of genes in transformed cell lines and tumours (Baylin et al., 2001). 
In vertebrates, DNA cytosine C5 methyltransferases (DNMTs) methylate the 
cytosine base in the symmetrical DNA sequence 5'-CG-3' (Bestor, 2000). There are 
two classes of vertebrate DNMTs; de novo DNMTs and maintenance DNMTs. The 
de novo methyltransferases DNMT3a and DNMT3b methylate the cytosine base in 
the symmetrical sequence 5'-CG-3' to create a fully methylated CpG dinucleotide. 
DNIMT3a and 3b are involved in the re-establishment of DNA methylation patterns 
in germ cells and pre-implantation embryos (Reik et al., 2001). Several potential 
mechanisms may target the de novo methyltransferases DNTM3a and DNIMT3b to 
specific CpG dinucleotides (Klosè and Bird, 2006). These include recognition of 
DNA or chromatin via a specific DNMT3 domain, recruitment by a sequence-
specific DNA-binding protein, or targeting by the RNA-mediated interference 
5 
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(RNAi) pathway. The maintenance methyltransferase DNMT1 methylates cytosine 
bases within hemi-methylated CpG dinucleotides to create a fully methylated CpG 
dmucleotide (Bestor, 1988). The DNMT 1-mediated methylatiOn of hemi-methylated 
CpG sites after DNA replication is facilitated by the interaction of DNMT1 with 
PCNA (lida et al., 2002), thereby ensuring that DNA methylation patterns are 
maintained during cell division. The importance of DNA methylation is shown by, 
the fact that Dnmtl and Dnmt3b single knockout mice die during embryogenesis (Li 
et al., 1992; Okano et al., 1999). Dnmt3a knockout mice survive to birth but are 
runted and die at around four weeks of age (Okano etal., 1999). 
The major function of DNA methylation in eukaryotes appears to be the repression 
of transcription. One way in which DNA methylation can repress transcription is by 
preventing a transcription factor from binding to a specific DNA sequence, e.g. at the 
paternal H1911gJ2 locus, the imprinting control region (ICR) is methylated, and the 
CTCF insulator protein cannot bind (Bell and Felsenfeld, 2000; Hark et al., 2000). In 
the absence Of ICR-bound CTCF, enhancers downstream of the H1 9 gene activate 
transcription of the paternal 1gJ2 gene. At the maternal H1911g12 locus, the imprinting 
control region (ICR) is unmethylated, therefore CTCF can bind and block enhancer-
mediated transcriptional activation of the maternal 1g)2 gene. DNA methylation can 
also repress transcription by enabling a methyl-CpG-binding protein to bind to a 
specific DNA sequence. Methyl-CpG-binding proteins interact with co-repressor 
proteins such as histone deacetylases and histone methyltrarisferases (Nan et al., 
1998; Ng et al., 1999; Wade et al., 1998), which modify the histories in the 
surrounding chromatin, thereby bringing about transcriptional repression. 
Five mammalian methyl-CpG-binding proteins have been characterised to date; 
MeCP2, MBD1, MBD2, MBD4 and Kaiso (Hendrich and Bird, 1998; Prokhortchouk 
et al., 2001). These proteins are shown in Figure 1.2. MeCP2, MBD1, MBD2 and 
MBD4 belong to the methyl-CpG-binding domain (MBD; Pfam accession number 
PFO 1429) family of proteins and can bind to a single symmetrically methylated CpG 
dinucleotide via the MBD. The final member of the MBD protein family, MBD3, 
contains amino acid substitutions that prevent binding to methylated DNA (Hendrich 
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and Bird, 1998; Ohki et al., 2001). The MBD is relatively highly conserved within 
MBD proteins (Figure 1.3). However, with the exception of MBD2 and MBD3, the 
MBD proteins share no sequence similarity outside the MBD. The solution structures 
of the MBDs of MBD1 and MeCP2 have been determined (Ohki et al., 1999; 
Wakefield et al., 1999); the tertiary structures of the MBD1 and MeCP2 MBDs are 
broadly similar, and consist of a non-symmetrical wedge-shaped structure that 
contains an N-terminal four-stranded 3-sheet, a carboxy-proximal cc-helix and a C-
terminal hairpin-loop. The structure of the MBD of MBD1 bound to an 
oligonucleotide containing a fully methylated CpG dinucleotide has also been 
determined (Ohki et al., 2001). The principal DNA interface of the MBD is 
composed of the inner antiparallel n-strands and an extended loop (which forms a 
hairpin-like structure upon DNA binding) that links the two strands. A small number 
of highly conserved amino acids contact the symmetrically methylated CpG 
dinucleotide exclusively via the major groove. The DNA in the MBD1 MBD-DNA 
complex is not bent, although the major groove is wIdened slightly. Kaiso, the 
remaining methyl-CpG-binding protein, binds to methylated DNA not via an MBD. 
but via three zinc fingers (Prokhortchouk et al., 2001). Kaiso requires at least two 
fully methylated CpG dinucleotides, preferably within the sequence 5'-
5meCpGp5meCpG-3', for DNA binding to occur. 
I 	II 	II 	I MeCP2 
MBDI 
 
_I!4I_I MBD2 F 
I.E1iiJI_I MBD3 
F 	II MBD4 
--- 
Kaiso - - - 
Figure 1.2: Schematic of the MBD family of proteins and Kaiso. MBD = methyl-CpG-binding 
domain (the MBD of MBD3, which cannot bind to a methylated CpG dinucleotide, is denoted 
by MBD*), TRD = transcription repression domain, C = CxxC domain, GR = GR repeat, HhH 
= helix-hairpin-helix domain, Z = zinc finger domain. 
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MeCP2 90DR pmy D T E T KLK. R -Y QJA 	134 
MBD1 	1 	 45 
MBD2 145 ESMDP_PKKEVI 	t!SK 	 189 
)IBD3 	1 MERKWE_LAPQEVPI 45 
MBD4 76 	 120 
so 	60 	 70 
MeCP2 135 	 FTVT 160 
MBD1 	46 VE!TttTG. .PACDTL' QIL 69 
MBD2 190 	 .NTVS' RTKM 213 
MBD3 	46 69 
MBD4 121 SS 	NESKE' FTVL 146 
Figure 1.3: Amino acid alignment of the MBDs of the human MBD protein family. Identical 
amino acids are shaded black, conserved amino acids are shaded dark grey, and similar 
amino acids are shaded light grey. The residues of the MBD of MBD1 that interact with the 
two methyl groups in a methylated CpG dinucleotide are indicated by asterisks below the 
alignment (Ohki et al., 2001). 
1.3 5-methylcytosine deamination 
All DNA bases with an exocyclic amino group (-NH 2) can undergo spontaneous 
hydrolytic deamination (Lindahi, 1982). Adenine can deaminate to form 
hypoxanthine, guanine can deaminate to form xanthine, cytosine can deaminate to 
form uracil and 5meC can deaminate to form thymine. However, only cytosine and 
5meC deaminate at an appreciable rate in vivo (Figure 1.4). The rates of hydrolytic 
deamination of cytosine and 5-methylcytosine in double-stranded DNA at 
temperatures ranging from 37°C to 80°C were measured using a sensitive genetic 
reversion assay (Shen et al., 1994). At 37°C, the rate of cytosine deaminatibn was 
2.6x10' 3  s' and the rate of 5meC deamination was 23-fold higher at 5.8x10 13 sW'. 
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Figure 1.4: The sponthneous hydrolytic deamination of cytosine and 5meC. (A) Cytosine can 
undergo deamination to form uracil. (B) 5meC can undergo deamination to form thymine. 
Thymine differs from uracil only by the presence of a methyl group at cyclic carbon 5. The N-
glycosylic bond that links the bases to cyclic carbon 1 of deoxyribose is shown, and the 
5meC methyl group is highlighted in bold. 
When cytosine undergoes spontaneous hydrolytic deamination to form uracil, a U:G 
mismatch is formed in DNA. Uracil base pairs with adenine, therefore if the U:G 
mismatch is not repaired prior to DNA replication, a C:G to T:A transition mutation 
is fixed in one of the two daughter DNA molecules. However, as uracil is not usually 
present in DNA, it is easily recognised and removed from U:G mismatches by 
prokaryotic and eukaryotic DNA repair pathways (Lindahi, 1993). In contrast, when 
5meC undergoes spontaneous hydrolytic deamination to form thymine, a T:G 
mismatch is formed in DNA. As thymine is one of the four bases that are usually 
present in DNA, the directional repair of 5meC-deamination induced T:G 
mismatches poses an interesting biological problem. If DNA replication occurs 
before the T:G mismatch is repaired, the C:G to T:A transition mutation becomes 
fixed in one of the two daughter DNA molecules (Figure 1.5). A C:G to T:A 
transition mutation also becomes fixed if the T:G mismatch is repaired incorrectly 
(i.e. by excision of the mismatched guanine). The T:G mismatch must therefore be 
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repaired correctly (i.e. by excision of the mismatched thymine) if the fixation of the 
C:G to T:A transition mutation is to be avoided. The prokaryotic and eukaryotic 
DNA repair pathways that can repair the product of 5meC deamination are described 
in Section 1.4. 











C:G to T:A transition mutation 
	 no mutation 
Figure 1.5: 5meC deamination can cause C:G to T:A transition mutations. 5meC can 
deaminate to form thymine and a T:G mismatch in the DNA molecule. If this mismatch is 
replicated prior to being directionally repaired, a C:G to T:A transition mutation is fixed in one 
of the two daughter DNA molecules. M = 5meC. The T in the T:G mismatch, and the C:G to 
T:A transition mutation in one of the two daughter DNA molecules are highlighted in bold. 
The mutability of 5meC is reflected by the occurrence of mutation hotspots at DNA 
cytosine C5 methyltransferase recognition sequences in prokaryotes and eukaryotes 
(Coulondre et al., 1978; Cooper and Youssoufian, 1988). The high mutation rate of 
5meC relative to cytosine is reflected by the frequency of C:G to T:A transition 
mutations at CpG sites that cause human disease and the frequency of the CpG 
dmucleotide in vertebrate genomes. Approximately one-third of germline point 
mutations that cause human genetic disorders are C:G to T:A transitions at CpG sites 
(Cooper and Youssoufian, 1988). The deamination of 5meC also contributes to the 
somatic mutation spectrum of genes encoding tumour suppressor proteins such as 
p53 and retinoblastoma (Rideout et aL, 1990). Furthermore, the CpG dinucleotide is 
present at only 20% of the predicted frequency in bulk vertebrate DNA, which is 
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methylated, but occurs at the expected frequency within CpG islands, which are 
generally unmethylated (Bird, 1980; Cooper et al., 1983). 
1.4 The repair of 5meC deamination 
1.4.1 The repair of 5meC deamination in prokäryotes 
In E. coli, Dcm methylates the second cytosine base in the sequence 5'-CC(A/T)GG-
3' (Marinus and Morris, 1973; Boyer et al., 1973), therefore the product of 5meC 
deamination is a T:G mismatch within the Dcm recognition sequence, i.e. 5'-C(T-
G)(AIT)GG-3'. This mismatch is recognised by the sequence- and mismatch-
dependent endonuclease Vsr, which initiates the very short patch (VSP) repair 
pathway (Gabbara et al., 1994). Vsr produces a single strand nick 5' to the 
mismatched thymine, then DNA polymerase I performs nick translation and DNA 
ligase completes the VSP repair pathway by re-ligation of the phosphodiester DNA 
backbone (Hennecke et al., 1991). Interestingly, the vsr gene overlaps the 3' end of 
the dcm gene by six codons, and the translation of Vsr is dependent on the translation 
of Dcm (Sohail etal., 1990; Dar and Bhagwat, 1993). The close genomic association 
of dcm and vsr highlights the importance of a 5meC deamination DNA repair 
pathway to organisms such as E. co!i that have 5meC-containing genomes. 
1.4.2 The repair of 5meC deamination in eukaryotes 
In eukaryotes, DNMTs methylate the cytosine base in the symmetrical DNA 
sequence 5'-CG-3' (Bestor, 2000), therefore the product of 5meC deamination is a 
T:G mismatch within a methylated CpG dinucleotide, i.e. TpG/5meCpG. There is not 
a eukaryotic ortholog of Vsr, therefore 5meC deamination-induced TpG/5meCpG 
mismatches in eukaryotes are not subject to VSP repair. Instead, these mismatches 
are repaired by the base excision repair (BER) pathway. This DNA repair pathway 
repairs damaged DNA bases and base damage-associated base-base mismatches 
(Lindahi, 1993; Lindahi, 2000). Damaged DNA bases and base damage-associated 
base-base mismatches can arise in DNA as the result of expOsure to endogenous or 
exogenous chemicals, e.g. cytosine and 5meC can undergo spontaneous hydrolytic 
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deamination to produce U:G and T:G mismatches respectively (as described in 
Section 1.3), reactive oxygen species produced during aerobic- metabolism can cause 
the formation of thymine glycol and 8-oxoguanine, exogenous alkylating agents can 
cause methylation at the N3 position of purines, and metabolites of the carcinogenic 
compounds vinyl chloride and ethyl carbamate can generate cyclic adducts such as 
3,N4-ethenocytosine. DNA N-glycosylases determine the specificity of the BER 
pathway for a particular damaged DNA base or base damage-associated base-base 
mismatch by the excision of a subset of damaged or mismatched bases (Table 1.1). 
Two DNA N-glycosylases,. MBD4 and TDG, can excise thymine from T:G 
mismatches in vitro, and may therefore repair 5rneC deamination-induced T:G 
mismatches in vivo. MBD4 and TDG are discussed in detail in Sections 1.5 and 1.6. 
DNA N- Major base AP lyase Prokaryotic Reference 
glycosylase excised activity ortholog 
AAG 3-methylA, No AlkA Engelward et 
ethenoA, al. (1997) 
hypoxanthine 
MBD4 T, U opposite No - Hendrich et al. 
G (1999) 
MYH A opposite 8- Weak/no MutY Slupska et al. 
oxoG (1999) 
NEIL 1/2/3 Oxidative Yes EndoIVINei Takao et al. 
pyrimidine- (2002) 
derived lesions 
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DNA N- Major base AP lyase ProkaryOtic Reference 
glycosylase excised activity ortholog 
OGG1 8 oxoG Yes Fpg/MutM Aburatani et 
opposite C - al. (1997) 
SMUG 1 U opposite G No - Nilsen et al. 
(2001) 
TDG U, ethenoC, T No Mug Neddermann 
opposite G and Jiricny 
(1993) 
UNG1I2 U opposite G No Udg Slupphaug et 
al. (1995) 
Table 1.1: Mammalian DNA N-glycosylases 
The BER pathway is initiated by a DNA N-glycosylase by cleavage of the N-
glycosylic bond between a damaged or mismatched base and the deoxyribose sugar 
to create an abasic or apurinic/apyrimidinic (AP) site within DNA. AP endonuclease 
cleaves the phosphodiester bond 5' to the AP site (Evans et al., 2000), then DNA 
polymerase P removes the 5' sugar-phosphate and inserts a single nucleotide into the 
gap (Allinson et al., 2001; Nealon et al., 1996). The XRCC1-DNA ligase 3 
heterodimer completes the BER pathway by re-ligation of the phosphodiester DNA 
backbone (Cappelli et al., 1997). A schematic of the chemical bonds that are cleaved 
during BER is shown in Figure 1.6. Mono-functional DNA glycosylases can only 
cleave the N-glycosylic bond, whereas bi-functional, DNA N-glycosylases can also 
cleave the phosphodiester bond 3' to the AP site (Scharer and Jiricny, 2001). 
13 
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0' 
HC 	 Base 
Figure 1.6: Chemical bond cleavage during BER. Mono-functional DNA N-glycosylases 
cleave the N-glycosylic bond (highlighted in red) that links the base to cyclic carbon I of 
deoxyribose. An AP endonuclease then cleaves the phosphodiester bond 5' to the excised 
base (the 5' phosphodiester bond is highlighted in blue). Bi-functional DNA N-glycosylases 
cleave the N-glycosylic bond and the phosphodiester bond 3' to the excised base (the 3' 
phosphodiester bond is highlighted in green). 
The majority of the core BER proteins have been knocked out in mice, e.g. Apex 
which encodes AP endonuclease (Xanthoudakis et al., 1996) and Polf3 which 
encodes DNA polymerase P (Gu et al., 1994), and strikingly, the absence of any of 
the core BER proteins results in embryonic lethality. In contrast, mouse knockouts of 
14 
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the DNA N-glycosylases are viable and fertile, e.g. Nth] which encodes Nthl DNA 
glycosylase (Ocampo et al., 2002), Udg which encodes uràcil DNA glycosylase 
(Nilsen et al.., 2000), and Myh which encodes A:8-oxoguánine mismatch-specific 
DNA glycosylase (Xie et al., 2004) have all been knocked out to produce viable and 
fertile mice. The apparent discrepancy between the embryonic lethality of core BER 
protein knockout mice and the relatively mild phenotypes of DNA N-glycosylase 
knockout mice occurs because the core BER pathway repairs AP sites and single 
strand breaks that are generated by spontaneous hydrolysis, in addition to repairing 
AP sites produced by DNA N- glycosylases (Lindahl, 1993). 
1.5 Methyl-CpG binding domain protein 4 
MBD4 was identified in a database search for proteins with homology to the methyl-
CpG-binding domains of the transcriptional repressors MeCP2 and MBD1 (Hendrich 
and Bird, 1998). The amino acid sequence of the MBD of MBD4 is most similar to 
that of MeCP2; however, there is no homology between MBD4 and MeCP2, or 
MBD4 and any of the other MBD proteins, outside this region. In addition to the N-
terminal MBD, MBD4 has a C-terminal region with homology to the helix-hairpin-
helix (HhH) motif of a number of BER DNA N-glycosylases, including the thymine 
glycol Endolli glycosylase of E. co/i, the U:G and T:G mismatch-specific uracil and 
thymine glycosylase Mig of Pyrobaculum aerophilum, and the photodimer-specific 
UV glycosylase of Micrococcus luteus (Figure 1.7 and Figure 1.8). On the basis of 
homology to these DNA N-glycosylases, MBD4 belongs to the EndoIII/NTH sub-
family of the HhH DNA N-glycosylase superfamily (Denver et al., 2003; Nash etal., 
1996). The FIhH motif is found in diverse DNA-binding proteins including DNA 
polymerases, DNA ligases and the Holliday junction-binding protein RuvA (Doherty 
et al., 1996; Rafferty et al., 1998). HhH DNA N-glycosylases have a conserved 
aspartate residue that is involved in the catalysis of base excision, and bi-functional 
HuH DNA N-glycosylases contain a conserved lysine residue within the HhH motif 
that is necessary to cleave the phosphodiester bond 3' to the excised base. MBD4 
contains the conserved aspartate residue that is required for glycosylic bond 
cleavage, but has a tyrosine residue in place of the lysine residue that is required for 
15 
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position of the MBD is indicated by a solid box, and the region of MBD4 that is homologous 
to BER DNA glycosylases is indicated by a dashed box. 
	
10 	. 	20 	. 	30 	. 	40 
MBD4 	455 	 499 
  
9
t A-Ggly 98 fFMRkffARR I2A VVRVYEEFLRRYKLRED 142 U/T-Ggly 38 	 82 
EndoIll 	28 VSMNKATAKLYPVANTP MLELGVG 72 
tJVgly 43 	 87 
50 	. 	60 	. 	70 	. 	80 	 90 
MBD4 	500 SLKL QWKYP IEHI 537 
A-g1y 143 ;
TY
ELIRPIBQR 	 187 
U/T-Ggly 83 	 127 
EndoIll 	73 	 IKTI 	NSKENTIKTCRILLEQHNEVPRA 	AV1 117 
UVgly 88 QVRSTFRNKSA RQ VG 	 132 
- 	100 	. 	110 	- 	120 	. 	130 
MB4 	538 	 580 
A-Ggly 188 IEACSPEPIL 'RNM ILVLGVKSAK 	228 
U/T-Ggly 128 	AAEj1 r cKPEPLIRN!jR 1IERVFGII 5 KR 168 
EndoIll 118 RK. .NV J.•.& FGPIAV'THIFRCNR•TQFAPCENVEQ 158 
tlVgly 	133 RK. 	 173 
* * 
Figure 1.8: Amino acid alignment of the HhH motif of MBD4 and other DNA N-glycosylases. 
MBD4 = human MBD4, A-Ggly. = A:G specific adenine glycosylase of Aeropyrum pernix, 
U/T-Ggly = U:G and T:G specific uracil and thymine glycosylase of Pyrobaculum aerophllum, 
Endoill = thymine glycol Endoill glycosylase of Escherichia co/i, Uvgly = photodimer-specific 
UV glycosylase of Micrococcus luteus. Identical amino acids are shaded black, conserved 
amino acids are shaded dark grey, and similar amino acids are shaded light grey. The 
position of the HhH motif is indicated by a line below the alignment, and the invariant 
aspartate residue that is involved in the catalysis of base excision is indicated by a black 
asterisk. A lysine residue within the HhH motif that is responsible for the AP lyase activity of 
bi-functional DNA N-glycosylases is indicated by a grey asterisk. 
The presence of an MBD in a protein with homology to DNA N-glycosylases 
suggested that MBD4 may excise thymine from 5meC deamination-induced 
TpG/5meCpG mismatches in vivo. In support of this hypothesis, MBD4 was shown 
to excise thymine from mismatches with guanine in vitro, and the thymine DNA 
glycosylase activity of MBD4 was shown to act preferentially on T:G mismatches in 
the context of either a methylated CpG dinucleotide (i.e. TpG!5meCpG) or an 
unmethylated CpG dinucleotide (i.e. TpG/CpG) (Hendrich et al., 1999; Petronzelli et 
al., 2000b). The hypothetical role of MBD4 as a thymine DNA glycosylase that 
initiates the repair of 5meC deamination-induced T:G mismatches in vivo is 
consistent with the observation that MBD4 orthologs are present in organisms which 
have genomes that contain 5meC, e.g. human, mouse and Xenopus laevis, but absent 
from organisms such as D. melanogaster and S. cerevisiae, which have little or no 
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cytosine methylation. An investigation of the in vivo substrate specificity of MBD4 is 
presented in Chapter 3. 
As MBD4 is likely to act as a DNA repair protein in vivo, it is possible that the 
absence of functional MBD4 may contribute to the occurrence of mutations and the 
development of cancers. MBD4 mutations have been shown to occur in human 
colorectal, endometrial and pancreatic carcinomas with microsatellite instability 
(MSI) (Riccio et al., 1999; Bader et al., 1999; Bader et al., 2000). MSI can arise due 
to the mutation of genes encoding MMR proteins or the transcriptional silencing of 
MIvIR genes by methylation of MMR gene promoter-associated CpG islands. The 
MBD4 mutations that were identified in MSI carcinomas are frameshift mutations 
within the poly(A) 6 microsatellite at codons 247-248 or, more commonly, the 
poly(A) lo microsatellite at codons 310-313 of the MBD4 locus, and result in the 
synthesis of truncated MBD4 proteins that lack the C-terminal glycosylase domain. 
The microdissection of human MSI colorectal carcinomas revealed considerable 
heterogeneity with respect to MBD4 frameshift mutations; separate sites within the 
tumours often contained different MBD4 frameshifts, while other sites contained no 
MBD4 frameshift mutations (Bader et al., 2000). This suggests that the MBD4 
frameshift mutations occur at a relatively late stage of tumour development and are 
not necessary during the early stages of tumour initiation. However, the mutation of 
MBD4 may still play an important secondary role in the pathogenesis of MSI 
tumours. I4BD4 is often bi-allelically inactivated in MSI carcinomas, either by 
mutation of both MBD4 alleles or by loss of heterozygoity (LOH) (Riccio et al., 
1999; Bader et al., 2000). The absence of MBD4 would presumably result in the 
accumulation of C:G to T:A transition mutations at methylated CpG sites in these 
tumours, and may therefore contribute to DNA instability and tumour progression. 
Inactivating MBD4 mutations have not yet been identified in microsatellite- stable 
(MSS) cancers (Riccio et al., 1999; Bader et al., 1999), although it has been reported 
that MBD4 mRNA expression is significantly reduced in hepatocellular carcinomas 
with a low level of differentiation and involvement of the portal vein (Saito et al., 
2001). The MBD4 Glu346Lys single nucleotide polymorphism (SNP) was also 
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shown to correlate with the risk of developing esophogeal squamous cell carcinoma 
(ESCC) in a Chinese population (Hao et al., 2004). Glutamate 346 is localised 
between the MBD and the glycosylase domain of MBD4 and is not highly conserved 
in MBD4 orthologs. Nonetheless it would be interesting to determine the effect that 
this polymorphism has on the activity of MBD4 in vitro. Further studies are therefore 
required to determine whether the absence or reduction of MBD4 activity can 
contribute to the development of cancers by causing an increase in mutation 
frequency. 
An additional mechanism by which the absence of MBD4 may contribute to the 
development of cancers is by a failure to initiate DNA damage-induced apoptosis. 
Mbd4 knockout mouse cells undergo reduced apoptosis when exposed to the DNA 
damaging agents N-methyl-1V 1 -nitro-N-nitrosoguanidine (MNNG), cisplatin, 
oxaliplatin, 5-fluorouracil (5-FU) and irinotecan (Cortellino et al., 2003). 
Furthermore, Mbd4 knockout mice also show a reduced ãpoptotic response to 
various DNA damaging agents including cisplatin and 5-FU in the small intestine 
(Sansom et al., 2003). This subsequently leads to increased clonogenic survival of 
intestinal crypts in vivo. MBD4 has been shown to interact with the MMR protein 
MLH1 by the yeast two-hybrid assay and by co-immunoprecipitation of the 
endogenous MBD4 and MLH1 proteins (Bellacosa et al., 1999; Millar, 2002). As 
MLH 1 can initiate a number of signalling pathways leading to cell cycle arrest and 
apoptosis, MBD4 may mediate DNA damage-induced apoptosis via its interaction 
with MLII 1. Indeed, Mbd4 and Mlhl single knockout mice and Mbd4IMlhl double 
knockout mice show a similar reduction in the apoptotic response to 5-FU and 
temozolamide in the small intestine, supporting the hypothesis that MBD4 and 
MLH1 are components of the same apoptotic signalling pathway (Sansom et al., 
2003). However, Mbd4 knockout mice show a greater reduction in the apoptotic 
response to cisplatin than Mlhl knockout mice, and Mbd4, but not Mlhl, knockout 
mice show reduced apoptosis in response to y-irradiation, suggesting that MBD4 can 
also mediate MLII 1 -independent apoptosis. Interestingly, MBD4 has also been 
shown to interact with Fas-associated death domain protein (FADD), and Mbd4 
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knockout mice show an increased apoptotic response in liver, small intestine and 
large intestine after injection with a Fas agonistic antibody (Screaton et al., 2003). 
The involvement of MBD4 in both pro- and anti-apoptotic signalling pathways is 
therefore an interesting area of research with direct relevance to the 
chemotherapeutic treatment of MBD4-deficient cancers. 
The biological role of the MBD of MBD4 is not known, although the MBD has been 
shown to bind to methylated DNA in vitro and in vivo (Hendrich and Bird, 1998). 
The glycosylase domain of MBD4 has the same substrate specificity as the full 
length protein in vitro (Hendrich et al., 1999; Petronzelli et al., 2000b), which has led 
to the suggestion that the MBD of MBD4 is dispensable for DNA repair in vivo 
(Petronzelli et al., 2000b). However, two models that describe potential roles of the 
MBD of MBD4 in DNA repair in vivo have been proposed The first model was 
proposed by Bellacosa (2001) and suggests that MBD4 is localised to highly 
methylated regions of the genome by binding of the MID to a symmetrically 
meihylated CpG dinucleotide. When 5meC within an adjacent methylated CpG 
dinucleotide deaminates, the tethered glycosylase domain of MBD4 initiates BER by 
excision of thymine from the T:G mismatch. The second model was proposed by 
Mol et al. (2002), and incorporates the preference of the MBD of MBD4 for binding 
to a T:G mismatch in the context of a methylated CpG site (Hendrich et al., 1999). 
This model proposes that the MBD and the glycosylase domain of MBD4 bind 
simultaneously to a TpG/5meCpG mismatch via the major and minor grooves 
respectively, prior to the excision of thymine by the glycosylase domain. However, 
the MBD of MBD4 is unlikely to bend the DNA helix upon binding (Ohki et al., 
2001), whereas the glycosylase domain is predicted to induce a bend of 
approximately 70 degrees within DNA (Wu et al., 2003), therefore the second model 
could perhaps be refined to include only transient binding of the TpG/5meCpG 
mismatch by the MBD and the glycosylase domain of M804. In this modified 
model, the MBD of MBD4 binds to a TpG/5meCpG mismatch, and the glycosylase 
domain then binds to the MBD-bound mismatch resulting in DNA helix bending and 
MBD dissociation from the mismatch. Finally, the glycosylase domain excises 
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thymine from the T:G mismatch. It is interesting to note that HhH DNA N-
glycosylases usually contain four cysteine residues that chelate an Fe 4S4 cluster, 
which is believed to facilitate the localisation of damaged DNA (Lukianova and 
David, 2005). MBD4 does not contain the group of cysteine residues necessary to 
chelate an Fe4S4 cluster, therefore it is possible that the MBD of MBD4 provides an 
additional specificity determinant that is required to localise damaged DNA bases in 
vivo. 
1.6 Thymine DNA glycosylase 
An additional DNA N-glycosylase that can excise thymme from T:G mismatches 
was purified from Hela cells and was named T:G mismatch-specific thymine DNA 
glycosylase (TDG) (Wiebauer and Jiricny, 1990; Neddermann and Jiricny, 1993). 
Like MBD4, the thymine DNA glycosylase activity of TDG acts preferentially on 
T:G mismatches in the context of a CpG dinucleotide (Waters and Swann, 1998), 
suggesting that TDG may also excise thy-mine from Smec deamination-induced 
TpGI5meCpG mismatches. However, MBD4 and TDG do not share any sequence or 
structural homology. Instead, TDG is related to the U:G mismatch-specific uracil 
DNA glycosylase Mug of E. coli (Figure 1.9), which only has very limited thymine 
DNA glycosylase activity (Gallinari and Jiricny, 1996; Lutsenko and Bhagwat, 
1999). Although Mug was initially characterised as a U:G mismatch-specific uracil 
DNA glycosylase, Mug also has limited uracil DNA glycosylase activity (Lutsenko 
and Bhagwat, 1999). Mug and TDG can excise the modified base 3N, 4ethenocytosine 
(which can be generated by metabolites of the carcinogenic compounds vinyl 
chloride and ethyl carbamate, and by endogenous products of lipid peroxidation) 
from 3N,4ethenocytosine:guanine base pairs with high efficiency, and it has been 
proposed that the primary role of both Mug and TDG is to excise 3N, 4ethenocyto sine 
from DNA in vivo (Saparbaev and Lava!, 1998). 
MBD4 and TDG are the only known DNA N-glycosylases that can excise thymine 
from T:G mismatches in vitro, and that may therefore repair 5meC deamination- 
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induced T:G mismatches in vivo. An investigation of the in vivo substrate 
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1.7 Research aims 
The ultimate aim of the research presented in this thesis was to characterise the 
activity of the thymine DNA glycosylase MBD4 within the cellular environment. 
Three principal areas of research were investigated: 
The in vivo substrate specificities of MBD4 and TOG (Chapter 3). The in 
vivo Big Bliie cli mutation assay was used to determine the frequency and 
spectra of mutations in wild type and Mbd4 knockout mice. The Big Blue 
assay was also used to determine the frequency and spectra of mutations 
in wild type, Mbd4 knockout, Tdg knockout and Mbd4/Tdg double 
knockout cell lines 
The interaction between MBD4 and the uncharácterised protein ZSWIM3 
(Chapter 4). The yeast two-hybrid assay was used to map the interaction 
domains of MBD4 and ZSWIM3. Additionally, immunocytochemistry 
was used to analyse the intracellular localisation of ZSWIM3, and the 
dependence of ZSWIM3 localisation on both MBD4 and DNA 
methylation. 
ill) 	The potential post-translational modification of MBD4 by sumoylation 
(Chapter 5). The potential sumoylation Of MBD4 was investigated by the 
reconstitution of SUMO conjugation pathways in bacteria, and by the 
over-expression of E3 SUMO ligases in mammalian cells. The existence• 
of endogenous sumoylated MBD4 in mammalian cells was also 
investigated. 
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Chapter 2 
Materials and methods 
2.1 Materials 
2.1.1 DNA manipulation reagents 
Bisuiphite modification solution: 3.8g sodium hydrogensuiphite (a mixture of 
sodium bisulphite, NaHS0 3 , and sodium metabisuiphite, Na2S 205) was dissolved in 
5m1 dH20 and 1. 5ml  2M NaOH while protected from light. 0.11 g hydroquinone was 
dissolved in imi dH20 at 50°C. The sodium bisulphite and the hydroquinone 
solutions were then mixed to give a solution with a final pH of 5.0. Bisuiphite 
modification solution was prepared immediately prior to use. 
Digestion solution: 20il RNace-It ribonuclease cocktail/ml Digestion buffer (both 
Stratagene). Prepared immediately prior to use. 
DNA isolation buffer: 10mM Tris HC1 pH8.0, 400mM NaC1, 3mM EDTA, 1% 
(wlv) SDS. Stored at 4°C. 
Lysis buffer: lOniM Tris HC1 pH8.3, 140mM NaCl, 3mM KC1, 12% (w/v) sucrose, 
1 m EDTA, 1% (v/v) Triton X-100. 
Orange G loading buffer (6x): 0.198% (w/v) Orange G, 12% (w/v) Ficoll, 120mM 
EDTA p118.0, 4.2% (wlv) SDS. Stored at —20°C (long-term) or nt (short-term). 
Proteinase K stock solution: 2mg/mi proteinase K, 100mM EDTA pH7.5, 2% (w/v) 
SDS. Stored at —20°C. 
TAE electrophoresis buffer: 40mM Tris base, 20mM glacial acetic acid, 1mM 
EDTA p118.0. 
TE pH7.4 or 7.5: 10mM Tris HCl p117.4 or 7.5, 1 m EDTA. 
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2.1.2 RNA manipulation reagents 	 fl 
5x MOPS buffer: 200mM MOPS, 50mM NaOAc, 5mM EDTA. pH adjusted to 7.0 
with NaOH. 
RNA loading buffer: 50% (vlv) glycerol, 1mM EDTA pH8.0, 0.4% (w/v) 
bromophenol blue, lmg/ml ethidium bromide. Stored at —20°C. 
RNA sample buffer: lOml deionised formamamide, 3.5m1 37 6/o formaldehyde, 2ml 
5x MOPS buffer. Stored at —20°C. 
2.1.3 Protein manipulation reagents 
Bacterial lysis buffer: 50mM sodium phosphate buffer pH8.0, 300mM NaCl, 10% 
(v/v) glycerol, 15mM 3-mercaptoethanol, 0.5mM PMSF, complete protease 
inhibitors. -mercaptoethanol, PMSF and complete protease inhibitors were added 
immediately prior to use. Stored at 4°C. 
Complete cracking buffer: 8M urea, 5% (w/v) SDS, 40mM Tris HCl p116.8, 
0.1mM EDTA, 0.4mg/mi bromophenol blue, 143m1V1 13-mercaptoethanol, 5mM 
PMSF, complete protease inhibitors. j3-mercaptoethanol, PMSF and complete 
protease inhibitors were added immediately prior to use. 
Complete protease inhibitors: A cocktail of several serine and cysteine protease 
inhibitors in tablet form (does not contain metalloproteases; Roche). Stored at 4°C. 
Coomassie Brilliant Blue R-250 staining solution: 50% (v/v) methanol, 10% (v/v) 
glacial acetic acid, 0.1% (w/v) Coomassie Brilliant Blue R-250. Filtered through a 
Whatman number 1 filter. 
ECL solution 1: 100mM Tris HCl p118.5, 0.396mM p-coumaric acid, 2.5mM 
luminol. Stored at 4°C protected from light. 
ECL solution 2: 100mM Tris HC1 pH8.5, 5.632mM H202 . Stored at 4°C. 
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NE!: 20mM Hepes pH7.0, 10mM KC1, 1mM M902, 0.1% (v/v) Triton X-100, 20% 
(v/v) glycerol, 0.5mM DTT, 2mM PMSF, complete protease inhibitors. 10mM N-
ethylmaleimide (NEM; a SUMO protease inhibitor) was also included when 
required. DTT, PMSF, complete protease inhibitors and NEM were added 
immediately prior to use. Stored at 4°C. 
NE2: 20mM Hepes p117.0, 420mM NaCl, 10mM KC1, 1mM M902, 0.1% (v/v) 
Triton X-100, 20% (v/v) glycerol, 0.5mM DTT, 2mM PMSF, complete protease 
inhibitors. 10mM NEM was also included when required. DTT, PMSF, complete 
protease inhibitors and NEM were added immediately prior to use. Stored at 4°C. 
Nicking buffer (lOx): 500mM Tris HC1 p118.0, 10mM DTT, 10mM EDTA, 1mg/mi 
BSA. Stored at -20°C. 
PBS: 140mM NaC1, 3mM KC1, 2mM KH 2PO4, 10mM Na2HPO4 . 
Ponceau S staining solution: 1% (v/v) glacial acetic acid, 0.5% (w/v) Ponceau S. 
SDS PAGE loading buffer (2x): 100mM Tris HC1 pH6.8, 4% (w/v) SDS, 20% 
(v/v) glycerol, 200mM DTT, 0.2% (w/v) bromophenol blue. Stored at —20°C. 
SDS PAGE separating gel: 8-15% (w/v) 29:1 acrylamide:bis-acrylamide, 0.1% 
(w/v) SDS, 390mM Tris HC1 pH8.8, 0.08% (v/v) TEMP-D, 0.1% (w/v) APS. 
Prepared immediately prior to use. 
SDS PAGE stacking gel: 5% (w/v) 29;1 acrylamide:bis-acrylamide, 0.1% (w/v) 
SDS, 129mM Tris HC1 pH6.8, 0.1% (v/v) TEMED, 0.1% (w/v) APS. Prepared 
immediately prior to use. 
Semi-dry transfer buffer: 48mM Tris, 39mM glycine, 0.037% (w/v) SDS, 20% 
(v/v) methanol. The final pH should be 9.0-9.4. 
TBST: 20mM Tris pH8.0, 100mM NaCl, 0.05% (v/v) Tween 20. 
Tris-glycine electrophoresis buffer: 25mM Tris, 250m1V1 glycine, 0.1% (w/v) SDS. 
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2.1.4 Bacterial strains 
D115a: supE44 AlacU169 (80 1acZAM15) hsdR17 recAl endAl gyrA96 thi-1 
re/Al. Invitrogen. 
ER2566: F XjhuA2 [ion] ompT/acZ::T7 genel gal su/A1 1 A(mcrC-mrr)111::IS1O 
R(mcr-73:.miniTnlO--Te?)2 R(zgb-210::TnlO )(Te?) endAl [dcm]. New England 
BioLabs. 
G1250: A(mcrA)183 A(mcrCB-hsdSMR-mrr)173 endAl supE44 supF thi-1 gyrA96 
re/Al lac hflB29(linked to TnlO) hflA::Tn5 T-res. Stratagene. 
TOP10F': F' {/aclq TnlO (TetR)} mcrA A(mrr-hsdRMS-mcrBC) 801acZAM1 5 
AiacX74 recAl araD 139 A(ara-/eu)7697 gaIIJ gaIK rpsL endAl nupG. Invitrogen. 
XL1-Blue: recAl endAl gyrA96 thi-1 hsdR17 supE44 re/Al lac [F' proAB 
lacPZAM15 TnlO (Tet1)]. Stratagene. 
With the exception of E. coli strain G1250, all bacterial strains were grown on/in LB 
medium at 37°C. G1250 was grown on/in TB1 medium at 30°C. 
2.1.5 Bacterial cell culture media and related reagents 
Ampicillin stock solution: 50mg/mi ampicillin in dH20. 0.2tm filter sterilised and 
stored at —20°C. Added to LB medium to 100tg/m1. 
Blue/white selection LB agar plates: 40tl 100mM IPTG and 40tl 40mg/mi X-gal 
was spread over LB agar plates containing the appropriate antibiotic(s). The plates 
were dried at nt before being used the same day. 
Choramphenicol stock solution: 34mg/mi chloramphenicol in 96% (v/v) ethanol. 
Stored at —20°C protected from light. Added to LB medium to 34tg/ml. 
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Competent cell buffer A: 100mM RbC1, 50mM MnC12, 30mM KOAc, 10mM 
CaC12, 15% (vlv) glycerol. The pH was adjusted to 5.8. 0.2.tm filter sterilised and 
stored at 4°C. 
Competent cell buffer B: 10mM MOPS, 10mM RbC1, 75m  CaCl2, 15% (v/v) 
glycerol. The pH was adjusted to 6.8. 0.2tm filter sterilised and stored at 4°C. 
IPTG stock solution: 1M IPTG in dH20. 0.2im filter sterilised and stored at —20°C. 
Kanamycin stock solution: 10mg/mi kanamycin in dH20. 0.2tm filter sterilised 
and stored at —20°C. Added to LB medium to 40tg/ml. 
LB medium: lOg/l Bacto tryptone (Difco), 5g/1 Bacto yeast extract (Difco), 10g/l 
NaCl. The pH was adjusted to 7.0 with NaOH. 20g/l Bacto agar (Difco) was added if 
making LB agar, then the medium was autoclaved. LB agar plates (20m1 volumé) 
were stored inverted at 4°C and LB broth was stored at nt. 
Miniprep solution 1: 25mM Tris HC1 pH8.0, 10mM EDTA, 50mM glucose. Stored 
at 4°C. 
Miniprep solution 2: 200mlVI NaOH, 1% (w/v) SDS. Prepared immediately prior to 
use. 
SM buffer: 50mM Tris HC1 pH7.5, 0.01% (w/v) gelatin, 2g/l MgSO 4.7H20, 5.8g/l 
NaCl. Autoclaved. 
TB! medium: lOg/i casein peptone, 5g/l NaCl, 0.0001% (w/v) thiamine 
hydrochloride. pH adjusted to 7.0 with NaOH. 12g/l Bacto agar was added if making 
TB 1 agar, 7g/l Bacto agar was added if making TB 1 top agar, then the medium was 
autoclaved. TB 1 agar plates (40m1 volume) were stored inverted at 4°C, and TB 1 top 
agar and TB 1 broth was stored at nt. 
X-gal stock solution: 40mg/ml X-gal (Melford Laboratories Ltd) in 
dimethylformamide (DMF). Stored at —20°C protected from light. 
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2.1.6 Yeast strains 
PJ69-4a: MATa tip]-901 leu2-3,112 ura3-52 his3-200 gal4A ga180A LYS2::GALJ-
HIS3 GAL2-ADE2 met2:. GAL 7-lacZ (James et al., 1996). Clontech. 
2.1.7 YeastceIl culture media and related reagents 
Dropout supplements (lOx): Dropout supplements are components of minimal 
yeast media, and contain a specific mixture of amino acids and nucleosides (one or 
more constituents may be missing from a particular dropout supplement, thereby 
enabling selection Of yeasts with a particular phenotype). Dropout supplements 
(Bio 101) were dissolved in dH 20 to 1 Ox concentration, then 0.2im filter sterilised 
and stored at 4°C. 
Minimal SD base: Minimal SD base is a component of minimal yeast media, and 
contains a nitrogen base, a carbon source, and ammonium sulphate. Minimal SD base 
(containing glucose) was purchased from BD Biosciences. 
PEG/LiAc: 40% (wlv) PEG 3,350, 100mM LiOAc, 10mM Tris HC1 p117.5, 1mM 
EDTA.. 0.2im filter. sterilised. 
SD medium: A minimal yeast medium used to select for specific phenotypes. SD 
medium is prepared by combining a minimal SD base with a specific dropout 
supplement. 27g11 minimal SD base (BD Biosciences) was dissolved and made up to 
900m1 with dH20. 20g/i BactoAgar was added if making SD agar, then the medium 
was autoclaved and cooled to 55°C. lOx dropout supplement (warmed to 55°C) was 
added to lx and 1M 3-AT was added to 2.5mM as required. SD agar plates were 
stored inverted at 4°C and SD broth was stored at nt. 
TE p117.5: 1.0mM Tris HC1 p117.5, 1mM EDTA. 
TE/LiAc: 100mM LiOAc, 10mM Tris HCI p117.5, 1mM EDTA. 0.2tm filter 
sterilised. 
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YPDA medium: A complete yeast medium. lOg/i yeast extract, 20g/l peptone, 
0.003% (w/v) adenine hemisuiphate made up to 900m1 with dH20. 20g/l BactoAgar 
added if making YPDA agar, then the medium was autoclaved and cooled to 55°C. 
20% (w/v) glucose (warmed to 55°C) added to 2%. YPDA agar plates were stored 
inverted at 4°C and YPDA broth was stored at nt. 
2.1.8 Mammalian cell lines 
Dnmt1' 4  p53: Mouse embryonic fibroblast (MEF) cell lines derived from E9.5 
embryos (derived by Ittai Ben-Porath, Cedar laboratory, Hebrew University of 
Jerusalem). Grown in DMEM cell culture medium containing 15% (v/v) foetal 
bovine serum (FBS), 1mM sodium pyruvate (Invitrogen), 0.1mM non-essential 
amino acids (Invitrogen), 0.5mM -mercaptoethanol. 
Dnmtf" p53: DNA methylation-deficient mouse embryonic fibroblast cell lines 
derived from E9.5 embryos (derived by Ittai Ben-Porath). Grown in DMEM medium 
containing 15% (v/v) FBS, 1mM sodium pyruvate, 0.1mM non-essential amino 
acids, 14.3niM 3-mercaptoethanol. 
Hela: Human epithelial carcinoma cell line. Grown in DMEM medium containing 
10% (v/v) FBS. 
Mouse embryonic fibroblasts: MEF cell lines of different genotypes derived from 
ElO.5 embryos (derivation described in Chapter 3). Primary MEFs were grown in 
Amniomax medium. SV40-transformed MEFs were grown in GMEM medium with 
10 or 20% (vlv) FBS. 
NIH3T3: Mouse embryonic fibroblast cell line. Grown in DMEM medium 
containing 10% (vlv) FBS. 
-2/SV40: SV40 retrovirus-producing cell line (Jat et al., 1986). Grown in Alpha 
MEM medium containing 10% (v/v) FBS. 
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2.1.9 Mammalian cell culture media and related reagents 
Alpha MIIM medium: 500m1 Alpha MEM (Cambrex), 10% (vlv) FBS (Perbio), 
50U/ml penicillin, 50ig/ml streptomycin (penicillin-streptomycin solution; 
Cambrex), 2mM L-glutamine (Cambrex). Stored at 4°C. 
Amniomax medium: 450m1 Amniomax C-100 basal media, 75m1 Amniomax C-100 
supplement (both Invitrogen). Stored at 4°C. 
DMEM medium: 500m1 DMEM (Cambrex), 10 or 15% (vlv) FBS, 50U/ml 
penicillin, 50tg/m1 streptomycin, 4mM L-glutamine. Stored at 4°C. 
GMEM medium: 500m1 GMEM (Gibco), 10 or 20% (vlv) FBS, 50U/ml penicillin, 
50tg/ml streptomycin, 1mM sodium pyruvate, 0.1mM non-essential amino acids. 
Stored at 4°C. 
Opti-MEM medium: Opti-MEM I Reduced Serum medium (Invitrogen). Stored at 
4°C. 
4% (w/v) paraformaldehyde in PBS: 4g paraformaldehyde in lOOm! PBS. The 
mixture was heated to 60°C, then 5M NaOH was added dropwise until all of the 
paraformaldehyde dissolved. The pH was adjusted to 7.4 with HC1, and the solution 
was 0.2tm filter sterilised and stored at —20°C. 
PBS: 140mM NaCl, 3mM KC1, 2mM K112PO4, 10mM Na2HPO4 . 
Trypsin-EDTA: lOx trypsin-EDTA (Cambrex) diluted in PBS to 0.25% (w/v) 
trypsin, imIvI EDTA. Stored at —20'
. 
 C. 
2.1.10 Mouse strains 
Big Blue transgenic mice: Maintained as Big Blue' homozygotes on a C57BL16 
genetic background (Kohler et al., 1991). Big Blue transgenic mice were purchased 
from Taconic Laboratories. 
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Mbd4-deficient mice: Maintained as Mbde homozygotes on a mixed C57BL/6, 
129/01a genetic background (Millar et al., 2002). 
Tdg-deficient mice: Maintained as Tdg' heterozygotes on a mixed C57BL16, 
129/01a genetic background. Tdg-deficient mice were generated by a collaboration 




Custom oligonucleotides for PCR or DNA sequencing were purchased from Sigma-
Genosys. An oligonucleotide stock solution was prepared by the resuspension of 
lyophilised oligonucleotides in dH20 to 1 OOpmol4tl. This stock solution was diluted 
in d1420 to give a 25pmol/tl PCR primer solution or a 1pmol/tl DNA sequencing 
primer solution. Resuspended oligonucleotides were stored at —20°C. 
Table 2.1: PCR primers used in this thesis 
Name Reference Sequence (5'-3') Description 
BigBlueF X-select cli GTATTACCGCCATGC Forward primer fdr PCR 
handbook ATACTAG of lad 
(Stratagene, 
1998) 
BigBlueR X-select cli CCGTAATCATGGTCA Reverse primer for PCR 
handbook TAGCTGT of lad 
cliF X-select cli CCACACCTATGGTGT Forward primer for PCR 
handbook ATG and DNA sequencing of 
cli 
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Name Reference Sequence (5'-3') Description 
dIR X-select cli CCTCTGCCGAAGTTG Reverse primer for PCR 
handbook AGTAT and DNA sequencing of 
cli 
M4JF Jacky Guy AAGGTGGCACCTAGA Fohvard primer for PCR 
(Bird GCTGTCG of the Mbd4 wild type 
laboratory) allele 
M4JR Jacky Guy GGATATTCGGTGCTG Reverse primer for PCR 
TCGCTCG of the Mbd4 wild type 
and knockout alleles 
mTdgEx5 Primo Schär CGGATTCACCAAcAT Forward primer for PCR 
GGTGG of the Tdg wild type and 
knockout alleles 
mTdgEx6L Primo Schär GTTTCTGCACCAGGA Reverseprimer for PCR 
TGCG of the Tdg wild type allele 
NeoF Jacky Guy GTCATCTCACCTTGC Forward primer for PCR 
TCCTGCC of the Mbd4 knockout 
allele 
NeoR Jacky Guy GAAGGCGATAGAAG Reverse primer for PCR 
GCGATGCG of the Tdg knockout allele 
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Real-time PCR primers 
Table 2.2: Real-time PCR primers used in this thesis 
Name Reference Sequence (5'-3') Description 
mm-Gapdh- Skirmantas TACCCCCAATGTGTC Forward primer for real- 
F 1 Kriaucionas CGTCG time PCR of mouse 
(Bird Gapdh 
laboratory) 
mm-Gapdh- Skirmantas CCTGCTTCACCACCT Reverse primer for real- 
RI Kriaucionas TCTTG time PCR of mouse 
- Gapdh 
hs-GAPDH- This thesis CAGCAAGAGCACAA Forward primer for real- 
Fl GAGGAAG time PCR of human 
GAPDH 
hs-GAPDH- This thesis GTCTACATGGCAACT Reverse primer for real- 
RI GTGAGGAG time PCR of human 
GAPDH 
mm-Mbd4- This thesis GCAGAACCTCAAGAC Forward primer for real- 
Fl ACGAAG time PCR of mouse Mbd4 
mm-Mbd4- This thesis AATAGCAAGCAAGCC Reverse primer for real- 
RI GAGTTAG time PCR of mouse Mbd4 
hs-MBD4- This thesis CCGAAGATCGTAGAG Forward primer for real- 
F3 ACCAAGAG time PCR of human 
MBD4 
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Name Reference Sequence (5'-3') Description 
hs-MBD4- This thesis TCTGCTCAGTTTGGT Reverse primer for real- 
R3 GCTACTG time PCR of human 
MBD4 
mm-Tdg-F3 This thesis CTGTGAACAATGAGG Forward primer for real- 
GAAGCAG time PCR of mouse Tdg 
mm-Tdg-R3 This thesis CACAACCTGACCCAG Reverse primer for real- 
ACAGAAG time PCR of mouse Tdg 
hs-TDG-F1 This thesis AAGCTGAACTTCTGA Forward primer for real- 
CCAAGAC time PCR of human TDG 
hs-TDG-RI This thesis AGGGTAATGATGCCC Reverse primer for real- 
TTTG time PCR of human TDG 
mm- This thesis TTCTCCTGTGAACTG Forward primer for real- 
Zswim3-F2 CTGTGG time PCR of mouse 
Zswim3 
mm- This thesis TGTTCCCGAAAGAGG Reverse primer for real- 
Zswim3-R2 CTTG time PCR of mouse 
Zswim3 
hs- This thesis AGCAGTAAGATGACC Forward primer for real- 
ZSWIM3-F1 GACCTG time PCR of human 
ZSWIM3 
hs- This thesis ACTCGACTTTCTCGTT Reverse primer for real- 
ZSWIM3- CCTTG time PCR of human 
RI ZSWIM3 
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Oligonucleotides used as glycosylase assay substrates 
Custom oligonucleotides for use as glycosylase assay substrates in the in vitro DNA 
glycosylase assay were purchased from Sigma-Genosys. An bligonucleotide stock 
solution was prepared by the resuspension of' lyophilised oligonucleotides in TE 
pH7.4 to lOOpmol4tl. This stock solution was diluted in TE p117.4 to give a 
1 Opmol4tl working solution. Resuspended oligonucleotides were stored at —20°C, 
and were protected from light when a flourescein tag was present. 
Table 2.3: Oligonucleotides used as glycosylase assay substrates inthis thesis. M = 5meC, 
U = uracil, F = fluorescein. The position of the potential base-base mismatch is highlighted in 
bold. 
Name Reference Sequence (5'-3') 
ZZTop-C Hendrichet al. TAGACATTGCCCTCGAGGTACCATGG 
(1999) ATCCGATGTCGACCTCAAACCTAGAC 
GAATTCCG 
ZZTop-M Hendrich et al. TAGACATTGCCCTCGAGGTACCATGG 
(1999) ATCCGATGTMGACCTCAAACCTAGAC 
GAATTCCG 
ZZBottom-C Hendrich et al. FCGGAATTCGTCTAGGTTTGAGGTCGA 
(1999) CATCGGATCCATGGTACCTCGAGGGC 
AATGTCTA 
ZZBottom-T Hendrich et al. FCGGAATTCGTCTAGGTTTGAGGTTGA 
(1999) CATCGGATCCATGGTACCTCGAGGGC 
AATGTCTA 
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2.1.12 Plasmids 
Table 2.4: Plasmids used in thisthesis 
Name Reference or source Description 
pACT2 Clontech Yeast expression vector that 
encodes the GAL4 AD 
pBADE 12 Mencia and de Lorenzo Prokaryotic expression vector 
(2004) that encodes human HIS- 
AOS1, human UBA2 and 
mouse Ubc9 
pET6H hMBD4 Millar (2002) ProkaryOtic expression vector 
that encodes human HIS- 
MBD4 
pET6H mMbd4 Millar (2002) Prokaryotic expression vector 
that encodes mouse HIS- 
Mbd4 
pGBT9 Clontech Yeast expression vector that 
encodes the GAL4 DBD 
pGBT9 MBD4 Millar (2002) and this thesis Yeast expression vector that 
encodes 
pRSF Duet-1 HIS- Matthew Lyst, Stancheva Prokaryotic expression vector 
SUMO-1 laboratory, University of that encodes human HIS- 
Edinburgh SUMO- 1 
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Name Reference or source Description 
pRSF Duet-1 HIS- Matthew Lyst Prokaryotic expression vector 
SUMO-2 that encodes human HIS- 
SUMO-2 
2.1.13 Antibodies 
Table 2.5: Primary antibodies used in this thesis 
Name Source and Raised Type Western blotting (WB) 
catalogue against and/or 
number immunocytochemistry 
(IC) dilution 
Anti- Stratagene, Peptide Mouse 1:1,000 WB, 1:1,000 IC 
FLAG 200472 corresponding monoclonal 
M2 to the FLAG (IgGi) 
epitope tag 
Anti- Santa Cruz Full-length Mouse 1:200 WB 
GFP Biotechnology, Aequorea monoclonal 
(B-2) sc-9996 victoria GFP (IgG2a) 
HRP 
Anti- Santa Cruz Peptide Rabbit 11,000 WB, 1:200 IC 
HA (Y- BiotechnOlogy, corresponding polyclonal 
11) sc-805 to the HA antibody 
epitope tag 
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Name Source and Raised Type Western blotting (WB) 
catalogue against and/or 
number immunocytochemistry 
(IC) dilution 
Anti- Santa Cruz Peptide Rabbit 1:200 WB 
HIS (G- Biotechnology, corresponding polyclonal 
18) sc-804 to the poly-His antibody 
epitope tag 
Anti- Sigma, M9817 Peptide Rabbit 1: 9 000 WB 
MBD4 corresponding polyclonal 
M9817 toaa54l-554 antibody 
mouse Mbd4 
Anti- Steven Frisch Full-length Rabbit 1 : 1,000 WB 
MBD4 (West Virginia human MBD4 polyclonal 
417-3 University) antiserum 
Anti- Santa Cruz Full-length Mouse 1:1,000 WB 
PCNA Biotechnology, human PCNA monoclonal 
(PC1O) sc-56 (IgG2a) 
Anti- Santa Cruz Peptide from Goat 1 1,000 WB 
PIAS 1 Biotechnology, human PIAS 1 polyclonal 
(C-20) sc-8 152 antibody 
Anti- Abcam, Full-length Rabbit I 2,000 WB 
SUMO- abi 1672 human polyclonal 
1 SUMO-1 antibody 
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Name Source and Raised Type Western blotting (WB) 
catalogue against and/or 
number immunocytochemistry 
(IC) dilution 
Anti- Primo Schär Full-length Rabbit 1:10,000 WB 
Tdg mouse Tdg polyclonal 
L58 antiserum 
Table 2.6: Secondary antibodies used in this thesis 
Name Source and catalogue Western blotting (WB) 
number or immunocytochemistry 
(IC) dilution 
Anti-goat IgG HRP Sigma, A 9452 1:5,000 WB 
Anti-mouse IgG HRP GE Healthcare, NA 931 1:2,000 WB 
Anti-rabbit IgG HRP GE Healthcare, NA 934 1:10,000 WB 
Anti-mouse IgG Alexa Molecular Probes 	. 1: 1,000 IC 
594 (Invitrogen), Al 1005 
Anti-rabbit IgG Alexá 488 Molecular Probes 1:1,000 IC 
(Invitrogen), A 11008 
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2.2 Methods 
2.2.1 DNA manipulation 
Genomic DNA isolation 
Approximately 2x10 6 mammalian cells or 1cm mouse tail tip was incubated in 750.il 
DNA isolation buffer with 400ig/ml proteinase K at 55°C overnight (o/n). Cellular 
proteins were separated from DNA by the addition of an equal volume of 
phenol:chloroform (1:1), followed by vigorous mixing for 15s and centrifugation at 
14,000rpm for 10mm. The DNA-containing upper aqueous phase was transferred to 
a new tube, and the DNA was precipitated by the addition of an equal volume of 
isopropanol followed by centrifugation at 14,000rpm for 5mm. The DNA pellet was 
washed with 70% (v/v) ethanol, air-dried for 10-15mm, then resuspended in 150ii 
dH20. Genomic DNA prepared according to this protocol was stored at —20°C, and 
1 tl was used as a DNA template for PCR genotyping. - 
High molecular weight genomic DNA was isolated from mammalian cells and 
tissues using the RecoverEase DNA Isolation kit (Stratagene) according to the 
manufacturer's instructions. In brief, approximately 8.8x10 6 frozen cells were 
resuspended in 5m1 ice cold Lysis buffer, or 40mg frozen spleen was homogenised in 
5ml ice cold Lysis buffer using a Wheaton dotince tissue grinder with a loose-fitting 
pestle. Cell nuclei were then released using a Wheaton dounce tissue grinder with a 
tight-fitting pestle, and the sample was filtered through a strainer with a mesh size of 
100im. An additional 3m1 ice cold Lysis buffer was added, and the nuclei were 
pelleted at 1,100g for 12min at 4 °C. 70il Digestion solution (which contains a 
cocktail of RNases) was added to the pelleted nuclei, and the nuclei were transferred 
to a 50°C water bath. 70ti pre-warmed 2mg/mi proteinase K was added and the 
sample was gently mixed and then incubated at 50°C fOr 45mm (mixing was 
repeated every 10-15mm). The viscous sample was transferred using a wide bore 
pipette tip to a dialysis cup floating on 11 TE pH7.5, and was dialysed for 48h at nt 
with gentle stirring. The dialysis buffer was replaced after 24h to maximise the purity 
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of the recovered DNA. Finally, the viscous high molecular weight genomic DNA 
was transferred using a wide bore pipette tip to a microcentrifuge tube, and was 
stored at 4°C. High molecular weight genomic DNA prepared according to this 
protocol was used in the in vivo Big Blue cII.mutation assay. 
Measurement of DNA concentration 
The OD26Onm and OD280, of DNA samples were measured in a spectrophotometer. 
An OD260 of 1 = 50.tg/ml double-stranded DNA, and an OD260nm:01)280nm ratio of 
1.8-2.0 indicates the absence of residual protein or phenol from the DNA sample. An 
OD260nm :OD28onm ratio of <1.8 suggests the presence of these contaminants in the 
DNA sample. 
Restriction digestion 
Restriction digests contained 4U restriction enzyme (New England BioLabs)/ig 
DNA and the appropriate reaction buffer, and were supplemented with 1 OOtg/ml 
BSA if required. Restriction digests were incubated at the appropriate temperature 
for the restriction enzyme (usually 37°C) for a minimum of 2h 
DNA electrophoresis 
The separation of DNA on the basis of molecular weight was achieved by agarose 
gel electrophoresis using the , Sub-cell system (Bio-Rad). 0.8-2% (w/v) agarose gels 
were used depending on the molecular weight of the DNA fragment(s) of interest. 
Agarose gels were prepared with TAE and contained 0.5tg/ml ethidium bromide, a 
DNA intercalating agent that fluoresces in ultraviolet (UV) light. DNA samples and 
1kb Plus DNA ladder (100bp-12kb; Invitrogen) in Orange G loading buffer were 
loaded into the wells of the gel. Agarose gels were run at constant voltage (50-125V 
depending on the size of the gel) in TAE electrophoresis buffer, then DNA was 
visualised under UV light. If a DNA fragment was to be purified from the gel to be 
cloned, the exposure to. UV light was kept to a minimum. 
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Purification of DNA from agarose gels 
DNA fragments required for cloning were resolved by agarose gel electrophoresis 
and were purified using the QlAquick gel extraction kit (QIAGEN) according to the 
manufacturer's instructions. 
DNA ligation 
DNA ligation reactions were performed in a 20t1 volume, and contained 5 Weiss 
units T4 DNA ligase, Rapid ligation buffer (both Fermentas Life Science) and 50ng 
vector DNA. A 3:1 molar ratio of insert DNA to vector DNA was present in each 
reaction. DNA ligation reactions were incubated for lh at nt, then 5xl was 
transformed into a 200tl aliquot of competent bacterial cells. 
Polymerase chain reaction 
Specific DNA molecules were amplified from a DNA template by the polymerase 
chain reaction (PCR) as described by Mullis et al. (1986). Routine PCRs were 
prepared in a 50tl volume containing Red Hot PCR buffer (ABgene), 2.5mM 
MgC12, 1 .25U Red Hot DNA polymerase (ABgene), 0.5pmol4d forward and reverse 
primers, 0.25mM dNTPs and 1 tl genomic DNA template. A negative control that 
contained no template DNA was also prepared. The PCR cycling conditions were as 
follows: initial DNA denaturation at 95°C for 3mm, then 30 cycles of DNA 
denaturation at 95°C for 30s, primer annealing at 50-65°C for 30s, and DNA 
polymerase extension at 72 °C for 1mm/kb PCR product. The primer annealing 
temperature was based on primer-specific, recommendations from the oligonucleotide 
supplier and empirical observations. After PCR cycling, the PCRs were incubated at 
72°C for 10min in order to extend any remaining incomplete PCR products. 5[d of 
each Red Hot PCR was analysed by agarose gel electrophoresis. 
PCR reactions to amplify DNA molecules to be cloned were prepared in a 50il 
volume containing KOD PCR buffer (Novagen), 1mM MgSO 4, 1U KOD Hot Start 
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DNA pblymerase (Novagen), 0;5pmol4tl forward and reverse primers, 0.2mM 
dNTPs and ing plasmid DNA template. A negative .control that contained no 
template DNA was also prepared. The PCR cycling conditions were as follows: 
KOD Hot Start DNA polymerase activation and initial DNA denaturation at 94°C for 
2mm, then 35 cycles of DNA denaturation at 94°C for 15s, primer annealing at 55°C 
for 30s, and DNA polymerase extension at 72°C for 20s/kb PCR product. KOD 
DNA polymerase is from the species Thermococcus kodakaraensis, and has 3' to 5' 
proofreading activity and a very high elongation rate relative to other proofreading 
DNA polymerases. 5tl of each KOD PCR was analysed by agarose gel 
electrophoresis. Prior to restriction digestion, the amplified DNA in the remainder of 
the PCR was purified using the QlAquick PCR Purification kit (QIIAGEN) according 
to the manufacturer's instructions. 
Exonuclease 1/SAP reactions 
The following protocol describes a cost-effective and non-labour intensive 
alternative to the removal of PCR primers and dNTPs using a commercial column-
based PCR purification kit, and is particularly useful when handlinga large number 
of PCRs. 5!t1  of a PCR was incubated with 5U exonucleãse I (New England 
BioLabs) and 1U shrimp alkaline phosphatase (SAP; Roche) at 37°C for 5mm. 
Exonuclease I can degrade primers and SAP can dephosphorylate dNTPs, therefore 
these enzymes can prevent the participation of residual PCR primers and dNTPs in a 
subsequent sequencing reaction. Exonuclease I and SAP were inactivated by 
incubation at 80°C for 15mm. 2il exonuclease I/SAP-treated PCR was used in a 
DNA sequencing reaction. 
Bisuiphite modification of DNA 
The methylation status of CpG dinucleotides was determined according to the 
method of Frommer et al. (1992). Genomic DNA was digested with a restriction 
endonuclease that only cuts outside the region of DNA being analysed. The digested 
Fl 
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DNA was then purified using the QlAquick PCR Purification kit (QIAGEN) 
according to the manufacturer's instructions. 1ig digested DNA in 25tl TE pH7.4 
was denatured by incubation at 1OOC for 5mm, and the subsequent addition of 2.5 M 1 
3M NaOH and incubation at 37°C for 20mm. 270tl Bisuiphite modification solution 
was added to the denatured DNA, and the sample was covered with a mineral oil 
overlay and incubated at 55°C for 5h protected from light. The modified DNA was 
then isopropanol precipitated (in the presence of 50tg glycogen carrier) and 
resuspended in 25tl TE pH7.4. The DNA was then desulphonàted by the addition of 
2.5pA 3M NaOH and incubation at 37°C for 15mm. The bisuiphite-modified DNA 
was purified using the QlAquick PCR Purification kit (QIAGEN) and eluted in 30tl 
10mM Tns HC1 pH8.5. 
5iJ bisuiphite-modified DNA was used in a Red Hot PCR containing primers 
specific to the bisuiphite-modified cli locus, and the whole PCR was resolved by 
agarose gel electrophoresis. The amplified DNA (which has single 3' adenine 
overhangs) was purified from the gel using the QlAquick Gel Extraction kit 
(QIAGEN), and was cloned into the pCR2.1-TOPO plasmid using the TOPO TA 
cloning kit (Invitrogen) according to the manufacturer's instructions. TOPO TA 
cloning reactions were transformed into One Shot Chemically Competent TOP 1 OF' 
bacteria (Invitrogen) according to the manufacturer's instructions, and the 
transformed cells were plated onto LB agar plates containing ampicillin, IPTG and 
X-gal. 
Bacterial colonies transformed with an insert-containing plasmid were identified by 
blue/white selection; these colonies are white in colour because the DNA insert 
disrupts the coding sequence of the a-fragment of 3-galactosidase. Inserts were PCR 
amplified directly from a single colony by touching the surface of the colony with a 
disposable pipette tip, then incubating the pipette tip in a Red Hot PCR containing 
M13 forward and reverse primers (these primers anneal to sequences on either side 
of the pCR2.1 TOPO cloning site). After PCR cycling, half of each 50.t1 PCR was 
resolved by agarose gel electrophoresis to determine whether a DNA product of the 
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expected size was present. 5il of each of the positive PCRs was treated with 
exonuclease I and SAP, and 2tl exonuclease I/SAP-treated PCR was used in a DNA 
sequencing reaction. 
DNA sequencing 
Plasmid DNA to be sequenced was purified using a QIAGEN plasmid preparation kit 
according to the manufacturer's instructions. DNA sequencing was performed using 
the BigDye Terminator v3.1 Cycle Sequencing kit (ABI). DNA sequencing reactions 
contained 2tl BigDye Terminator v3.1, 3.2pmol primer and 50-300ng DNA template 
in a 10 [d volume, and were incubated under the following conditions: initial DNA 
denaturation at 96°C for 1mm, then 25 cycles of DNA denaturation at 96°C for lOs, 
primer annealing at 50°C for 5s, and DNA polymerase extension at 60°C for 4mm. 
Sequencing reactions were cleaned up and were run on an ABI 3730 capillary 
sequencer by the School of Biological Sciences Sequencing Service. DNA sequence 
data was analysed using Lasergene software (DNA Star). - 
2.2.2 RNA manipulation 
Total RNA isolation from mammalian cells and tissues 
Total RNA was isolated from mammalian cells and tissues with TRI Reagent 
(Sigma). Cells were washed quickly 2x with PBS, lysed in imi TRI ReagentllOcm 
diameter cell culture plate, and harvested using a cell scraper. Frozen tissues were 
transferred into lml ice cold TRI Reagenti100mg tissue and homogenised with a 
Polytron homogeniser for 15-30s. Cell and tissue samples in TRI Reagent were 
incubated for 5min at nt to allow dissociation of nucleoprotein complexes. 0.2m1 
chloroform/ml TRI Reagent was added and samples were mixed vigorously for 15s 
then incubated for 15min at nt. Samples were then centrifuged at 12,000g for 15mm 
at 4°C. The colourless aqueous upper phase was transferred into a new tube, and total 
RNA was precipitated by the addition of 0.5ml isopropanollml TRI Reagent. 
Samples were incubated for 10min at nt, then RNA was pelleted by centrifugation at 
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12,000g for 10min at 4°C. RNA pellets were washed with 15% (v/v) ethanol, air-
dried for 5-10mm, then resuspended in an appropriate volume of dH20. Total RNA 
samples were stored at —20°C 
Measurement of RNA concentration 
The OD26o, and OD280nm of RNA samples were measured in a spectrophotometer. 
An 0D260nm of 1 = 40.tgIml single-stranded RNA, and an OD260 nm :OD28o ratio of 
1.8-2.0 indicates the absence of residual protein or phenol from the RNA sample. An 
OD260nm :OD28onm ratio of <1.8 suggests the presence of these contaminants in the 
RNA sample. 
RNA electrophoresis 
The separation of RNA on the basis of molecular weight was achieved by the 
electrophoresis of RNA denatured in a formaldehyde-formamide sample buffer in 
non-denaturing TAE agarose gels. 5tg RNA samples and RNA Markers (28 lbp-
6.5 8kb; Promega) were mixed with 20p1 RNA sample -buffer and 5tl RNA loading 
buffer and incubated at 70°C for 1 0mm. RNA samples were then incubated on ice 
for 2min before loading into the wells of a 1% (w/v) TAE agarose gel containing 
0.5tg/ml ethidium bromide. RNA gels were run in TAE electrophoresis buffer under 
standard conditions, and RNA was visualised under UV light. RNA samples with 
compact ribosomal RNA (rRNA) bands and a 2:1 ratio of 28S:18S rRNA were 
considered to be of high quality. 
Reverse transcription of RNA 
Total RNA samples were treated with RQ1 RNase-free DNáse (Promega) prior to 
reverse transcription. The DNase was removed by phenol: chloroform: isoamyl 
alcohol (25:24:1) extraction and ethanol precipitation, and the RNA was resuspended 
in dH20. 10tg RNA and 10.6tg random hexanucleotides were mixed and were 
denatured in a 23.5pi volume by incubation at 70°C for 5mm, before being 
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immediately incubated on ice for 2mm. 24.5 il reverse transcription master mix was 
added (see below for final reaction concentrations) and the random hexanucleotides 
were annealed to the RNA at 25°C for 5mm. The 48tl volume was then split equally 
into two tubes; 1 il dH20 was added to one of the tubes labelled '- reverse 
transcriptase (RT) reaction', and 1 il M-MLV RT (RNase H minus; Promega) was 
added to the other tube which was labelled '+ RT reaction'. The final concentrations 
in the + RT reaction were lx M-MLV RT buffer (Promega), 8UItl M-MLV RT, 
200ng4tl RN., ,212ngItl random hexamers, 1mM dNTPs and 1.6U/iJ RNasin 
(RNase inhibitor; Promega). The RT reactions were incubated at 25°C for 10mm, 
then at 37°C for lh. Finally, the RT enzyme was inactivated by incubation at 70°C 
for. 1 0mm. The 25 tl RT reactions were diluted with 475[d dH20 and were stored at 
—20°C. 2.5iii eDNA was used in a PCR. 
Real-time PCR 
Real-time PCR was used to quantify the abundance of various cDNAs of interest 
using SYBR Green I detection chemistry and an iCycler. iQ Real-Time PCR 
detection system (Bio-Rad). SYBR Green I is a fluorescent molecule that can bind to 
double-stranded DNA and then absorb light with a wavelength of 498nm and emit 
light with a wavelength of 522nm. This enables the amplification of a PCR product 
to be measured continuously over time. Real-time PCR reactions were prepared in a 
25tl volume using iQ SYBR Green I Supermix (BioRad). This supermix contains 
PCR buffer, hot-start iTaq DNA polymerase, dNTPs and SYBR Green I dye. Prior to 
PCR cycling, a eDNA template and forward and reverse primers specific to a 
particular gene were added (2.5tl eDNA and a, final primer concentration of 
0.5pmol4tl). Each eDNA sample was assayed in quadruplicate with two primer 
pairs; one pair was specific to the gene of interest, and the other pair was specific to 
the reference gene (GAPDI-I). To evaluate the primers used and the efficiency. of the 
real-time PCR, a dilution series of a eDNA sample was also analysed in duplicate 
with each primer pair (the magnitude of the dilution used depended on the expected 
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differences in the abundance of the amplified cDNA). Finally, a duplicated negative 
control that contained no template cDNA was included. 
The PCR cycling conditions were as follows: 95°C for 3mm (initial DNA 
denaturation and iTaq DNA polymerase activation), then 45 cycles of DNA 
denaturation at 95°C for 45s and primer annealing at 55-60°C for 45s. The primer 
annealing temperature was based on primer-specific recommendations from the 
oligonucleotide supplier and on empirical observations. A DNA polymerase 
extension step at 72°C was not required as the amplicons are short enough to be 
copied as the thermal cycler increases in temperature from the primer annealing 
temperature to the DNA denaturation temperature (95°C). When PCR cycling was 
complete, melt curve analysis was performed. DNA was denatured at 95°C for 1mm 
and annealed at 35°C for. lOs. The temperature was then increased to 95°C in 120 
steps, each consisting of a lOs incubation at a temperature 0.5°C higher than the 
preceding step. The continuous measurement of fluorescence throughout the melt 
curve cycle allows the determination of the T m  of the double-stranded DNA 
molecule(s) present. 
The iCycler iQ software assigns a baseline of lOx the mean of the standard deviation 
of the fluorescence measurements collected over cycles 2-10. The number of cycles 
at which a particular reaction crosses the baseline is the cycle threshold for that 
reaction (CT). The CT should occur during the linear phase of the PCR, and the cycle 
thresholds of replicate reactions should occur within 0.5 cycles of one another. To 
calculate Q, which is the amount of cDNA of the gene of interest (GENE X) relative 
to the amount of eDNA of the reference gene (GAPDH), the following formula was 
used: 
Q = 2 (CTGENEX CTGAPDH) 
Q values were calculated for each replicate reaction, and the mean and standard 
deviation of the mean were calculated and displayed graphically using Microsoft 
Excel. 
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The dilution series of a cDNA sample with a specific primer pair allows the 
calculation of two values: the correlation coefficient and the PCR efficiency, which 
in turn allow the evaluation of the primer pair and the efficiency of the real-time 
PCR. The correlation coefficient is a measure of the correlation between the amount 
of eDNA template present and the amplification of the cDNA dilution series. The 
PCR efficiency is a measure of the amount of DNA that is copied per cycle. The melt 
curve is used to verify that the PCR amplifies a single double-stranded DNA product. 
Different amplicons have different melt curves because of different lengths and 
different base compositions. The melt curve can therefore be used to determine 
whether primer dimers are present because primer dimers are usually shorter than the 
PCR product and consequently have a lower T m. Finally, the absence of 
contaminating DNA is confirmed by verification that the fluorescence measurements 
of the duplicated negative control do not cross the baseline during the 45 cycles of 
the PCR. Representative PCR amplification, melt curve and standard curve graphs 
are shown in Figure 2.1. 
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Figure 2.1: Representative real-time PCR results. The GAPDH cDNA present within a five-
fold dilution series of human brain cDNA was quantified in duplicate. Four negative controls 
that contained no template DNA were also included. (A) PCR amplification graph. The 
baseline is shown in orange. The duplicates of the four members of the human brain cDNA 
dilution series have similar CTs. The fluorescence measurements of the negative controls do 
not cross the baseline. (B) Melt curve graph. A single double-stranded DNA product was 
amplified in the PCR, as shown by the presence of a single peak in the melt curves of the 
DNA-containing reactions (the melt curves of the negative controls do not contain any 
significant peaks). (C) Standard curve graph. The correlation coefficient and the PCR 
efficiency are indicated. 
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22.3 Protein manipulation 
Isolation of bacterial whole cell extracts 
Bacterial cultures were centrifuged at 4,200rpm for 20min at 4°C and the cell pellets 
were washed with ice cold PBS. The cell pellets were then frozen at -70°C, as 
freeze-thawing  contributes to the disruption of the bacterial cell wall. The cell pellets 
were thawed on ice and resuspended in 20ml Bacterial lysis buffer. The bacterial 
cells were then lysed by the addition of lysozyme to 1mg/mi and incubation on ice 
for 30mm (lysozyme hydrolyses the giycosidic bonds between N-acetyl glucosamine 
and N-acetyl muramate within the major polysaccharide of the bacterial cell wall). 
Finally, the lysate was sonicated for 5mm (Branson sonifier 250: duty cycle 30%, 
output 4, and atapered microtip) and centrifuged at 17,000g for 30min at 4°C. The 
supernatant (the bacterial whole cell extract) was transferred to a new tube and was 
stored at -70°C. 
Isolation of yeast whole cell extracts 
Yeast whole cell extracts were isolated by the UreaJSDS method of Printen and 
Sprague (1994). In this method, the yeast cell wall is broken by a combination of 
physical and chemical means, and the yeast proteases are inhibited by a cocktail of 
protease inhibitors. For each co-transformant to be analysed by western blotting, a 
5ml o/n culture in SD -LEU -TRP broth was prepared, and was incubated at 30°C 
with shaking at 200rpm for 16-18h. The culture was then vortexed at high speed for 
1mm, diluted into. 50m1 SD -LEU -TRP broth, and incubated at 30°C with shaking. 
When the OD6o0nm was 0.4-0.6 (after approximately 4h), the yeast cells were quickly 
chilled, and were pelleted by centrifugation at 1,000g for 5min at 4°C. The cells were 
then washed with 50ml ice cold dH 20, and the pellets were flash frozen and stored at 
-70°C 0/n. 
The following day, the cell pellets were resuspended in pre-warmed 60°C Complete 
cracking buffer. 100tl Complete cracking buffer was used for every 7.5 OD600 
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units of cells (total OD600n.  units = OD60On at the time of harvest x the culture 
volume). Initially, 5mM phenylmethylsulfonyl fluoride (PMSF; a serine protease 
inhibitor) was present in the Complete cracking buffer. However, PMSF has a half-
life of only 7min within aqueous solutions, therefore additional aliquots of PMSF 
were added after 1 5mm, and every 7niin thereafter throughout the protocol. 
Complete cracking buffer also contains a mixture of other serine and cysteine 
protease inhibitors. The resuspended cells were transferred into a tube containing 
80!11 of 425-600tm diameter glass beads per 7.5 OD600nm units of cells. The 
suspensions were heated at 70°C for 10min then vortexed at high speed for 1mm. 
The glass beads, unbroken cells and cell debris were then pelleted by centrifugation 
at 14,000rpm for 5min at 4°C. The supernatants were transferred to a new tube and 
incubated on ice. The pellets were incubated in a boiling water bath for 5mm, then 
vortexed at high speed for 1mm. This was followed by centrifugation at 14,000rpm 
for 5min at 4°C. The supernatants were then transferred into the tubes containing the 
first supernatants, and the combined supernatants (the yeast whole cell extracts) were 
incubatçd at 100°C for 5mm, flash frozen and stored at —70°C. 
Isolation of mammalian cell extracts 
Mammalian cells were separated into ai cytoplasmic extract (CE), a nuclear extract 
(NE) and a nuclear pellet (NP) using a modified protocol that was originally 
developed to isolate RNA polymerase II transcriptionally active NEs (Dignam et al., 
1983). Cells were trypsinised from a 15cm diameter cell culture plate and were 
washed with PBS. The cell pellet was resuspended in imi ice cold NE1 low salt 
buffer and nuclei were released using a Wheaton dounce tissue grinder with a tight-
fitting pestle. The nuclei were pelleted at 3,000rpm for 5min at 4°C and the 
supernatant (the CE) was transferred to a new tube on ice. The nuclei were 
resuspended in 300tl ice cold NE2 high salt buffer and were incubated on a rotating 
fly wheel for 1 h at 4°C. The nuclear extractions were then centrifuged at 13,000rpm 
for 25min at 4°C to separate the NE and the NP, and the NE was transferred to a new 
tube on ice. To prepare whole cell extracts (WCEs), whole nuclear extracts (WNEs) 
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or nuclear pellet extracts (NPEs), the appropriate pellet was resuspended in 300Ll ice 
cold NE2 high salt buffer, sonicated for 1mm (Branson sonifier 250: duty cycle 30%, 
output 4, and a double-step microtip) and centrifuged at 13,000rpm for 25min at 4°C. 
The supernatant (the WCE, WNE or NPE) was then transferred to a new tube. All 
mammalian cell protein extracts were stored at —70°C. 
Measurement of protein concentration 
Protein concentrations were measured using the Bio-Rad Protein assay, which is 
based on a method first described by Bradford (1976). This assay is based on protein 
binding by Coomassie Brilliant Blue G-250 in an acidic solution, and the associated 
change in the absorbance maximum from 465nm to 595nm. Protein samples were 
incubated with a 1:5 dilution of the dye reagent for 1 0mm, then the OD595 was 
measured in a spectrophotometer. 0.5, 1, 2, 5, 10 and 20ig bovine serum albumin 
(BSA) were used to prepare a standard curve each time the assay was performed. The 
concentrations of the protein samples of interest were determined by substitution of 
the measured 0D595nm values into the equation that described the BSA standard 
curve. 
SDS polyacrylamide gel electrophoresis 
The separation of proteins on the basis of molecular weight was achieved by 
denaturing SDS polyacrylamide gel electrophoresis (SDS PAGE) according to the 
method of Laemmli (1970), using the vertical electrophoresis Mini-PROTEAN 3 and 
PROTEAN II systems (both Bio-Rad). The polyacrylamide separating gels were 
between 8% and 15% (w/v) depending on the molecular weight of the protein(s) of 
interest. 5% (wlv) polyacrylamide stacking gels were used. Protein samples (in SDS 
PAGE loading buffer) and Pre-stained protein marker, broad range (6-175kD; New 
England BioLabs) were incubated at 100°C for 5mm, before being loaded into the 
wells of the stacking gel. SDS PAGE gels were run at constant current (mini-
PROTEAN 3 gels were run at 17.5mA, and PROTEAN II gels were run at 25mA) in 
Tris-glycine electrophoresis buffer. 
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SDS PAGE gels were Coomassie stained by incubating in Coomassie Brilliant Blue 
R-250 staining solution with shaking for 30min-oln. Gels were de-stained by 
immersion in 250m1 dH20 and heating in a microwave on high power for 5mm. This 
was repeated until the background staining was sufficiently reduced and protein 
bands were clearly visible. Coomassie stained gels were either scanned between two 
pieces of clear acetate or dried if a permanent record was required. 
Western blotting 
Proteins were transferred from SDS PAGE gels onto Protran nitrocellulose 
(Schleicher & Schuell BioScience) using a Trans-Blot SD semi-dry transfer cell 
(Bio-Rad) and Semi-dry transfer buffer. Blotting was performed at 200mA.constant 
current for 1 h- lh 1 0mm depending on the surface area of the gel(s). 
If verification of protein transfer was required, western blots were Ponceau S stained 
by washing 3x in dH 20 for 5mm, then incubating in Ponceau S staining solution with 
gentle shaking for 30s-2min. Blots were de-stained in dH20 until the background 
staining was sufficiently reduced and protein bands were clearly visible. The 
Ponceau S stained blot was then scanned between two pieces of acetate if a 
permanent record was required. Finally, blots were de-stained in dH 20 until protein 
bands were, no longer visible. 
Non-specific binding sites on the western blot were blocked by incubation in 5% 
(w/v) Marvel milk powder in TBST at 4°C 0/n, or for lh on a shaking platform at nt. 
All subsequent steps were also performed on a shaking platform at r/t. The blot was 
incubated with a primary antibody in 1% (w/v) milk in TBST for lh, before being 
washed 3x in 1% (w/v) milk in TBST for 10mm. The blot was then incubated with a 
horseradish peroxidase (HRP)-conjugated secondary antibody in 1% (w/v) milk in 
TBST for lh, then washed 2x with 1% (w/v) milk in TBST, and lx with TBST, for 
1 0mm. Equal volumes of ECL solutions 1 and 2 were mixed, and the composite ECL 
solution was incubated with the blot for Imin with gentle shaking. The blot was 
placed on a glass plate, covered with Saran wrap and exposed to Hyperfilm ECL (GE 
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Healthcare) for 30s, then for shorter or longer periods of time as required. Films were 
developed by a SRX-1O1A tabletop film processor (Konica Minolta). 
Primary and secondary HRP-conjugated antibody dilutions were based on 
recommendations from the antibody supplier(s) and on empirical observations. 
2.2.4 Bacterial cell culture and related methods 
Bacterial growth conditions 
Bacterial cells were recovered from frozen glycerol stocks by scraping the surface of 
the frozen stock with a sterile loop, and then streaking the loop across an LB agar 
plate containing the appropriate antibiotic(s). Plates were incubated inverted at 37°C 
0/n. 
Liquid bacterial cultures were grown in LB broth containing the appropriate 
antibiotic(s). A single bacterial colony was inoculated into a small volume of LB 
broth (usually 5m!) and the culture was incubated at 37°C with shaking at 200rpm 
o/n. 
Preparation of competent bacteria 
A Sm! 0/n bacterial culture in LB broth was prepared, and was diluted into 500m! LB 
broth the following morning (a culture flask with a volume of at least 4x the volume 
of the culture was used). The culture was then incubated at 37°C with shaking until 
an 0D650nm of 0.5 was reached (this takes approximately 2-3h depending on the 
bacterial strain). The bacterial cells were incubated on ice for 1 0mm, then pelleted by 
centrifugation at 2,400rpm for 15min at 4°C. The cell pellet was resuspended in 
1 65ml ice cold Competent cell buffer A, and the resuspended cells were incubated on 
ice for 45min before being pelleted again. The cell pellet was resuspended in. 40m1 
ice cold Competent cell buffer B, and the resuspended cells were incubated on ice for 
1 5mm. 200tl aliquots of the competent cells were flash frozen in liquid N 2 and were 
stored at —70°C. The transformation efficiency of the competent bacterial cells was 
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tested by the transformation of defined amounts of plasmid DNA (transformation 
efficiencies of >106  colonies/rig DNA were considered to be successful)i 
Transformation of bacteria by heat shock 
Aliquots of competent bacterial cells were thawed on ice. 10-1Ong of plasmid DNA, 
or 5il of a ligation reaction, was added to a tube of competent bacterial cells, and the 
tube was mixed gently. A positive control consisting of plasmid DNA of known 
quality, and a negative control consisting of dH 20 alone, was also included in each 
group of bacterial transformations. The mixture of cells and DNA was incubated on 
ice for 30mm, before being heat shocked in a 42°C water bath for 1 min3Os and 
incubated on ice for 2mm. 1 ml LB broth was added and the transformations were 
incubated at 37°C for lh with shaking. This incubation allows plasmid-encoded 
genes that confer antibiotic resistance to be expressed. Aliquots of the 
transformations were then plated out onto LB agar plates containing the appropriate 
antibiotic(s). When a high transformation efficiency was expected, e.g. when 
miniprepped plasmid DNA was transformed, 25d of the transformation was plated 
out. However, when a low transformation efficiency was expected, e.g. when a DNA 
ligation reaction was transformed, the whole transformation was plated out. The 
plates were inverted and incubated at 37°C o/n. 
Isolation of plasmid DNA from bacteria 
E. coli strains DH5ct and XL 1-Blue were routinely used for cloning and plasmid 
isolation. These strains have a mutation in the recA gene, which encodes a protein 
involved in DNA recombination. The absence of the recA protein therefore increases 
the stability of plasmid inserts within the host cells. DH5a and XL 1-Blue also have a 
mutation in the endA endonuclease gene, allowing the isolation of high quality 
plasmid DNA. Finally, both strains also have a mutation in hsdR; this inactivates the 
EcoKT endonuclease and thereby prevents the cleavage of plasmid DNA by the 
EcoKI R-M system. 
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The following protocol describes a cost-effective method to isolate crude plasmid 
DNA that is suitable for use in restriction digest-based screening of DNA constructs. 
2m1 o/n bacterial culture in LB broth was centrifuged at 6,000rpm for 1mm, and the 
cell pellet was resuspended in 100tl Miniprep solution 1 with 100tgIml RNase A. 
The cells were then lysed under alkaline conditions by the addition of 200xl 
Miniprep solution 2, and the mixture was neutralised with 150il 5M KOAc pH4.8. 
The cellular debris, cell wall-bound chromosomal DNA and the denatured proteins 
were pelleted by centrifugation at 14,000rpm for 5mm. The plasmid DNA was 
recovered from the supernatant by ethanol precipitation, and was resuspended in 
50pJ TE p117.4. 3pJ plasmid DNA prepared according to this protocol was used in 
analytical restriction digests. Plasmid DNA was stored at —20°C. 
When plasmids were required for DNA sequencing, or when largr quantities of 
plasmid were needed, plasmid DNA was isolated using QIAGEN Mini, Midi and 
Maxi prep kits according to the manufacturer's instructions. 
Expression of recombinant proteins in bacteria 
E. coil strain ER2566 was used as a host strain to over-express target genes under the 
control of a T7 promoter and a lac operator. ER2566 and the plasmid encoding the 
target protein encode the lacl repressor protein. ER2566 cells carry a chromosomal 
copy of the bacteriophage T7 RNA polymerase gene inserted into the endogenous 
iacZ gene, and thus under the control of the lac promoter and operator. In the 
absence of the non-cleavable lactose analog isopropyl-3-D-thiogalactoside (IPTG), 
the lacl repressor protein binds to the lac operators upstream of both T7 RNA 
polymerase and the target gene, and their expression is repressed. In the presence of 
IPTG, an IPTG-lacl complex forms; this complex cannot bind to the lac operators, 
and the T7 RNA polymerase gene is expressed. The T7 RNA polymerase protein 
then transcribes the target gene. The genes encoding the Ion and OmpT proteases are 
deleted in strain ER2566, which may increase the yields of some target proteins. 
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ER2566 cells were transformed with a plasmid(s) carrying a T7 promoter//ac 
operator-controlled target gene. A 1 Oml o/n bacterial culture in LB broth was 
prepared. The 0/n culture was added to 500m1 LB broth the following morning, and 
the diluted culture was incubated at 37°C with shaking until an OD600, of 0.5 was 
reached. Protein expression was induced by the addition of IPTG to 1 mM, and the 
bacterial culture was incubated at 37°C with shaking for a further 2h. Bacterial whole 
cell extracts were then isolated as described in Section 2.2.3 (sub-section 'Isolation 
of bacterial whole cell extracts'). 
2.2.5 Yeast cell culture and related methods 
Yeast growth conditions 
Yeast cells were recovered from frozen glycerol stocks by scraping the surface of the 
frozen stock with a sterile loop, and then streaking the loop across a YPDA agar 
plate. Plates were sealed with Paraflim to prevent desiccation, and were incubated 
inverted at 30°C until colonies grew to 2-3mm in diameter (2-3d). Working stock 
plates were then stored at 4°C for up to two months. 
Liquid yeast cultures were grown in YPDA or SD broth. A single yeast colony of 2-
3mm in diameter was inoculated into imi broth. The broth was vortexed at high 
speed for 5min to disperse the cells, then diluted into a larger volume (up to 50m1). 
Liquid yeast cultures were incubated at 30°C with shaking at 200rpm o/n. 
Lithium acetate-mediated transformation of yeast 
Plasmid DNA was introduced into yeast cells by lithium acetate (LiAc)-mediated 
transformation, as described in the Yeast protocols handbook (Clontech, 2000). This 
is a modified version of a method originally developed by Ito et a/. (1983). A 50m1 
o/n yeast culture in YPDA broth was prepared, and the OD 600 was, measured the 
following morning. The culture was deemed to be in stationary phase when the 
OD600 > 1.5. The culture was diluted into 300ml YPDA broth to an OD600 of 0.2- 
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0.3 (early log phase), then incubated at 30°C with shaking. until an 013 600,, of 0.4-0.6 
was reached (mid log phase). The yeast cells were pelleted by centrifugation at 
1,000g for 5mm, and were washed with 25m1 TE pH7.5. The cells were then 
resuspended in 1 .5m1 TE/LiAc. 100il resuspended yeast cells was added to a tube 
containing 1 OOng of each plasmid DNA to be transformed (i.e. 200ng plasmid 
DNA/co-transformation) and 100tg herring sperm single-stranded DNA. The tube 
was then vortexed at high speed for lOs. 600tl PEG/LiAc was added, and the 
transformations were mixed again by vortexing. The transformations were then 
incubated at 30°C with shaking for 30mm. 70tl dimethyl suphoxide (DMSO) was 
added and the transformations were mixed gently by inversion, before being heat 
shocked in a 42°C water bath for 1 5mm then incubated on ice for 2mm. Finally, the 
transformed yeast cells were pelleted by a brief centrifugation and were resuspended 
in lml TE pH7.5. 100t1 of the resuspended yeast cells was plated onto the 
appropriate SD agar plates, and the plates were incubated inverted at 30 °C for 3-4d. 
Replica plating single yeast colonies 
A sterile loop was used to transfer a single colony into a tube containing 200tl 
dH20. The tube was then vortexed at high speed for lOs and 1 pJ of the resuspended 
yeast cells was replica plated onto the required agar plates The plates were incubated 
inverted at 30°C and growth was scored after 2, 3 and 4d. 
2.2.6 Mammalian cell culture and related methods 
Mammalian cell growth conditions 
Prior to defrosting mammalian cells, the appropriate cell culture medium was pre-
warmed to 37 0C. The stock of frozen cells was quickly thawed in a 37°C water bath. 
5m1 medium was added drop-wise to the cells, and the cell suspension was incubated 
at r/t for 2min. A further 1 Omi medium was added drop-wise. The cells were then 
pelleted by centrifugation at 1,300rpm for 3min. A single cell suspension was 
prepared in fresh medium and transferred to 'a cell culture plate (1 Oml mediun/ 10cm 
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diameter plate). The volume of medium and the diameter of the plate used were 
determined by the amount of cells in the stock. Plates were incubated at 37°C in 5% 
Co2 . 
When the cells were confluent, the plate was washed with PBS before being 
incubated with-trypsn-EDTA (lmIIlOcm diameter plate) for 3-5mm. Trypsin is a 
serine protease that can mediate the detachment of cells from the cell culture plate 
surface. After cell dissociation from the surface, fresh medium (1 0m111 0cm diameter 
plate) was added, and a single cell suspension was prepared. The cells were pelleted 
by centrifugation at 1,300rpm for 3min and were resuspended in fresh medium. The 
required volume of the cell suspension was transferred into a new cell culture plate 
with an appropriate volume of additional medium. As commonly used mammalian 
adherent cell lines divide approximately once every 24h, and cells were routinely 
passaged to 12.5-25% confluency, passaging was carried out once every 2-4d. 
When preparing a stock of frozen cells, cells were trypsinised and spun down as 
described above. The cell pellet was then resuspended in cell culture medium 
containing 10% (vlv) DMSO (cells from a 10cm diameter plate were resuspended in 
imi total volume). The presence of DMSO increases the percentage of cells that 
survive freezing and thawing by minimising the formation of ice crystals within the 
cells. The cell stocks were stored at —20°C for lh, then at —70°C o/n, before being 
transferred to a liquid N2 cryostore for indefinite storage. 
Isolation of primary mouse embryonic fibroblasts 
E10.5 embryos were carefully dissected from uteri and the yolk sacs were removed. 
The risk of contamination with - maternally derived cells , was minimised by washing 
embryos several times in PBS. Embryos were then incubated in 250tl trypsin-EDTA 
at 37°C for 20min with regular mixing. 1 Oml Amniomax cell culture medium was 
added and the embryos were disaggregated'by gentle pipetting. The cell suspension 
was transferred into a 10cm diameter cell culture plate with Sml additional medium. 
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The primary MEFs were incubated at 37°C in 5% CO2 and were passaged to 25% 
confluency. 
Transformation of mouse embryonic fibroblasts 
Primary MEFs were transformed with a recombinant Moloney murine leukaemia 
virus (MoMLV) that encodes the simian virus 40 (SV40). large T antigen (Jat and 
Sharp, 1986; Jat et al., 1986). The SV40 retrovirus lacks several proteins that are 
required for packaging of the retroviral RNA, therefore the ip-2 packaging cell line 
was used to produce the SV40 retrovirus. The W-2  cell line is derived from NIH3T3 
cells and contains an integrated defective MoMLV (Mann et al., 1983). This 
defective retrovirus encodes all of the proteins necessary for packaging of the 
retroviral RNAbut, because the retroviral RNA lacks the RNA packaging sequence, 
the defective retrovirus cannot be packaged or released. However, in 'tp-2/SV40 cells 
the defective retrovirus can supply the proteins necessary for packaging of the SV40 
retroviral RNA in trans, therefore the SV40 retrovirus can be packaged and released. 
SV40 retrovirus cannot be produced by any cells other than ip-2 cells due to the 
absence of the retroviral RNA packaging proteins. 
The day before SV40 retroviral infection, the primary MEFs were passaged (in 
Amniomax medium) so that they would be 20% confluent the following morning, 
and the medium from a 20% confluent plate of ip-2/SV40 cells was replaced with 
Amniomax medium. The next morning, the SV40 retrovirus-containing medium was 
removed from the. W-2/SV4O cells, supplemented with 8.tg/ml polybrene (Sigma; 
polybrene is a cationic polymer that increases the efficiency of retroviral infection by 
neutralising the negative charge of the cell surface), and 0.45iim filtered to remove 
any W-2/SV40 cells. The SV40 retrovirus-containing medium was then added to the 
primary MEFs. Retroviral infection was allowed to proceed for 8h at 37°C in 5% 
CO2 before the retrovirus-containing medium was replaced with fresh Amniomax 
medium. 
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After SV40 retroviral infection, MEFs were passaged 3x in Amniomax, 3x in 
GMEM with 20% (vlv) FBS, then in GMEM with 10% (vlv) FBS thereafter. 
Transient transfection of mammalian cells 
Plasmid DNA was transiently, transfected into mammalian cells using Lipofectamine 
2000 (Invitrogen) and a ig DNA to t1 Lipofectamine 2000 ratio of 1:1.5. The 
following protocol is based on the transfection of a 10cm diameter cell culture plate; 
to transfect cells in plates of different diameters, all amounts and volumes were 
scaled up or down accordingly. The day before transfection, cells were passaged so 
that they would be 90-95% confluent at the time of transfection (if cells were being 
transfected for immunocytochemistry, they were passaged so that they would be 25% 
confluent at the time of transfection). On the day of transfection, 12tg DNA was 
diluted in 750tl Opti-MEM, and 18tl Lipofectamine 2000 was diluted in 750p1 
Opti-MEM and incubated for 5min at nt. The diluted DNA was then combined with 
the diluted Lipofectamine 2000, and the mixture was incubated for 20min at nt to 
allow DNA-Lipofectamine 2000 complex formation. Cells were washed with PBS to 
remove serum and antibiotics, and the DNA-Lipofectamine 2000 complexes were 
added with an additional 3 .5m1 Opti-MEM. Transfections were incubated for 4h at 
37°C in 5% CO2 before the transfection mix was replaced with the original cell 
culture medium. Transfected cells were then incubated for 24h at 37°C in 5% CO2 
before transgene expression analysis. The transfection efficiency was monitored in 
each experiment by the transfection of a plasmid encoding A. victoria GFP, and 
direct visualisation with a Zeiss Axiovert 40 CFL fluorescence microscope. 
Immunocytochemistry of mammalian cells 
The day before transfection, 1.5x 105  cells were passaged into 6 well plates that 
contained 22x22mni glass coverslips. On the day of transfection, cells were 
approximately 25% confluent and were transfected as described above. The day after 
transfection, coverslips were washed quickly 2x with PBS and the cells were fixed 
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by incubation in 4% (w/v) paraformaldehyde in PBS for 20mm. Coverslips were then 
washed 2x with PBS and the cells were permeabolised by incubation in 0.2% (v/v) 
Triton X-100 in PBS for 10mm. Coverslips were washed again 2x with PBS. Non-
specific binding sites were blocked by incubation in 3% (w/v) BSA in PBS for 
30mm. Coverslips were inverted (i.e. cell-side down) onto 1 20tl primary antibody in 
3% (wlv) BSA in PBS for lh, then washed 4x with PBS for 3mm. Coverslips were 
then inverted onto 120tl Alexa Fluor-conjugated secondary antibody for lh 
protected from light. Finally, coverslips were washed 4x with PBS for 3mm, then 
mounted in Vectashield mounting medium with DAPI (Vector Laboratories) onto a 
glass slide. Coverslip edges were sealed with clear varnish. Immunostained cells 
were examined with a Zeiss Axioscop fluorescence microscope and images were 
captured using IPLab v3.2 (Scanalytic) software. 
Primary and secondary Alexa Fluor-conjugated antibody dilutions were based on 
recommendations from the antibody supplier(s) and on empirical observations. 
2.2.7 Mouse procedures 
Timed matings and embryo recovery 
Timed matings were set up between mice of various genotypes in order to produce 
bd4Tdg, bd4Tdg, Mbd4Tdg and d4Tdg embryos. Female 
mice were examined every morning until a vaginal plug was identified; this was 
designated embryonic day (E) 0.5. At E1 0.5, pregnant female mice were euthanised 
by cervical dislocation, and the embryo-containing uteri were quickly dissected and 
transferred into PBS. Primary MEFs were then isolated as described in Section 2.2.6 
(sub-section 'Isolation of primary mouse embryonic fibroblasts'). 
Tissue recovery 
Mice were euthanised by cervical dislocation. The required tissues were quickly 
dissected and flash frozen in liquid N2. Tissues were then stored at —70°C. 
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2.2.8 DNA repair assays 
The in vitro DNA glycosylase assay 
In vitro DNA glycosylase assay oligonucleotide substrates were prepared by 
incubating a 2:1 molar ratio of unlabelled oligonucleotide to fluorescein-labelled 
oligonucleotide in 50mM NaCl in TE p117.4 at 100°C for 5mm, then cooling slowly 
to room temperature over 4-5h. The efficiency of oligonucleotide annealing was 
verified by non-denaturing PAGE. In vitro DNA glycosylase assay reactions 
contained 2pmol fluorescein-labelled oligonucleotide substrate (either with or 
without a base-base mismatch), lOpmol recombinant Mbd4 or 20tg nuclear extract, 
and lx Nicking buffer (the final NaC1 concentration was adjusted to 75mM in all 
reactions), and were incubated at 30°C for 16h. The reactions were stopped by the 
addition of NaOH to 90mM and incubation at, 90°C for 30mm; this also causes 
cleavage of the sugar-phosphate backbone at the site of base excision due to a 
elimination reaction. The unrepaired 60 base long fluorescein-labelled 
oligonucleotides (i.e. the substrate) and the repaired 23 base long fluorescein-labelled 
oligonucleotides (i.e. the product) were resolved by denaturing PAGE and were 
visualised using a Storm 860 Phosphorimager. 
The in vivo Big Blue cli mutation assay 
The in vivo Big Blue dl mutation assay was performed as outlined in the ?. select -W 
mutation detection system for Big Blue rodents handbook (Stratagene, 1998). The 
Big Blue assay involves five key steps: 1. Isolation of high molecular weight 
genomic DNA from Big Blue cells or tissues of interest. 2. In vitro packaging of the 
X phage shuttle vector into viable X phage. 3. X phage infection of E. coli and 
identification of putative cIT plaques. 4. Plaque verification. 5. PCR amplification 
and DNA sequencing of the mutated cli gene from a verified plaque. 
High molecular weight genomic DNA was isolated from Big Blue cells and tissues 
using the RecoverEase DNA Isolation kit as described in Section 2.2.1 (sub-section 
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'Genomic DNA isolation'). 8xl Big Blue genomic DNA was mixed with 22pi 
Transpack packaging extract (Stratagene) and was incubated at 30°C according to the 
manufacturer's instructions. The packaging extract excises the ? phage shuttle vector 
from the Big Blue genomic DNA and packages it into viable X phage. The efficiency 
of the in vitro packaging of X phage was assessed by using control Big Blue genomic 
DNA (Stratagene) in a packaging reaction. The X phage packaging reactions were 
diluted with 1.1 ml SM buffer and were stored on ice until used to infect E. co/i cells. 
E. co/i strain G1250 was used as the host strain for X phage infection. G1250 cells 
were recovered from a frozen glycerol stock by plating out onto a TB 1 agar plate 
- containing 50tg/ml kanamycin. The plate was incubated inverted at 30°C for 2d 
(G1250 is a relatively slow growing strain). The day before X phage infection, 
several G1250 colonies were inoculated into 1 Oml TB 1 broth supplemented with 
10mM MgSO4 and 0.2% (w/v) maltose. The liquid G1250 culture was incubated at 
30°C with vigorous shaking (250-300rpm) o/n. The following morning, the G1250 
cells were pelleted at 1,500g for 10min and a single cell suspension was prepared in 
lOmlvI MgSO4 to an OD600nm of 0.5. The G1250 cell suspensiOn is hereafter referred 
to as the G1250 plating culture. - 
200tl of the G1250 plating culture was incubated with five 200tl aliquots of the in 
vitro packaged X phage for 30min at nt. 2.5ml 55 °C TB  top agar was mixed with 
the X phage-adsorbed G1250 cells, and the mixture was quickly poured onto a TB 1 
agar plate and allowed to set. The screening plates were incubated inverted at 24°C 
for 46-48h (these are the selective conditions) to allow plaques to develop within the 
G1250 bacterial lawn. Control X phage (a mixture of wild type and cIT X phage; 
Stratagene) were also used to infect the G1250 plating culture to ensure that the 
selective conditions for cIT plaque formation were sufficient. 
After incubation at 24°C, the screening plates were inspected and putative cIT 
plaques were identified. The putative plaques were cored using a glass Pasteur 
pipette and the agar core was incubated in 500tl SM buffer for 2h at nt or 0/n at 4°C. 
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1 il eluted X phage was used to infect a freshly prepared G1250 plating culture, and 
the X phage-infected bacteria were plated out. The secondary screening plates were 
incubated inverted at 24°C for 46-48h to allow plaques to develop. After this 
incubation, the secondary screening plates were inspected for the presence or 
absence of cIT plaques. The X phage cli gene from verified plaques was amplified 
by PCR. A sterile pipette tip was used to transfer the plaque top agar into a tube 
containing 25tl dH20. The tube was then incubated at 100°C for 5min and 
centrifuged at 14,000rpm for 3mm. 25tl of the X phage DNA-containing H 20 was 
transferred to a Red Hot PCR containing cli forward and reverse primers. After PCR 
cycling, half of each 50tI PCR was analysed by agarose gel electrophoresis to 
determine whether a DNA product of the expected size was present. 5 [d of each of 
the positive PCRs was treated with Exonuclease I and SAP, and 2il exonuclease 
I/SAP-treated PCR was used in a DNA sequencing reaction. 
In order to determine the number of X phage screened per X phage packaging 
reaction, three 1:100 dilutions of X phage were also used to infect the original G1250 
plating culture. After plating out, the titre plates were incubated at 37°C for 1 6h 
(these are the non-selective conditions; all X phage enter the lytic pathway at 37°C 
resulting in plaque formation irrespective of the presence or absence of a cii 
inactivating mutation). Several packaging reactions were performed for each Big 
Blue genomic DNA sample so that a minimum of 300,000 ) phage were screened 
per genotype. 
The cli mutant frequency is the ratio of cIT plaques to the total number of X phage 
screened. The corrected cii mutation frequency is the ratio of independent cii 
mutations to the total number of X phage screened. 
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The activity of MBD4 and TDG in vivo 
3.1 Introduction 
The DNA glycosylases MBD4 and TDG can both excise thymine from 
TpG/5meCpG mismatches in vitro (Hendrich et al., 1999; Neddermann et al., 1996). 
These mismatches arise in vivo when 5meC undergoes spontaneous hydrolytic 
deamination to form thymine, therefore MBD4 and TDG may repair the product of 
5meC deamination in vivo. In order to investigate this hypothesis, Mbd4- and Tdg-
deficient mice were generated; Mbd4-deficient mice were generated by Millar et al. 
(2002), and Tdg-deficient mice were generated by a collaboration between Primo 
Schär (Jiricny laboratory, University of Zurich) and Jim Selfridge (Bird laboratory). 
These mice were then crossed with Big Blue mice, which have approximately 40 
copies of a 45.5kb X phage shuttle vector (Figure 3.1) integrated into chromosome 
number four in a head-to-tail array (Kohler et al., 1991). The presence of the X phage 
shuttle vector within the genomic DNA of Big Blue mice allows the frequency and 
spectrum of in vivo mutations within the ? phage cli gene to be assayed (Jakubczak 
et al., 1996). If MBD4 and TDG repair 5meC deamination-induced T:G mismatches 
in vivo, an increased frequency of C:G to T:A transition mutations at CpG 
dinucleotides would be expected to occur in the absence of either of these proteins. 
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Figure 3.1: The structure of the Big Blue ?. phage shuttle vector. The location of the X phage 
ci/ gene is indicated. This figure was adapted from the X select-cll mutation detection system 
for Big Blue rodents handbook (Stratagene, 1998). 
3.1.1 The in vivo Big Blue cli mutation assay 
In the in vivo Big Blue cIImutation assay, genomic DNA is isolated from Big Blue 
cells or tissues of interest and the X phage shuttle vector is packaged in vitro into 
viable X phage. Each X phage represents a single rescued cii gene. The cli gene can 
be used as a mutation reporter gene in the Big Blue assay because the activity of the 
cli protein is the critical factor in the X phage choice -between the lytic and the 
lysogenic pathways upon infection of a bacterial host cell (Herskowitz and Hagen, 
1980), as shown in Figure 3.2. When a wild type X phage infects a bacterial host cell, 
the cIT protein activates transcription of the ci repressor, and the ci repressor protein 
represses genes required for the X phage lytic pathway. This causes the X phage to 
enter the lysogenic pathway instead and a continuous bacterial lawn develops at 
24°C. In contrast, when a X phage with a mutated cli gene that encodes a non-
functional cIT protein infects a host cell, the ci repressor is not transcribed. In the 
absence of the ci repressor protein, genes required for the X phage lytic pathway are 
expressed. The X phage enters the lytic pathway and a transparent plaque forms 
within a bacterial lawn at 24°C. 
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Figure 3.2: The activity of the cli protein is the critical factor in the X phage lysisllysogeny 
decision. See the text for further details. This figure was adapted from the X select-cll 
mutation detection system for Big Blue rodents handbook (Stratagene, 1998). 
In the Big Blue assay, the in vitro packaged X phage are used to infect E. co/i strain 
G1250. The X phage-infected bacteria are plated out onto nutrient-poor TB 1 agar and 
the screening plates are incubated at 24°C for 46 to 48h (these are the selective 
conditions). G1250 has mutations in the hflB and hflA genes, which encode a cli 
protease and a positive regulator of the hflB-encoded cIT protease respectively 
(Kihara et al., 1997). The combination of the G1250 genotype and the nutrient-poor 
growth medium favours the X phage lysogenic pathway, and ensures that only X 
phage with a mutated cli gene enter the lytic pathway and give rise to a plaque 
within the bacterial lawn at 24°C. 
After incubation at 24°C, the Big Blue screening plates are inspected and putative 
cit plaques are identified. The k phage from these plaques are recovered and used to 
re-infect G 1250 bacteria at low density. The X phage-infected bacteria are then plated 
out onto TB 1 agar and the secondary screening plates are incubated at 24°C for 46 to 
48h. The verification of cuT plaques is necessary as plating artefacts can be mistaken 
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for small plaques. Additionally, plaques on the screening plates may contain 
contaminating wild type X phage, whereas plaques on the secondary screening plates 
should only contain c11 X phage. X phage DNA is isolated from secondary plaques 
and is used as a template for PCR amplification of the X phage cli gene, followed by 
DNA sequencing to identify the inactivating cli mutation. 
In order to determine the number of X phage screened per X phage packaging 
reaction, three 1:100 dilutions of X phage are also used to infect G1250 bacteria. 
After plating out, the titre plates are incubated at 37°C for 16h (these are the non-
selective conditions). The X phage gene that encodes the ci repressor protein contains 
a temperature sensitive mutation (c1857) that inactivates the ci protein at 37°C 
(Daniels et al., 1983), therefore all X phage on the titre plates enter the lytic pathway 
and form a plaque irrespective of the presence or absence of an inactivating cli 
mutation (see Figure 3.2). An overview of the in vivo Big Blue cli mutation assay is 
shown in Figure 3.3. 
CG1 D 
Big Blue mouse/cells 	 Genomic DNA 	 ) phage 	 E. coli infection 
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Figure 3.3: Overview of the in vivo Big Blue cli mutation assay. See the text for further 
details. 
An important advantage of using a transgene as a mutation reporter gene rather than 
an endogenous gene such as Hprt (Gocke et al., 1983) or Dib-] (Winton et al., 
1988), is that transgene mutation assays can be performed using any cells or tissues 
from a transgenic mouse, whereas endogenous gene mutation assays can usually only 
be performed in a particular cell population or tissue (e.g. the Hprt mutation assay 
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can only be performed in splenocytes and the Dib-] mutation assay can only be 
performed in the epithelium of the small intestine). A further advantage of the in vivo 
Big Blue cli mutation assay over endogenous gene mutation assays is that the cli 
transgene is only 294 bases long, which is significantly shorter than most 
endogenous genes (e.g. the Hprt gene is over 30kb long). The short length of the cli 
transgene therefore facilitates the identification of inactivating mutations by DNA 
sequencing. The main disadvantage of using transgenic mutation assays is that 
transgenes are not expressed in mouse tissues because of the absence of a 
mammalian promoter and a polyA addition site, and because they are usually present 
within highly methylated loci (Nohmi et al., 2000). Transgenic heterochromatic loci 
may therefore be repaired less efficiently than endogenoüs euchromatic loci, 
resulting in differences in mutation frequencies measured at transgenic and 
endogenous genes (Cosentino and Heddle, 2000). 
The Big Blue X phage shuttle vector contains two genes in addition to cli that can be 
used as in vivo mutation reporter transgenes; lacZ and lad. The use of lacZ or lacI as 
mutation reporter genes requires colour-based screening in the presence of X-gal, 
whereas inactivating cii mutations can be positively selected for in the absence of 
any expensive reagents (Jakubczak et al., 1996). Big Blue cii mutation assays are 
therefore more cost-effective than lacZ or lacI mutation assays Furthermore, the cli 
gene is shorter than both lacZ and lad, facilitating the identification of inactivating 
mutations. Despite being only 97 amino acids long, the cIT prOtein is highly sensitive 
to inactivation by mutation due to the presence of three domains (a helix-turn-helix 
DNA binding domain, an oligomerisation domain and a transcriptional activation 
domain), each of which are required for the activity of the protein, and which 
together span nearly the full length of the protein (Ho et al., 1988). Although the cli 
gene is relatively insensitive to large insertions and deletions (as the X phage shuttle 
vector must be within a limited size range in order to be packaged efficiently), it is 
sensitive to all other categories of mutation including transition and transversion 
mutations, and small insertions and deletions at the poly(G)6 and poly(A)6 
microsatellite sequences. Indeed, the cii gene is particularly sensitive to mutations at 
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CpG dinucleotides due to the presence of 22 CpG dinucleotides within the relatively 
short coding sequence. As the X phage shuttle vector genes are highly methylated in 
Big Blue mice (You et al., 1998), and the cli gene contains a high density of CpG 
dinucleotides, the cii gene is particularly well suited for use as a mutation reporter 
gene in this study. 
3.2 The activity of MBD4 in vivo 
3.2.1 The generation of Mbd4-deficient mice 
In order to determine whether MBD4 repairs the product of 5meC deamination in 
vivo, Mbd4-deficient mice were generated (Millar et al., 2002). A promoterless - 
geo cassette was inserted into the first intron of the Mbd4 gene in the ES cell line 
E14 TG2a (Figure 3.4). The 3-geo cassette contains a splice acceptor sequence (this 
causes a translational frameshift and the termination of Mbd4 mRNA translation after 
only 24 amino acids of the Mbd4 protein) and a polyadenylation signal. Correctly 
targeted ES cells were injected into C57BL/6 blastocysts, and chimaeric mice were 
crossed with C5713L16 mice. The resulting Mbd4 heterozygote (A4bd4) mice were 
intercrossed to produce Mbd4 knockout (Mbd4) mice. These mice are viable and 
fertile. 
1 	 2 	3 	 45 	67 	8 
13-geo cassette 	I - 
Figure 3.4: The structure of the Mbd4 genomic locus. Mbd4 exons are numbered 18: The 5' 
and 3' untranslated regions (UTR5) are denoted by open boxes, and the translated regions 
are denoted by solid boxes. The 3-geo cassette insertion site in the Mbd4 knockout allele is 
indicated. The wild type Mbd4 locus spans 10.87kb of genomic DNA. 
Mbd4 knockout mice were then crossed with Big Blue homozygote (Big Blue) 
mice. The resulting Mbd4 Big Blue mice were intercrossed and Mbd4 Big Blue 
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and Mbd4 Big Blue' 4 offspring were identified. The Big Blue genotyping PCR 
consists of PCR amplification of the lacI gene from the Big Blue X phage shuttle 
' 
vector, therefore mice identified as Big Blue
+  may be homozygous: 	(Big Blue +1+  ) or 
hemizygous (Big Blue) for the Big Blue X phage shuttle vector. Jim Selfridge set up 
these mouse crosses and performed the Mbd4 and Big Blue genotyping PCRs. 
As this study aimed to determine the effect that the absence of Mbd4 has on the 
repair of 5meC deamination-induced T:G mismatches in the X phage shuttle vector 
cli gene, it is critical that the 22 CpG dinucleotides within the cli gene are highly 
methylated. The presence of 5meC within a particular DNA sequence can be 
determined using, the bisulphite modification method of Frommer et al. (1992). In 
this protocol, sodium bisulphite is used to deaminate cytosine bases to form uracil in 
single-stranded DNA (5meC does not deaminate to form thymine under .  the 
experimental conditions used). After sodium bisulphite modification, the two DNA 
strands are no longer complementary and can be separately amplified using strand-
specific primers that are complementary to the sodium bisulphite-modified DNA. 
During this PCR amplification, the cytosine bases that were present in the DNA prior 
to bisuiphite modification amplify as thymine, and the 5meC bases (which are 
unchanged) amplify as cytosine. The PCR products are then cloned and the clones 
are sequenced to identify the methylation status of cytosine bases within the original 
single DNA strand. Catherine Millar (Bird laboratory, University of Edinburgh) 
performed bisulphite modification and sequencing of the X phage shuttle vector cli 
gene from the spleen and liver of Mbd4+1+  and Mbd'f I- Big Blue mice (Millar, 2002; 
Millar et al., 2002). On average, 95% of the cli gene CpG dinucleotides are 
methylated in spleen and 88% of the cii CpG dinucleotides are methylated in liver 
from these mice. There is no difference in the amount of cli CpG methylation in 
+1+ 	 -I- Mbd4 and Mbd4 mice. This therefore confirms that the cli gene is suitable for 
use as a mutation reporter gene in this study. 
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3.2.2 cli mutant frequencies 
+1+ 	 + 	 I- Mbd4 Big Blue and Mbd4 Big Blue ' mice were euthanised at 105 or 183 days 
of age, and the spleen and liver were recovered. Genomic DNA was isolated from 
these tissues and was used in the in vivo Big Blue cii mutation assay as described in 
Section 3.1.1. The number of A phage screened was calculated from 37°C titre plates, 
and putative cit plaques were identified on 24°C screening plates and verified on 
secondary screening plates. The cii mutant frequency was calculated by dividing the 
number of cit plaques by the number of A phage screened (i.e. the number of cii 
genes screened). The number of cit plaques identified and the cii mutant 
frequencies in wild type and Mbd4 knockout mice are shown in Table 3.1. Catherine 
Millar collected data from 6 of the 10 mice used in the Big Blue assay. 




cIT plaques cli mutant 
frequency 
(x10 5) 
A'Ibd4 	(3) 105, liver 656,165 15 2.29 
Mbd4 	(3) 105, liver 991,900 39 3.93 
bd4' (4) 105, spleen 1,340,250 45 3.36 
bd4' (4) 105, spleen 1,201,833 88 7.32 
Mhd4 	(1) 183, spleen 200,500 11 5.49 
Mbd4(1) 183, spleen 227 5433 38 16.71. 
Table 3.1: cli mutant frequencies in wild type and Mbd4 knockout mice. n = number of mice. 
The cli mutant frequency is the ratio of cif plaques to the total number of X phage screened. 
The cii mutant frequency in Mbd4 mice is significantly higher than in wild type 
mice (P < 0.0001 using a log likelihood ratio test; Peter Keightley, University of 
Edinburgh, carried out the statistical analysis of the Big Blue assay data), which is 
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consistent with the hypothesis that Mbd4 is involved in DNA repair in vivo. The cli 
mutant frequency in Mbd4 knockout spleen and liver is also significantly higher than 
in wild type spleen and liver respectively (P < 0.001). It is interesting to note that the 
cli mutant frequency is higher in 183 day old mice than in 105 day old mice. This is 
true for both wild type spleen (5.49x10 5 at 183 days of age compared to 3.36x10 5 
at 105 days of age) and Mbd4 knockout spleen (16.71x10 5 at 183 days of age 
compared to 7.32x10 5  at 105 days of age). Similar age-related increases in mutant 
frequencies have been shown to occur in a number of tissues including spleen (Ono 
et al., 2000), and the accumulation of mutations has been proposed to contribute to 
the ageing process (Lombard et al., 2005). 
3.2.3 Corrected cli mutation frequencies 
In order to identify the inactivating cli mutations, X phage DNA was isolated from 
each of the 236 cIF plaques from wild type and Mbd4 knockout mice, and the cii 
gene was PCR amplified and bi-directionally sequenced. All of the X phage from 
wild type and Mbd4 knockout mice had a cli mutation that would give rise to an 
amino acid change in the encoded cIT protein. A number Of cli mutations were 
recovered several times from a particular tissue. There are two possible origins for 
these clonal mutations: • 1. The same cli mutation occurred independently in different 
X phage shuttle vectors, either within a single cell or within different cells. 2. The cli 
mutation occurred once in al phage shuttle vector within a single cell, which then 
underwent clonal expansion to form a population of cells each containing the same 
mutation. In order to correct for the second possibility, the additional occurrences of 
a cli mutation from a particular tissue were omitted from the analysis and the number 
of 'corrected cli mutations' was calculated. This may be an underestimate of the true 
number of independent cli mutations as the same dl mutation may have occurred 
independently in different X phage shuttle vectors within a particular tissue. The 
corrected cli mutation frequency was then calculated by dividing the number of 
corrected cli mutations by the number of X phage screened. The number of corrected 
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cli mutations and the corrected cii mutation frequencies in wild type and Mbd4 
knockout mice are shown in Table 3.2. 










Mbd4 	(3) 105, liver 656,165 15 2.29 
Mbd4(3) 105, liver 991,900 32 3.23 
IvIbd4 	(4) 105, spleen 1,340,250 38 2.84 
bd4' (4) 105, spleen 1,201,833 39 3.25 
Abd4' (1) 183, spleen 200,500 11 5.49 
bd4'(1) 183, spleen 227,433 27 11.87 
Table 3.2: Corrected cii mutation frequencies in wild type and Mbd4 knockout mice. n = 
number of mice. The corrected cli mutation frequency is the ratio Of corrected cli mutations 
to the total number of X phagescreened. 
The corrected cii mutation frequency in Mbd4 knockout mice is significantly higher 
than in wild type mice (P < 0.05). However, the difference between the corrected cli 
mutation frequencies is smaller than the difference between the cii mutant 
frequencies (Figure 3.5). This is because the Mbd4 knockout tissues had a high 
frequency of clonal mutations, whereas the wild type tissues had a low frequency of 
clonal mutations. Interestingly, all of the clonal mutations in the Mbd4 knockout 
tissues were C:G to T:A transition mutations at CpG sites, whereas the clonal 
mutations in the wild type tissues consisted of several different categories of 
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U Mbd4' 
- 	 -- U Mbd44- 
Corrected 
cli mutation 
Figure 3.5: cii mutant and corrected cli mutation frequencies in wild type and Mbd4 knockout 
mice 
The higher cli mutant and corrected cii mutation frequencies in Mbd4 knockout 
mice relative to wild type mice support the hypothesis that Mbd4 is involved in DNA 
repair in vivo. It should be borne in mind that the true cii mutation frequency is likely 
to lie between the cli mutant and the corrected cii mutation frequencies because of 
the correction for clonal expansion that was applied to the total number of cii 
mutations identified. 
3.2.4 cli mutation frequencies at CpG dinucleotides 
The cii mutations that were identified in wild type and Mbd4 knockout mice were 
categorised as CpG dinucleotide mutations or non-CpG dinucicotide mutations. The 
total and corrected CpG mutation frequencies in wild type and Mbd4 knockout mice 
are shown in Figure 3.6. The total and corrected CpG mutation frequencies in Mbd4 
knockout mice are higher than in wild type mice. Again, the difference between the 
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difference between the uncorrected data (the total CpG mutation frequencies). 
Nonetheless, the higher total and corrected CpG dinucleotide mutation frequencies in 
Mbd4 knockout mice relative to wild type mice are consistent with the Mbd4-
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Figure 3.6: Total and corrected CpG mutation frequencies in wild type and Mbd4 knockout 
mice 
3.2.5 cli mutational spectra 
If Mbd4 repairs the product of 5mcC deamination in vivo. Mbd4 knockout mice 
would be expected to have an increased frequency of C:G to TA transition mutations 
at CpG dinucleotides. The cli mutations that occurred within wild type and Mbd4 
knockout mice were therefore further sub-categorised as C:G-T:A or T:A-C:G 
transition mutations; G:C-T:A, G:C-C:G, T:A-A:T or T:A-G:C transversion 
mutations; +/—lbp frameshift mutations; or deletions of a2bp. The corrected cli 
mutational spectra in wild type and Mbd4 knockout mice are shown in Figure 3.7. 
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Figure IT Corrected cli mutational spectra in Mbd4 and Mbd41 Big Blue mice. CpG 
mutations are shown in black, and non-CpG mutations are shown in grey. +1-1 = +1- lbp 
frameshift mutation, deletion = deletion of 2w2bp. 
The different categories of mutation occurred at similar frequencies in wild type and 
Mbd4 knockout mice, with only one exception; C:G to T:A transition mutations at 
CpG dinucleotides occurred at a three-fold higher frequency in Mbd4 knockout mice 
than in wild type mice. This difference is highly significant (P < 0.0001). The 
frequencies of mutations other than C:G to T:A transition mutations at CpG sites did 
not differ significantly between Mbd4 knockout and wild type mice (P > 0.1). As 
C:G to T:A transition mutations can arise at methylated CpG sites when 5meC 
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undergoes deamination, the high frequency of C:G to T:A transition mutations at 
CpG sites in Mbd4 knockout mice confirms the hypothesis that Mbd4 repairs 5meC 
deamination- induced T:G mismatches in vivo. 
Data from the Big Blue assays using wild type and Mbd4 knockout mouse tissues 
were submitted as part of the requirement for an MSc by Research in the Life 
Sciences, which is awarded after the first year of the Wellcome Trust Four Year PhD 
Programme 'The cellular and molecular basis of disease'. 
3.3 The activity of TDG in vivo 
Although Mbd4 knockout mice have a significantly increased frequency of C:G to 
T:A transition mutations at CpG sites, these mice may retain a DNA repair activity 
that can repair TpG/5meCpG mismatches. A complex calculation based on several 
factors including the number of C:G to T:A transition mutations at cli CpG sites that 
would cause an amino acid change in the cli protein, the mcthylation status of the cli 
CpG sites in the Big Blue mice and the dcamination rate of 5meC in double-stranded 
DNA at 37°C as measured by Shen et al. (1994), determined that the frequency of 
detectable C:G to T:A transition mutations at cii CpG sites in the absence of repair 
would be 1.25x10 4 in 105 day old Big Blue mice (Millar, 2002; Millar etal., 2002). 
If this calculation is accurate, the results of the Big Blue assays presented in Section 
3.2 suggest that wild type mice can repair TpG/5meCpG mismatches with 96% 
efficiency, and Mbd4 knockout mice can repair TpG/5mcCpG mismatches with 88% 
efficiency. The in vitro substrate specificity of Tdg suggests that Tdg may mediate 
the residual repair of TpG/5meCpG mismatches in Mbd4 knockout mice. If this 
hypothesis is correct, and both Mbd4 and Tdg repair 5meC deamination-induced T:G 
mismatches with efficiencies of approximately 80%, a combined repair efficiency of 
96% would result. 
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3.3.1 The expression of MBD4 and TDG in mouse and human 
tissues 
If both MBD4 and TDG contribute to the repair of 5meC dcami nation- induced T:G 
mismatches in vivo, the relative importance of MBD4 and TDG may vary in different 
tissues depending on the levels of MBD4 and TDG expression. However, a 
systematic investigation of MBD4 and TDG expression in a range of adult tissues 
has not been reported. Mouse Mbd4 transcripts are likely to be expressed at a very 
low level as they could not be detected on a northern blot of total RNA from various 
mouse tissues, although mouse and human MBD4 transcripts could be detected by 
RT-PCR (Hendrich and Bird, 1998). In situ hybridisation experiments showed that 
mouse Tdg transcripts are expressed ubiquitously and relatively uniformly during 
embryonic development (Niederreither et al., 1998), and a northern blot-based 
analysis of human TDG RNA levels relative to fl-act in RNA levels suggests that 
human TDG transcripts are expressed ubiquitously and uniformly in several human 
adult tissues (Sard et al., 1997). 
In order to perform a systematic analysis of mouse Mbd4 and Tdg transcript 
expression, total RNA was isolated from heart, brain, liver, spleen, kidneys, lung, 
thymus, testes and ovaries of C57BL/6 mice. The mouse RNA samples were 
resolved by denaturing gel electrophoresis to verify sample quality (Figure 3.8A), 
and were treated with DNase to remove any DNA contamination. A FirstChoice 
Human Total RNA Survey Panel, which contains pools of DNase-treated total RNA 
from human heart, brain, liver, spleen, kidneys, lung, thymus, testes and ovaries, was 
purchased from Ambion. The mouse and human RNA samples were reverse 
transcribed to produce mouse and human cDNA panels. The efficiency of the DNase 
treatments and the reverse transcription reactions was confirmed by a test PCR of the 
mouse and human cDNA panels using primers specific to the commonly used 
reference gene glyceraldehyde 3-phosphate dehydrogenase (GAPDI-J) as shown in 
Figure 3.813. 
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Figure 3.8: The preparation of mouse and human tissue cDNA panels. (A) Total RNA from a 
panel of mouse tissues. Total RNA was isolated from a panel of mouse tissues, and was 
resolved by denaturing gel electrophoresis. The 28S and 18S rRNAs are indicated. (B) Test 
RT-PCR of mouse and human total RNA using GAPDH primers. +1- indicates 
presence/absence of reverse transcriptase (RT) in the reverse transcription reaction; dH 20 
indicates the water only PCR control. 
Real-time PCR was then performed to determine the levels of MBD4 and TDG 
cDNAs relative to the level of GAPDH reference gene eDNA in the mouse and 
human eDNA panels (Figure 3.9). Although at first glance the mouse and human 
expression profiles of MBD4 and TDG (both relative to GAPDH) appear very 
different, there are several similarities between these profiles, e.g. low levels of 
mouse and human MBD4 transcripts are present in the heart and brain, and high 
levels are present in the spleen and testes. Similarly, low levels of mouse and human 
TDG transcripts are present in the heart and kidneys, and high levels are present in 
the lung and thymus. However, as with all real-time PCR results using different 
tissues, these results may not accurately reflect the absolute levels of M8D4 and 
TDG transcripts as the level of the GAPDH transcript may vary between the nine 
tissues tested (Radonic ci al., 2004). It is perhaps more informative to compare the 
relative expression of MBD4 and TDG transcripts within a single mouse or human 
tissue. Somewhat surprisingly, all nine human tissues express more MBD4 than TDG 
transcripts. In mouse tissues, the relative levels of Mbd4 and Tdg transcripts are more 
B 
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varied; testes express more Mbd4 than Tdg transcripts, several tissues (including 
liver) express more Tdg than Mbd4 transcripts, and spleen expresses a similar 
amount of Mbd4 and Tdg transcripts. The expression levels of Mbd4 and Tdg 
transcripts in mouse spleen and liver are of particular interest as these tissues were 
shown to have increased mutation frequencies in the absence of Mbd4. It would be 
interesting to analyse the level of Mbd4 and Tdg protein expression in the same 
panel of mouse tissues (and in particular in spleen and liver) to determine whether 
the observed Mbd4 and Tdg transcript expression levels correlate with protein 
expression levels. 




































Figure 3.9: Real-time RT-PCR analysis of MBD4 and TDG transcript expression in mouse 
and human tissues. The expression of MBD4 and TDG transcripts relative to GAPDH 
transcripts are shown. The error bars indicate the standard deviation of the mean. 
3.3.2 The generation of Tdg-deficient mice 
In order to determine whether TDG contributes to the repair of 5meC deamination-
induced T:G mismatches in vivo, a promoterless 3-geo cassette was inserted into the 
Tdg locus in E14 TG2a ES cells by Primo Schär (Figure 3.10). The insertion of the 
3-geo cassette (which contains a splice acceptor sequence and a polyadenylation 
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signal) causes the termination of transcription after exon 5 of Tdg, and the deletion of 
exons 6 and 7 of the Tdg locus. Correctly targeted ES cells were injected into 
C57BL/6 blastocysts, and chimaeric mice were crossed with C57BL/6 mice by Jim 
Selfridge. The resulting Tdj' mice were then intercrossed in order to produce 
Tdg - mice. However, when the first 31 pups from this cross were genotyped, no 
Tdg nulls were identified (10 of the pups were wild type and 21 were Tdg 
heterozygotes), suggesting that the absence of Tdg results in embryonic lethality. 
This was verified by timed matings between Tdg
+1-  mice and the recovery of 
embryos at different embryonic stages. The embryos were examined with respect to 
morphology and size, and the Tdg genotype was determined by PCR. The ratios of 
Tdg, Tdg and Tdg embryos recovered on different embryonic days suggested 
that Tdg knockout-induced embryonic lethality occurs between El 1.5 and E16.5 
(Table 3.3). 
1 	 2 	34 	567 	89 	10 
Figure 3.10: The structure of the Tdg genomic locus. Tdg exons are numbered 1-10. The 5' 
and 3' UTRs are denoted by open boxes, and the translated regions are denoted by solid 
boxes. The -geo cassette insertion site in the Tdg knockout allele is indicated (the insertion 
of the cassette causes deletion of exons 6 and 7). The wild type Tdg locus spans 20.89kb of 
genomic DNA. 
M. 




Td +/+  
+1- 
Me 
-I- Tdg Ratio of 
genotypes 
E8.5 5 11 4 1:2:1 
E9.5 5 6 4 1:1:1 
E10.5 2 10 3 1:5:1 
El 1.5 1 9 6 1:9:6 
E16.5 2 7 0 1:3:0 
- 10 21 0 1:2:0 
Table 3.3: The pre-natal and post-natal recovery of Tdg, Tdg and Tdg embryos. These 
data were collected by Jim Selfridge. 
The E10.5 and E11.5 Tdg knockout mouse embryos were also used to isolate 
primary mouse embryonic fibroblast cell lines; all three of the E10.5 Tdg embryos 
were successfully cultured, whereas only two of the six Eli .5 Tdg embryos could 
be cultured. This suggests that Tdg knockout-induced embryonic lethality actually 
occurs between El0.5 and El 1.5, a hypothesis which is supported by the observation 
that the reabsorption of Tdg embryos appears to be at a relatively advanced stage 
by E12.5 (Figure 3.11). E10.5 Tdg embryos are normal with respect to morphology 
and size. 





Figure 311: Tdg and Tdg embryos at El 0.5 and E12.5. These photographs were taken 
and provided by Jim Selfridge. 
3.3.3 The isolation of Mbd4' Tdg', Mbd4 Tdg', Mbd4' 
Tdg and Mbd4T Tdg' Big Blue cell lines 
In order to circumvent the problem of Tdg knockout-induced embryonic lethality, 
wild type and Tdg knockout cell lines were isolated from ElO.5 embryos, and the 
frequency and spectrum of mutations in the cell lines was determined by the in vivo 
Big Blue cli mutation assay. An Mbd4 knockout cell line was included in this study 
in order to allow the frequencies and spectra of mutations in the wild type and Mbd4 
knockout cell lines to be compared to the frequencies and spectra of mutations in 
wild type and Mbd4 knockout spleen and liver. Finally, an Mbd4/Tdg double 
knockout cell line was also included in this study. If the hypothesis that both Mbd4 
and Tdg act to repair the product of 5meC deamination in vivo is correct, the Mbd4 
and Tdg single knockout cell lines would be expected to have increased frequencies 
of C:G to T:A transition mutations at CpG sites. Furthermore, the Mbd4/Tdg double 
knockout cell line (which should lack any DNA repair activity capable of excising 
thymine from TpG/5meCpG mismatches) would be expected to have an even higher 
frequency of C:G to T:A transition mutations at CpG sites than either the Mbd4 or 
Tdg single knockout cell lines. 
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Timed matings were set up between mice of various genotypes in order to produce 
Mbd4 Tdg, Mbd4 Tdg, Mbd4 Tdg and Mbd4 Tdg Big Blue 
embryos. At E1 0.5, pregnant females were euthanised and the embryo-containing 
uteri were removed. The embryos were dissected from the uteri and incubated with 
trypsin for 20mm, before the addition of Amniomax cell culture medium and 
disaggregation of the embryos by gentle pipetting. The embryonic cells were then 
transferred into cell culture plates and incubated at 37°C in 5% CO2. Amniomax 
medium is intended for use in the culture of small numbers of human amniotic fluid 
cells prior to in vitro prenatal diagnostic tests, and is therefore an ideal nutrient-rich 
growth medium for the culture of primary mouse embryonic cells. When the 
embryonic cells were confluent, they were passaged to 25% confluency, and 
genomic DNA was isolated from the remaining cells and used as a template in Mbd4, 
Tdg and Big Blue genotyping PCRs. Primary embryonic cell lines were isolated from 
over 70 embryos. The results of Mbd4 and Tdg PCR genotyping of a wild type, 
Mbd4 knockout, Tdg knockout and an Mbd4/Tdg double knockout cell line are 
shown in Figure 3.12, and the results of Big Blue lad and cli PCR genotyping of the 
same cell lines are shown in Figure 3.13. 
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Figure 3.12: Mbd4 and Tdg genotyping PCRs of Mbd4' Tdg, Mbd4 Tdg', Mbd4 
Tdg' and Mbd4 Tdg cell lines. (A) Mbd4 genotyping. The Mbd4 wild type allele was 
amplified using M4JF and M4JR primers (M4JF and M4JR anneal to Mbd4 exons 1 and 2 
respectively). The Mbd4 knockout allele was amplified using NeoF and M4JR primers (NeoF 
and M4JR anneal to the i-geo cassette and Mbd4 exon 2 respectively). Control PCRs 
containing no DNA (-ye), and Mbd4", Mbd4 and Mbd4 1 DNA are also shown. (B) Tdg 
genotyping. The Tdg wild type allele was amplified using mTdgEx5 and mTdgEx6L primers 
(mTdgEx5 and mTdgEx6L anneal to Tdg exons 5 and 6 respectively). The Tdg knockout 
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allele was amplified using mTdgEx5 and NeoR primers (mTdgEx5 and NeoR anneal to Tdg 
exon 5 and the -geo cassette respectively). Control PCRs containing no DNA (-ye), and 
Tdg, Tdg and Tdg DNA are also shown. 
S' I 
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Figure 3.13: Big Blue genotyping PCRs of Mbd4' Tdg, Mbd4 Tdg', Mbd4 Tdg and 
Mbd4 Tdg cell lines. The X phage lacl gene was amplified using BigBIueF and BigBlueR 
primers, and the cli gene was amplified using OF and diR primers. Control PCRs 
containing no DNA (-ye), and Big Blue' and wild type DNA are also shown. 
The Big Blue primary cell lines were transformed with a recombinant retrovirus that 
encodes the SV40 large I antigen (Jat et al., 1986) in order to enable the cells to be 
cultured for an extended period of time (and therefore to allow the deamination of 
5meC bases within the c/I transgcne). The cell lines retained fibroblast-like 
morphologies after SV40-mediated transformation (Figure 3.14), as has been seen 
previously (Jat et al., 1986). The transformed cell lines were adapted from growing 
in Amniomax medium to growing in GMEM with 20% FBS, then GMEM with 10% 
FBS, and were cultured by passaging to approximately 25% confluency every two 
days until the cell lines had been cultured for 105 days in total. This was to allow the 
frequencies and spectra of mutations in the wild type and Mbd4 knockout cell lines 
to be compared to the frequencies and spectra of mutations in spleen and liver from 
wild type and Mbd4 knockout mice of 105 days of age. Although Big Blue cell lines 
have been isolated from Big Blue adult mice and embryos previously (Wyborski, 
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1997; Ercxson et al., 1999), these cell lines have only been utilised in short-term 
mutagenesis studies, therefore the effect that an extended period of culture would 
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Figure 3.14: Mbd4 Tdg, Mbd4 Tdg, Mbd4 Tdg and Mbd4 Tdg' cell lines. A 
phase contrast microscope was used to visualise and photograph the cells. 
3.3.4 The characterisation of the Big Blue cell lines 
Expression of Mbd4 and Tdg 
The expression of Mbd4 and Tdg was analysed in the Mbd4 Tdg, Mbd4 - 
Tdg, Mbd4' Tdg and Mbd4 Tdg cell lines by RT-PCR and western blotting 
(Figure 3.15). The results show that both Mbd4 and Tdg are expressed in the wild 
type cell line, Tdg alone is expressed in the Mbd4 knockout cell line, Mbd4 alone is 
expressed in the Tdg knockout cell line, and neither Mbd4 or Tdg are expressed in 
the Mbd4/Tdg double knockout cell line. These cell lines are therefore suitable for 
use in the analysis of Mbd4 and Tdg DNA repair activity. 
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Figure 3.15: Analysis of Mbd4 and Tdg expression in Mbd4' Tdg Mbd4 Tdg', Mbd41* 
Tdg and Mbd4 Tdg' cell lines. (A) RT-PCR analysis of Mbd4 and Tdg transcript 
expression. Gapdh transcript expression is shown as a positive control. +/- indicates 
presence/absence of reverse transcriptase (RT) in the reverse transcription reaction; dH 20 
indicates the water only PCR control. (B) Western blot analyses of Mbd4 and Tdg protein 
expression. The western blots were both cut in half and hybridised with an anti-PCNA 
antibody as a loading control. 
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A phage cli trans gene CpG methylation 
The X phage shuttle vector cli gene from the Big Blue cell lines was subject to 
bisulphite modification and sequencing to ensure that the 22 cii CpG dinucleotides 
are methylated (Figure 3.16). As in the Big Blue mice, the ci! gene CpG sites are 
highly methylated in the Big Blue cell lines. On average, 97% of the cli gene CpG 
dinucicotides are methylated in the wild type cell line, 95% are methylated in the 
Mbd4 knockout cell line, 96% are methylated in the Tdg knockout cell line and 93% 
are methylated in the Mbd4/Tdg double knockout cell line. The high level of cii CpG 
methylation confirms that that cii gene can be used to measure the repair of 5meC 
deami nation- induced TpG/5meCpG mismatches in these cell lines. 
M. 




























Figure 3.16: ci! gene CpG methylation in Mbd4 Tdg, Mbd4' Tdg', Mbd4 Tdg and 
Mbd4' Tdg' cell lines. The methylation status of the 22 CpGs within the cli gene was 
determined by bisulphite modification of DNA followed by DNA sequencing. Methylated 
CpGs are denoted by solid squares, non-methylated CpGs are denoted by open squares. 
The number of sequenced clones with a particular CpG methylation pattern is indicated. 
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3.3.5 cli mutant frequencies 
Genomic DNA was isolated from the Mbd4 Tdg41 , Mbde Tdg', bd4' Tdg 
and bd4' Tdg cell lines that had been cultured for 105 days, and used in the in 
vivo Big Blue cli mutation assay. The number of X phage screened was calculated 
from 37°C titre plates, and putative c11 plaques were identified on 24°C screening 
plates and verified on secondary screening plates as previously. The cli mutant 
frequency was calculated by dividing the number of cit plaques by the number of X 
phage screened. The number of cIT plaques identified and the cli mutant frequencies 
in the Big Blue cell lines are shown in Table 3.4. 
Genotype A. phage screened cIt plaques cli mutant 
frequency (x 1O) 
821,667 93 11.32 
Mbd4Tdg 391,333 78 19.93 
Mbd4 	Tdg 475,733 67 14.08 
bd4'Tdg 339,667 53 15.60 
Table 3.4: cli mutant frequencies in Mbd4 Tdg, Mbd4 Tdg", Mbd4' Tdg and 
Mbd4 Tdg cell lines. The cii mutant frequency is the ratio of dr plaques to the total 
number of X phage screened. 
A comparison of the cii mutant frequencies in the Big Blue mouse cell lines and the 
Big Blue mouse tissues shows that the cli mutant frequencies in the cell lines are 
higher than the cli mutant frequencies in the tissues of mice of 105 days of age, e.g. 
the cli mutant frequency in the wild type cell line is over three times higher than the 
ell mutant frequencies in the spleen and liver of wild type mice of 105 days of age. 
This is likely to be caused by the rapid fixation of mutations in the Big Blue cell lines 
as a result of continuous cell division. When the cli mutant frequencies in the Big 
Blue cell lines are compared to each other, it is interesting to note that the cli mutant 
frequency in the Mbd4 knockout cell line is nearly double that in the wild type cell 
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line, which would appear to be in agreement with the Big Blue mouse data, and to 
reflect the involvement of Mbd4 in DNA repair in vivo. However, the cii mutant 
frequencies in the Tdg knockout and Mbd4/Tdg double knockout cell lines are 
intermediate between those of the wild type and 1\4bd4 knockout cell lines, therefore 
the cii mutant frequencies in all four of the Big Blue cell lines are not consistent with 
either Mbd4 alone, or both Mbd4 and Tdg, being involved in DNA repair in vivo. 
3.3.6 Corrected cli mutation frequencies 
In order to identify the inactivating cii mutations, X phage DNA was isolated from 
each of the 291 c11 plaques recovered from the Mbd4 Tdg, Mbd4 Tdg, 
Mbd4' Tdg and Mbd4 Tdg cell lines. The X phage cii gene was then PCR 
amplified and bi-directionally sequenced. In the previous Big Blue assays on mouse 
tissues, all of the X phage recovered had a cii mutation that gives rise to an amino 
acid change in the encoded cii protein. However, in these Big Blue assays on mouse 
cell lines, 19 of the 291 X phage that were recovered had a wild type cii gene (13 of 
the 19 cIt X phage were recovered from the Mbd4 Tdg' cell line, five were 
recovered from the Mbd4 Tdg cell line and one was recovered from the Mbd4 
Tdg cell line). In an attempt to identify the mutation that caused these cIt X phage 
to form a plaque within a bacterial lawn, the ci gene from the 19 cIt ). phage was 
PCR amplified and sequenced (X phage with a wild type cii gene can give rise to a 
plaque within a bacterial lawn if the ci gene contains a ci protein-inactivating 
mutation; see Figure 3.2). Each of the X phage contained the c1857 temperature 
sensitive mutation as expected (this mutation is present within the Big Blue X phage 
shuttle vector to facilitate the quantitation of in vitro packaged X phage). The c1857 
temperature sensitive mutation is a G to A transition mutation at nucleotide 199 of 
the ci coding sequence, and results in the replacement of alanine with threonine at 
amino acid 67 of the ci protein (Daniels et al., 1983). No ci mutations other than the 
cI857 temperature sensitive mutation were identified in any of the 19 cIt X phage. 
The mutation(s) that cause these X phage to give rise to plaques within a bacterial 
lawn at 24°C are therefore not within the cli or ci coding sequences (or within the 
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PRE DNA sequence that the cli protein binds to in order to bring about transcription 
of the ci gene, as this DNA sequence overlaps with the cii coding sequence). An 
untested possibility that could explain the formation of plaques by the cIt ct X 
phage is that the OR  DNA sequence that the ci protein binds to in order to repress 
genes required for lysis contains a mutation that prevents ci protein binding. 
The number of corrected cii mutations in the Mbd4
+1+  Tdg+1+  , Mbd4-I-  Tdg+1+  
Mbd4' Tdg and Mbd4 Tdg' cell lines was calculated by omitting the 
additional occurrences of a cii mutation from a particular cell line when that 
mutation was recovered more than once. As discussed previously, this may result in 
an underestimate of the true number of independent cli mutations. The corrected cli 
mutation frequency was then calculated by dividing the number of corrected cii 
mutations by the number of X phage screened. The number of corrected cli mutations 
and the corrected cli mutation frequencies in the Big Blue cell lines are shown in 
Table 3.5. 
Genotype X phage screened Corrected cli Corrected cli 
mutations mutation 
frequency (x 10) 
bd4Tdg' 821,667 51 6.21 
bd4Tdg 391,333 	. 39 9.97 
Mbd4 	Tdg 475,733 42 8.83 
Mbd4 1 Tdg 339,667 35 10.30 
Table 3.5: Corrected c/I mutation frequencies in cell lines lacking Mbd4 and/or Tdg. The 
corrected c/I mutation frequency is the ratio of corrected c// mutations to the total number of 
X phage screened. 
The correction for the occurrence of clonal mutations causes a large difference 
between the cii mutant and the corrected cli mutation frequencies in each of the Big 
Blue cell lines (Figure 3.17); 45% of the cii mutations in the wild type cell line were 
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clonal, 50% of the cli mutations in the Mbd4 knockout cell line were clonal, 37% of 
the cli mutations in the Tdg knockout cell lines were clonal, and 34% of the ci! 
mutations in the Mbd4/Tdg double knockout cell line were clonal. The clonal 
mutations in each of the Big Blue cell lines included several different categories of 
mutation including C:G to T:A transition mutations at CpG dinucleotides irrespective 
of genotype. The corrected cli mutation frequency in the Mbd4 knockout cell line is 
higher than in the wild type cell line (as is the uncorrected cli mutant frequency), 
which appears to be consistent with the Big Blue mouse data and to suggest that 
Mbd4 is involved in DNA repair in vivo. However, the corrected cii mutation 
frequencies in the Mbd4 knockout, Tdg knockout and Mbd4/Tdg double knockout 
cell lines are similar, therefore the corrected cli mutation frequencies in all four of 
the Big Blue cell lines are not consistent with either Mbd4 alone, or both Mbd4 and 
Tdg, acting to repair DNA in vivo. 
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Figure 3.17: cli mutant and corrected cli mutation frequencies in Mbd4 Tdg, Mbd4 
Tdg", Mbd4 Tdg4 and Mbd4 Tdg cell lines. 
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3.3.7 cli mutation frequencies at CpG dinucleotides 
The cli mutations that occurred within the .tIb14 TrI," . .ih04 - Tilg, Mbd4 
Tdg ° and Mbd4 Tdg ° cell lines were categorised as CpG dinucleotide mutations 
or non CpG di nucleotide mutations. The total CpG mutation and corrected CpG 
mutation frequencies in the Big Blue cell lines are shown in Figure 3.18. The total 
CpG mutation frequencies in the Big Blue cell lines are consistent with the 
involvement of Mbd4, but not Tdg, in the repair of mutations at CpG sites (as the 
total CpG mutation frequencies in the Mbd4 knockout and Mbd4ITdg double 
knockout cell lines are higher than in the wild type and Tdg knockout cell lines). 
However, the corrected CpG mutation frequencies (which are similar in the wild 
type, and the Mbd4 and Tdg single knockout cell lines, but over twice as high in the 
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Figure 3.18: Total and corrected CpG mutation frequencies in Mbd4' Tdg', Mbd4 Tdg+e 
Mbd4' Tdg° and Mbd4° Tdg ° cell lines. 
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3.3.8 cli mutational spectra 
When the Big Blue assay was performed using wild type and Mbd4 knockout mouse 
tissues, the frequency of C:G to TA transition mutations at CpG sites was higher in 
Mbd4 knockout tissues than in wild type tissues, confirming that Mbd4 can repair 
5meCpGITpG mismatches in vivo. The Mbd4 knockout cell line was included in this 
study to verify that the effect of the absence of Mbd4 on the frequency of C:G to TA 
transition mutations at CpG sites is recapitulated in cells that have undergone an 
extended period in culture, and therefore to ascertain whether cultured cells are a 
suitable experimental system in which to investigate the accumulation of mutations 
i 
j-.  
n the absence of Tdg. The cli mutations that occurred within Mbd4
+1+  Tdg+1+  
Mbd4 Tdg, Mbd4 Tdg' and Mbde Tdg' cell lines were therefore further 
sub-categorised as C:G-T:A or T:A-C:G transition mutations; G:C-T:A, G:C-C:G, 
T:A-A:T or T:A-G:C transversion mutations; +/—lbp frameshift mutations; insertions 
of 2t2bp; deletions of a2bp; or complex mutations involving two proximal base pairs. 
The total and corrected cii mutational spectra in the Big Blue cell lines are shown in 
Figure 3.19 and Figure 3.20 respectively. 
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Figure 3.19: Total cli mutational spectra in Mbd4' Tdg', Mbd4 Tdg, Mbd4' Tdg' 
and Mbd4' Tdg cell lines. CpG dinucleotide mutations are shown in black, and non-CpG 
dinucleotide mutations are shown in grey. +1-1 +1- lbp frameshift mutation, insertion = 
insertion of a2bp, deletion = deletion of a2bp, 2bp = mutation of 2 proximal base pairs. 
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Figure 3.20: Corrected cli mutational spectra in Mbd4 Tdg, Mbd4 Tdg', Mbd4 
Tdg' and Mbd4 Tdg cell lines. CpG dinucleotide mutations are shown in black, and 
non-CpG dinucleotide mutations are shown in grey. +1-1 = +1- lbp frameshift mutation, 
insertion = insertion of a2bp, deletion = deletion of 2-2bp, 2bp = mutation of 2 bases. 
The frequencies of total C:G to T:A transition mutations at CpG sites in the Big Blue 
cell lines appear to be consistent with the Mbd4-mediated repair of 5meC 
deamination-induced T:G mismatches (Figure 3.19). However, the frequencies of 
corrected C:G to T:A transition mutations at CpG sites do not support this conclusion 
(Figure 3.20). Furthermore, both the total and corrected cli mutational spectra of the 
Big Blue cell lines contain a high level of 'mutational noise', e.g. the frequencies of 
G:C to C:G transversion mutations vary between the Big Blue cell lines irrespective 
of either Mbd4 or Tdg genotype. This is in contrast with the cli mutational spectra of 
wild type and Mbd4 knockout mice, where the only significant difference is a three-
fold increase in the frequency of C:G to T:A transition mutations at CpG sites in 
Mbd4 knockout mice. The mutational noise in the cii mutational spectra of the Big 
Blue cell lines is likely to be caused by the high frequencies of mutations in these 
cell lines, and to be exacerbated by random sampling effects as a result of repeated 
passaging of the cell lines. Unfortunately, the presence of this mutational noise 
appears to have obscured the expected increase in the corrected frequency of C:G to 
T:A transition mutations at CpG sites in the Mbd4 knockout cell line (while there 
appears to be an increase in the uncorrected total frequency of C:G to T:A transition 
mutations at CpG sites in the Mbd4 knockout cell line, there is no suggestion that the 
absence of Tdg causes a similar change in the cii mutational spectrum). The presence 
of mutational noise in both the total and corrected cii mutational spectra of the Big 
Bluô cell lines therefore prevents the formation of any conclusions with regard to the 
substrate specificity of Tdg in vivo. 
3.4 Conclusions 
The DNA glycosylase MBD4 can excise thymine from T:G mismatches within a 
methylated CpG dinucleotide in vitro (Hendrich et al., 1999; Petronze1li et al., 
2000a), suggesting that MBD4 may repair the product of 5meC deamination in vivo. 
This hypothesis was investigated by crossing Mbd4-deficient mice with transgenic 
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• Big Blue mice. The presence of a X phage shuttle vector integrated into chromosome 
number four of Big Blue mice allows the frequency and spectrum of mutations 
within the X phage cli gene to be determined by the in vivo Big Blue cli mutation 
assay (Kohler et al., 1991; Jakubczak et al., 1996). This assay showed that Mbd4 
knockout mice have a significantly higher frequency of mutations than wild type 
mice, and that the higher frequency of mutations is specifically due to a higher 
frequency of C:G to T:A transition mutations at CpG sites. These mutations arise 
when 5meC deamination-induced TpG/5meCpG mismatches are not repaired, 
therefore these data provide conclusive evidence that MBD4 repairs the product of 
5meC deamination in vivo. 
The DNA glycosylase TDG can also excise thymine from T:G mismatches within a 
methylated CpG dinucleotide in vitro (Neddermann and Jiricny, 1993), therefore, 
like MBD4, TDG may repair the product of 5meC deamination in vivo. Tdg-deficient 
mice were generated with the aim of determining the frequency and spectrum of 
mutations in Tdg knockout mice using the Big Blue assay. However, the absence of 
Tdg results in embryonic lethality between E1 0. 5  and E11 . 5, therefore an alternative 
approach to investigate the in vivo substrate specificity of Tdg was employed. This 
approach involved the isolation of cell lines from Ivlbd Tdg
+1+. , M -I-  bd4 Tdg+1+  
-I 	 I 	-I- Mbd4+1+  Tdg -  and Mbd4 - Tdg Big Blue embryos, and the determination of the 
frequency and spectrum of mutations in each of the four cell lines using the Big Blue 
assay. Disappointingly, the total and corrected cli mutational spectra of the Mbd4 
Tdg', Mbdf F Tdg, Mbd4 Tdg and Mbd4 Tdg Big Blue cell lines 
contain a high level of mutational noise, therefore it is still not known whether Tdg 
can repair the product of 5meC deamination in vivo. 
The ideal experiment to investigate the in vivo substrate specificity of Tdg would be 
to make a conditional Tdg mouse knockout, and then to determine the frequency and 
spectrum of mutations in Tdg-deficient tissues using the Big Blue assay. Although 
this experiment would be relatively time-consuming, it should also be very 
informative. As an alternative and less time-consuming experiment to determine 
whether Tdg can repair the product of 5meC deamination in vivo, the TpG/5meCpG 
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mismatch repair activity present within the Mbd 
A-/+  Tdg+1+  , Mbd'f I- 	+1+ Tdg , Mbd 
Tdg' and Mbd4' Tdg cell lines could be quantitated using the double mismatch 
reversion (DMR) assay as described by Waters and Akman (2001). In the DMR 
assay, a plasmid that encodes the suppressor tRNA gene supF, and that has two 
mismatches on opposite DNA strands of the supF gene, is transiently transfected into 
different cell lines. The plasmids are recovered after 48 hours, during which time the 
mismatches may or may not have been repaired, and the functional status of the supF 
gene is determined by transformation of the plasmids into the E. coli reporter strain 
MBL50. The Big Blue mouse data suggest that the cell lines lacking Mbd4 would 
repair the TpG/5meCpG mismatches in the supF gene with lower efficiency than the 
wild type cell line, and it would be interesting to determine whether this is true of 
both cell lines that lack Mbd4 and cell lines that lack Tdg. 
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Chapter 4 
An interaction between MBD4 and ZSWIM3 
4.1 Introduction 
The yeast two-hybrid assay is a highly sensitive assay that can be used to identify 
novel protein-protein interactions, to confirm suspected protein-protein interactions, 
and to map interacting protein domains (Fields and Song, 1989). MBD4 was shown 
to interact with three proteins in a yeast two-hybrid screen; the mismatch repair 
protein MLH1, the pro-apoptotic kinase ZIP kinase and an uncharacterised protein 
ZSWIM3 (Millar, 2002). The interaction between MBD4 and MLH1 was previously 
shown in a yeast two-hybrid screen in which MBD4 was identified as an interaction 
partner of MLFI1 (Bellacosa et al., 1999). The interactions between MBD4 and 
MLH1, and MBD4 and ZIP kinase, have been confirmed by co-localisation and co-
immunoprecipitation experiments (Bellacosa et al., 1999; Millar, 2002), but the 
interaction between MBD4 and ZSWIM3 has not been 'confirmed or characterised. 
The protein-protein interactions of MBD4 are of interest as they may regulate the 
thymine DNA glycosylase activity of MBD4 in vivo. An investigation of the 
interaction between MBD4 and ZSWIM3 is presented in this chapter. 
4.2 The activity of MBD4 and TDG in nuclear extracts 
The activity of DNA glycosylases can be investigated by the use of an in vitro DNA 
glycosylase assay (Figure 4. 1A). A double-stranded oligonucleotide containing a 
damaged DNA base or a base damage-associated base-base mismatch is incubated 
with either a recombinant DNA glycosylase or a cellular extract. The oligonucleotide 
substrate is fluorescently or radioactively labelled at one end of the DNA strand that 
contains the damaged or mismatched base in order to allow the identification of 
oligonucleotides in which the damaged or mismatched base has been excised. After 
incubation with the recombinant DNA glycosylase or cell extract, the oligonucleotide 
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is incubated with 90mM NaOH at 90°C. This denatures the DNA glycosylase(s) and 
causes cleavage of the sugar-phosphate backbone at any sites of DNA glycosylase-
mediated base excision. The full-length unrepaired labelled oligonucleotides (i.e. the 
substrate) and the shorter repaired labelled oligonucleotides (i.e the product) are then 





+ recombinant DNA glycosylase or NE 
















Figure 4.1: An in vitro DNA glycosylase assay to detect TG mismatch-specific thymine DNA 
glycosylase activity. (A) Schematic of an in vitro DNA glycosylase assay to detect T:G 
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mismatch-specific thymine DNA glycosylase activity. F = fiuorescëin label, NE = nuclear 
extract. See text for details. (B) The TpG/CpG mismatch-containing oligonucleotide used in 
the in vitro DNA glycosylase assay in this study. 
An in vitro DNA glycosylase assay with a fluorescein-labelled oligonucleotide that 
contained a T:G mismatch in the context of an unmethylated CpG dinucleotide 
(Figure 4.1B) was used to investigate the T:G mismatch-specific thymine DNA 
glycosylase activity present within Mbd4 Tdg, Mbd4 Tdg, Mbd4 Tdg' 
and Mbd4 Tdg mouse embryonic fibroblast cell lines; The derivation and 
characterisation of these cell lines was described in Chapter 3; where it was shown 
by RT-PCR and western blotting that both Mbd4 and Tdg are expressed in the wild 
type cell line, Tdg alone is expressed in the Mbd4 knockout cell line, Mbd4 alone is 
expressed in the Tdg knockout cell line, and neither Mbd4 or Tdg are expressed in 
the Mbd4/Tdg double knockout cell line. Nuclear extracts were prepared from each 
of the four cell lines according to the method of Dignam et al. 1983). In vitro DNA 
glycosylase assays were then performed using the four nuclear extracts and the 
TpG/CpG oligonucleotide (Figure 4.2). Three additional oligonucleotides were also 
used in this experiment. These oligonucleotides were identical to the TpG/CpG 
oligonucleotide, but instead of a TpG/CpG mismatch contained either a T:G 
mismatch in the context of a methylated CpG dinucleotide (TpG/5meCpG), a U:G 
mismatch in the context of an unmethylated CpG dinucleotide (UpG/CpG), or no 
base-base mismatches' (CpG/CpG). The UpGICpG oligonucleotide is a positive 
control for base excision as there are several DNA glycosylases other than MBD4 
and TDG that can excise uracil from a U:G mismatch. The CpG/CpG 
oligonucleotide, which contains no base-base mismatches, is a negative control for 
base excision. As a further set of negative and positive controls, the CpG/CpG and 
TpG/CpG oligonucleotides were also incubated with either no added protein or with 
recombinant Mbd4. 
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Figure 4.2: The T:G mismatch-specific thymine DNA glycosylase activity present in Mbd4 
Tdgt Mbd4 Tdg, Mbd4 Tdg and Mbd4 Tdg- ' cells. Nuclear extracts were 
prepared from the four cell lines, and were incubated with the oligonucleotides indicated. The 
oligonucleotide sugar-phosphate backbone was then cleaved at abasic sites by the addition 
of NaOH, and the 60 base long unrepaired fluorescein-labelled oligonucleotides (Substrate) 
were resolved from the 23 base long repaired fluorescein-labelled oligonucleotides (Product) 
by denaturing SDS PAGE. 
As expected, when the CpGICpG and TpGICpG oligonucleotides were incubated in 
the absence of any added protein, no base excision occurred and only the full-length 
CpGICpG and TpG/CpG oligonucleotide substrates were detectable by denaturing 
SDS PAGE. Similarly, when the CpG/CpG oligonucleotide was incubated with 
recombinant Mbd4, no base excision occurred and only the fill-length CpG/CpG 
oligonucleotide substrate was detectable. However, when the TpG/CpG 
oligonucleotide was incubated with recombinant Mbd4, both full-length 60 base long 
TpG/CpG substrate oligonucleotide and short 23 base long TpG/CpG product 
oligonucleotide were detectable. The presence of the product oligonucleotide 
confirms that Mbd4 can excise the mismatched thymine base from the TpG/CpG 
mismatch in the TpG/CpG oligonucleotide under the conditions of the assay. The 
Mbd4' Tdj', Mbd4' Tdg, Mbd4 Tdg and Mbd4 Tdg nuclear extracts 
did not cause base excision from the negative control CpG/CpG oligonucicotide, but 
did cause base excision from the positive control UpG/CpG oligonucleotide. This 
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nlvcosylase(s). T:G mismatch-specific thymine DNA glycosylase activity (as 
udicated by the formation of product oligonucleotides from both the TpG/CpG and 
he TpG/5meCpG oligonucleotides) is present in the wild type and Mbd4 knockout 
uclear extracts, but not in the Tdg knockout and Mbd4/Tdg double knockout 
nuclear extracts. This suggests that the T:G mismatch-specific thyrnine DNA 
glycosylase activity detected within the wild type and Mbd4 knockout nuclear 
extracts is attributable to Tdg, and that the T:G mismatch-specific thymine DNA 
glycosylase activity of Mbd4 cannot be detected within nuclear extracts. Mbd4 has 
previously been shown to have T:G mismatch-specific thymine DNA glycosylase 
activity in vitro (Hendrich et al., 1999; Petronzclli el al., 2000b), and Mbd4 knockout 
mice have a significantly increased frequency of C:G to T:A transition mutations at 
CpG sites in vivo (Millar et al., 2002; Wong et al., 2002), suggesting  that Mbd4 also 
has T:G mismatch-specific thymine DNA glycosylase activity in vivo. It is therefore 
surprising that Mbd4-mediated thyminc DNA glycosylase activity cannot be detected 
within the Mbd4' Tdg and Mbd4 + Tdg nuclear extracts. There are several 
possibilities that could explain the absence of detectable Mbd4 thymine DNA 
glycosylase activity within these nuclear extracts, and these possibilities are outlined 
below. 
Mbd4 thyminc DNA glycosylase activity may be present within nuclear extracts, 
but the assay may lack sufficient sensitivity to detect this activity. Radioactively 
(a32P) labelled oligonucleotides were used to repeat the assay with a higher level of 
sensitivity, but Mbd4-mediated thymine DNA glycosylase activity was still 
undetectable (data not shown). 
The TpG/CpG and TpG/5meCpG oligonucleotides may undergo complete Mbd4-
initiated BER in the presence of nuclear extracts, and may therefore give rise to 
oligonucleotide products that are indistinguishable from the substrates. If the core 
BER pathway proteins are present and active within the nuclear extracts, the 
complete BER of the TpG/CpG and TpG/5meCpG oligonucleotides would give rise 
to full-length product oligonucleotides (with no base-base mismatches) that would be 
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indistinguishable from full-length substrate oligonucleotides by denaturing SDS 
PAGE. In order to investigate this possibility, the in vitro DNA glycosylase assay 
was repeated with the Mbd4 Tdj, Mbd4 Tdg, Mbd4' Tdg and Mbd4 
Tdg nuclear extracts in the presence of either all four ddNTPs (ddATP, ddCTP, 
ddGTP and ddTTP) or each ddNTP alone (Figure 4.3). If complete Mbd4-initiated 
BER of the TpG/CpG and TpG/5meCpG oligonucleotides was occurring in the 
previous experiment, the inclusion of ddCTP, which lacks a 3' hydroxyl group and 
cannot be ligated to a 5' phosphate group, would be expected to cause an increase in 
the amount of product oligonucleotide in the Mbd4 Tdg nuclear extract-
containing reaction, and the appearance of product oligonucleotide in the Mbd4 
Tdg' nuclear extract-containing reaction. However, this was not observed, 
suggesting that complete Mbd4-initiated BER does not occur in the presence of 
nuclear extracts. Interestingly, the migration of the product oligonucleotide within 
1 
the denaturing SDS PAGE gel is perceptibly slower when Mbd4
++  Tdg +1+  or Mbd4-I--
Tdg nuclear extracts are incubated with either all four ddNTPs or with ddCTP 
alone. This is most likely due to the incorporation of ddCMP opposite the guanine of 
the original T:G mismatch, and therefore suggests that AP endonuclease and DNA 
polymerase fi are present and active within the nuclear extracts. As complete Mbd4-
initiated BER does not occur even though AP endonuclease and DNA polymerase 
are present and active, it is possible that DNA ligase 3 may not be present or active 
within the nuclear extracts. When the ddNTPs used in this experiment were 
substituted with dNTPs, which have a 3' hydroxyl group and can be ligated to a 5' 
phosphate group, no decrease in the amount of product oligonucleotide in the 
Mbd4 Tdg and Mbd4 Tdg nuclear extract-containing reactions was observed 
(data not shown), suggesting that DNA ligase 3 is indeed absent from the nuclear 
extracts, or that DNA ligase 3 is inactive under the conditions of the assay. These 
experiments therefore show that the TpG/CpG and TpG/5mcCpG oligonucleotides 
are not undergoing complete Mbd4-initiated BER. 
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Figure 4.3: The effect of ddCTP on theT:G mismatch-specific thymine DNA glycosylase 
activity present in Mbd4 Tdg, Mbd4 Tdg", Mbd4' Tdg and Mbd4 Tdg cells. 
Nuclear extracts were prepared from the four cell lines, and were then incubated with the 
oligonucleotides and ddNTPs indicated. N = all four ddNTPs, A = ddATP, C = ddCTP, G 
ddGTP, T = ddTTP. The oligonucleotide sugar-phosphate backbone was cleaved at abasic 
sites by the addition of NaOH, and the 60 base long unrepaired fluorescein-labelled 
oligonucleotides (Substrate) were resolved from the 23 base long repaired fluorescein-
labelled oligonucleotides (Product) by denaturing SDS PAGE. 
3. The thymine DNA glycosylase activity of Mbd4 may be inhibited by the reaction 
conditions of the in vitro DNA glycosylase assay. This possibility is argued against 
by the fact that the thymine DNA glycosylase activity of recombinant Mbd4 can be 
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detected in the assay, although it should be borne in mind that the reactions contain a 
molar excess of Mbd4 relative to substrate oligonucleotide. 
4. The thymine DNA glycosylase activity of Mbd4 within nuclear extracts may be 
inhibited by a protein interaction or a post-translational modification. An in vitro 
DNA glycosylase assay using the TpG/CpG oligonucleotide was used to investigate 
whether the T:G mismatch-specific thymine DNA glycosylase activity of 
recombinant Mbd4 is inhibited by the presence of nuclear extracts from Mbd4 
Tdg and Mbd4 Tdg cells (Figure 4.4). These nuclear extracts do not contain 
any detectable thyminc DNA glycosylase activity in this assay. As expected, the 
activity of recombinant Mbd4 decreased as the salt concentration in the DNA 
glycosylase reactions increased, as has been seen previously (Petronzelli et al., 
2000a). When recombinant Mbd4 was incubated with nuclear extracts from either 
Mbd4 Tdg or Mbd4 Tdg cells, the thyminc DNA glycosylase activity was 
lower than when recombinant Mbd4 was incubated at the same salt concentration but 
in the absence of any nuclear extract. This suggests that the presence of a nuclear 
extract can inhibit recombinant Mbd4. A possible explanation for this inhibition is 
that Mbd4 either interacts with, or is modified by, a protein within the nuclear 
extract, and that this interaction or post-translational modification inhibits the 
thymine DNA glycosylase activity of Mbd4. MLHI, ZIP kinase and ZSWIM3 are 
candidate mediators of MBD4 inhibition, and the interaction between MBD4 and 
ZSWIM3 is the focus of the remainder of this chapter. 
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Figure 44: The effect of Mbd4 Tdg and Mbd4 Tdg nuclear extracts on the T:G 
mismatch-specific thymine DNA glycosylase activity of recombinant Mbd4. Recombinant 
Mbd4 was incubated with the TpG/CpG oligonucleotide and with 5, 10 or 20Lg nuclear 
extracts isolated from Mbd4 Tdg' and Mbd4 Tdg' cells. The total NaCl concentration 
in the DNA glycosylase reactions is indicated (low: 22.5mM, intermediate: 45mM, high: 
90mM). The oligonucleotide sugar-phosphate backbone was cleaved at abasic sites by the 
addition of NaOH, and the 60 base long unrepaired fluorescein-labelled oligonucteotides 
(Substrate) were resolved from the 23 base long repaired fluorescein-labelled 
oligonucleotides (Product) by denaturing SDS PAGE. Intervening lanes have been removed 
for clarity. 
4.3 ZSWIM3 
Four clones encoding amino acids 71-696 of zinc finger SWIM domain-containing 
protein 3 (ZSWIM3) were identified in a yeast two-hybrid screen that used MBD4 as 
the bait protein (Millar, 2002). ZSWIM3 contains a SWI2/SNF2 and MuDR (SWIM; 
Pfam accession number PF04434) domain, which is found in a variety of prokaryotic 
and eukaryotic proteins, including bacterial ATPases of the SWI2/SNF2 family, 
plant MuDR transposases and transposase-dcrivcd Farl nuclear proteins, and 
vertebrate MEK kinase-1 (Makarova et al., 2002). The SWIM domain has a CxCx o.. 
25CxH pattern of zinc-chelating residues, and secondary structure predictions indicate 
that the domain consists of two n-strands and an a-helix. The SWIM domain may 
therefore adopt a 14a  fold similar to that of the classical C2H2 zinc finger domain 
(Laity et al., 2001). The SWIM domain of ZSWIM3 is highly conserved, as is the 
remainder of the protein (Figure 4.5). 
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When the SWIM domain was first described, it was suggested that it may have 
diverse DNA binding or protein-protein interaction functions depending on the 
context of the protein in which the domain is present (Makarova et al., 2002). The 
accuracy of this prediction remains to be seen as the functions of only two SWIM 
domains have been investigated to date. The SWIM domain of E. co/i glutamyl 
tRNA synthetase (G1uRS) positions the tRNA G ' u  acceptor arm in the active site of the 
enzyme, thereby enhancing glutamate binding and activation (Banerjee et al., 2004), 
whereas the SWIM domain of MEK kinase- 1-related protein X (MEX) has been 
proposed to have E3 ubiquitin ligase activity, and to promote MEX self-
ubiquitination and 26S proteasome-mediated degradation (Nishito et al., 2006). 
However, the SWIM domain of MEX is adjacent to a RING domain that also has E3 
ubiquitin ligase activity in both MEX (Nishito et al., 2006) and MEK kinase- 1 (Lu et 
al., 2002), therefore further investigation is required in order to ensure that the 
decrease in E3 ubiquitin ligase activity that is observed upon mutation of one of the 
zinc-chelating .cysteine residues within the SWIM domain of MEX is not actually 
due to reduced RING domain function as a result of a structural change caused by the 
disruption of the SWIM domain. The presence of a SWIM domain within ZSWIM3 
therefore provides little clue to suggest a possible biological function of an MBD4 
ZSWIM3 interaction. 
4.4 The expression of ZSWIM3 in mouse and human 
tissues 
The expression of ZSWIM3 transcripts was investigated in a range of adult mouse 
and human tissues. The preparation of mouse and human tissue eDNA panels was 
described in Chapter 3. Real-time PCR was performed to determine the level of 
ZSWIM3 eDNA relative to the level of GAPDH reference gene eDNA in the mouse 
and human eDNA panels (Figure 4.6). The expression profiles of ZSWJM3 
transcripts are very similar in the mouse and human eDNA panels, e.g. there are low 
levels of ZSWJM3 transcripts expressed in heart, liver and kidneys, and higher levels 
expressed in spleen, lung and thymus. However, strikingly, the expression of 
ZSWJM3 transcripts in mouse testes is over 17-fold higher than in human testes. 
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Figure 4.6: Real-time RT-PCR analysis of ZSWIM3 transcript expression in mouse and 
human tissues. The expression levels of ZSWIM3 transcripts relative to GAPDH transcripts 
are shown. The expression of Zswim3 in mouse testes (0.149±0.006) is not shown. The 
error bars indicate the standard deviation of the mean. 
4.5 Mapping the MBD4-ZSWIM3 interaction domains 
The interaction between MBD4 and ZSWJM3 was further characterised by mapping 
the minimum interaction domains using the yeast two-hybrid assay. 
4.5.1 The yeast two-hybrid assay 
The yeast two-hybrid assay exploits an elegant system that regulates the rapid and 
coordinated expression of several proteins involved in galactose metabolism in yeast. 
The key protein components of this system are GAL4 and GAL80. GAL4 is a 
transcriptional activator with a modular structure consisting of a DNA binding 
domain (DBD) and a transcriptional activation domain (AD). When galactose is 
present, GAL4 binds via the DBD to the promoters of genes encoding proteins 
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required in the galactose metabolism pathway, and activates transcription via the AD. 
When galactose is not present, GAL80 binds to the AD of GAL4 and prevents 
inappropriate transcriptional activation. However, when the favoured carbon source 
glucose is present, the expression of proteins involved in galactose metabolism is 
repressed, irrespective of the presence or absence of galactose. 
In the yeast two-hybrid assay, a protein of interest (the bait protein) is expressed as a 
GAL4 DBD fusion protein, while another protein (the prey protein), or a library of 
proteins, is expressed as a GAL4 AD fusion protein (Figure 4.7). The yeast host 
strain used in the assay has one or more reporter genes, the expression of which is 
regulated by a heterologous upstream activation sequence that can be bound by the 
GAL4 DBD (UAS(iAM). The GAL4 DBD-bait fusion protein binds to a UASGAL4 
within the promoter of the reporter gene and, if the bait and prey proteins can 
interact, the GAL4 AD (which is fused to the prey protein) activates transcription of 
the reporter gene. Yeast two-hybrid reporter genes often encode components of 
amino acid biosynthetic pathways; expression of the reporter gene can therefore be 
assayed by a growth test on medium lacking the amino acid synthesised by the 
relevant biosynthetic pathway. In order to avoid interference by the endogenous 
GAL4 and GAL80 proteins, the genes encoding these proteins are deleted in the 
yeast host strain. 
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UASGAL4 	TATA box 
Figure 4.7: The yeast two-hybrid assay. If the bait and prey proteins cannot interact, as in 
(A), the reporter gene is not expressed. If the bait and prey proteins can interact, as in (B), 
the reporter gene is expressed. 
4.5.2 Mapping the N-terminal border of the ZSWIM3 
interaction domain of MBD4 
Saccharornyces cerevisiae strain PJ69-4a (James et al., 1996) was used in these 
experiments. The genotype of PJ69-4a is shown in Table 4.1. This strain has two 
endogenous reporter genes (ADE2 and HIS3), and an exogenous reporter gene (lacZ 
from E. co/i). As the names of the genes suggest, ADE2 and I-11S3 encode enzymes 
required for adenine and histidine biosynthesis respectively. PJ69-4a can therefore 
only grow on medium lacking adenine and histidine if the ADE2 and HIS3 reporter 
genes are activated, either in the presence of transformed full-length GAL4, or GAL4 
that has been reconstituted by interaction of the bait and prey fusion proteins. The 
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Yeast strain Genotype Reporter genes Transformation 
markers 
PJ69-4z MATa trpl-901 Ieu2- HIS3 trpl 
3,112 ura3-52 his3- ADE2 Ieu2 




Table 4.1: PJ69-4a genotype. The genotype, reporter genes, and transformation markers of 
yeast strain PJ69-4ct. The GALl, GAL2, and GAL7 UASs can be bound by GAL4. 
In order to verify the phenotype of yeast strain PJ69-4(i, three single colonies were 
replica plated onto complete media (YPDA and SD media) and synthetic dropout 
(SD) media lacking various amino acids (Figure 4.8). As expected, the yeast grew on 
the two complete media and on medium lacking lysine, but not on media lacking 
adenine, histidine, leucine, methionine, tryptophan, or uracil. 
SD 	 SD-LEO 	 SD-TRP 
YPDA 	 SD -HIS 	 SD -MET 
SID -AIDE 	 SD-LYS 	 SD-URA 
Figure 4.8: PJ69-4c phenotype. In order to verify the phenotype of yeast strain PJ69-4ct, 
single colonies were replica plated onto complete media (YPDA and SD media) and various 
SD media (SD -ADE, -HIS, -LEU, -LYS, -MET, -TRP, and -URA media). The SD -HIS 
medium contained 2.5mM 3-amino-1 ,2,4-triazole (3-AT). 3-AT is a competitive inhibitor of the 
yeast HIS3 protein, and is used to inhibit low levels of HIS3 that are present due to leaky 
expression in the absence of interacting bait and prey proteins. 
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In the following series of yeast two-hybrid assays. PJ69-4u 	as usually co- 
transformed with two plasmids: pGBT9 which has a TRPI nutritional marker and 
encodes a bait protein fused to the GAL4 DBD (eta 1-147 of GAL4), and pACT2 
which has a LEU2 nutritional marker and encodes a prey protein fused to the GAL4 
AD (aa768-881 of GAL4). The bait and prey fusion proteins are targeted to the 
yeast nucleus by an endogenous nuclear localisation signal (NLS) within the GAL4 
DBD, and by the NLS of SV40 large T antigen fused in frame with the GAL4 AD 
respectively. Yeast co-transformed with a bait plasmid and a prey plasmid were 
selected for by plating on SD -LEU -TRP medium, and yeast expressing interacting 
bait and prey proteins were selected for by plating on SD -ADE -HIS -LEU -TRP 
medium (this growth test assays the activity of the HIS3 and ADE2 reporter genes; 
the activity of the lacZ reporter gene was not assayed in this study). SD -LEU -TRP 
and SD -ADE -HIS -LEU -TRP media will hereafter be referred to as double 
dropout (DDO) and quadruple dropout (QDO) media respectively. For the purposes 
of data presentation, single colonies grown on DDO medium were also replica plated 
onto DDO and QDO media. 
GAL4 (encoded by pCLI) was transformed as a positive control for activation of the 
ADE2 and HIS3 reporter genes, and enabled growth on QDO medium as expected 
(Figure 4.9). MBD4 and ZSWIM3 aa7l-696 (the original M13134-interacting clone) 
were each separately transformed in order to verify that these proteins have no 
intrinsic DNA binding and/or transcriptional activation properties that could 
influence the results of the assay. Neither of these transformations resulted in growth 
on QDO medium. Two final control co-transformations were performed: MBD4 and 
MLH I aa300-756 were co-transformed as a positive control for protein-protein 
interaction and HIS3 and ADE2 reporter gene activation (growth occurred on QDO 
medium), and lamin C aa66-230 (encoded by pLam5') and ZSWIM3 aa71-696 
were co-transformed as a negative control for protein-protein interaction and reporter 
gene activation (no growth occurred on QDO medium). Equivalent positive and 
negative controls were included in all subsequent yeast two-hybrid assays. 
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In the yeast two-hybrid assay that identified ZSWIM3 as an interaction partner of 
MBD4, full-length MBD4 interacted with aa7I-696 of ZSWIM3. The region of 
MBD4 that interacts with ZSWIM3 was investigated using various MBD4 deletion 
constructs (Figure 4.9). ZSWIM3 interacted with MBD4 deletions that retain cta430-
580, but could not interact with cxc1455-580 of MBD4. This suggests that ua430-454 
of MBD4 are required, but are not necessarily sufficient, to interact with ZSWIM3. 
Interestingly. ZIP kinase was also shown to interact with aa430-580, but not aa455-
580, of MBD4 (Millar, 2002). 
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Figure 4.9: Initial mapping of the N-terminal border of the ZSWIM3 interaction domain of 
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ty plating on DDO medium. Single colonies were then replica plated on DDO and QDO 
media. The QDO medium contained 2.5mM 3-AT. Activation of the GAL-4-responsive HIS3 
and ADE2 reporter genes enables growth on QDO medium. In addition to the positive and 
negative controls described in the text, ZSWIM3 aa71-696 and various MBD4 deletion 
construct co-transformations are shown. (B) Schematic of the MBD4 protein and the MBD4 
deletion series that was used for the initial mapping of the ZSWIM3 interaction domain N-
terminal border. + or - indicates the presence or absence of an interaction between ZSWIM3 
U(01696 and an MBD4 deletion construct. 
In the course of performing these assays, it was observed that yeast co-transformants 
expressing interacting bait and prey proteins generally form white colonies when 
grown on DDO medium, and that co-transformants expressing non-interacting bait 
and prey proteins form pink colonies when grown on the same medium. The pink 
coloration is due to the accumulation of an intermediate in the adenine biosynthetic 
pathway, and is known to occur when yeast lacking an active ADE2 gene are grown 
on medium containing low levels of adenine (Smirnov et al., 1967; Weisman et al., 
1987). However, although colony colour is suggestive of the presence or absence of a 
bait-prey interaction, it cannot be used as a robust alternative to a growth test on 
QDO medium. This is because a small number of co-transformants which form pink 
colonies on DDO medium can also form pink colonies on QDO medium, although 
these colonies grow relatively slowly. The most likely molecular explanation for this 
observation is that the bait and prey proteins expressed by these co-transformants can 
interact relatively inefficiently, resulting in a low level of ADE2 reporter gene 
expression which is only sufficient to allow a low rate of yeast cell division on 
medium lacking adenine. 
4.5.3 Fine mapping of the N-terminal borders of the ZSWIM3 
and ZIP kinase interaction domains 
In order to map the N-terminal borders of the ZSWIM3 and ZIP kinase interaction 
domains of MBD4 at higher resolution, and potentially to separate the two 
interaction domains, a series of additional MBD4 N-terminal deletions were 
constructed and tested in the yeast two-hybrid assay (Figure 4.10). ZSWIM3 
interacted with the MBD4 deletions that retained cta440-580, but could not interact 
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deletion series that was used for the initial mapping of the ZSWIM3 interaction domain N-
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uu71-696 and an MBD4 deletion construct. 
n the course of performing these assays, it was observed that yeast co-transformants 
cxpressing interacting bait and prey proteins generally form white colonies when 
grown on DDO medium, and that co-transformants expressing non-interacting bait 
and prey proteins form pink colonies when grown on the same medium. The pink 
coloration is due to the accumulation of an intermediate in the adenine biosynthetic 
pathway, and is known to occur when yeast lacking an active .4DE2 gene are grown 
on medium containing low levels of adenine (Smirnov etal., 1967; Weisman etal., 
1987). However, although colony colour is suggestive of the presence or absence of a 
bait-prey interaction, it cannot be used as a robust alternative to a growth test on 
QDO medium. This is because a small number of co-transfomiants which form pink 
colonies on DDO medium can also form pink colonies on QDO medium, although 
these colonies grow relatively slowly. The most likely molecular explanation for this 
observation is that the bait and prey proteins expressed by these co-transformants can 
interact relatively inefficiently, resulting in a low level of ADE2 reporter gene 
expression which is only sufficient to allow a low rate of yeast cell division on 
medium lacking adenine. 
4.5.3 Fine mapping of the N-terminal borders of the ZSWIM3 
and ZIP kinase interaction domains 
In order to map the N-terminal borders of the ZSWIM3 and ZIP kinase interaction 
domains of MBD4 at higher resolution, and potentially to separate the two 
interaction domains, a series of additional MBD4 N-terminal deletions were 
constructed and tested in the yeast two-hybrid assay (Figure 4.10). ZSWIM3 
interacted with the MBD4 deletions that retained ctu440-580, but could not interact 
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interact with ZSWIM3). ZIP kinase interacted with the MBD4 deletions that retained 
act435-580, as indicated by growth on QDO medium. MBD4 act440-580/ZIP kinase 
co-transformants also grew on QDO medium, although at a noticeably slower rate 
than either MBD4 cta435-580/ZIP kinase or MBD4 cta440-580/ZSWIM3 co-
transformants. Additionally, MBD4 au440-5 80/ZIP kinase co-transformants formed 
pink colonies on DDO and QDO media. As discussed in the previous paragraph, this 
is probably due to a low affinity interaction between MBD4 aa440-580 and ZIP 
kinase. The results therefore suggest that aa435-439 of MBD4 are required but are 
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Figure 4.10: Further mapping of the N-terminal borders of the ZSWIM3 and ZIP kinase 
interaction domains of MBD4. (A) The yeast two-hybrid assay was used to further refine the 
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ZSWIM3 and ZIP kinase interaction domains of MBD4. In addition to variants of the positive 
and negative controls described in the text, several co-transformations of MBD4 deletion 
constructs and ZSWIM3 au71-696 or ZIP kinase (LU274 -454 are shown. (B) Schematic of 
the MBD4 protein and the MBD4 deletion series that was used to refine the ZSWIM3 and 
ZIP kinase interaction domain N-terminal borders. + or - indicates the presence or absence 
of an interaction between ZSWIM3 ctci71-696 or ZIP kinase cxa274-454 and an MBD4 
deletion construct. +1- indicates the occurrence of a low affinity interaction. 
4.5.4 Mapping the C-terminal borders of the ZSWIM3 and ZIP 
kinase interaction domains 
After mapping the N-terminal borders of the ZSWIM3 and ZIP kinase interaction 
domains of MBD4, the C-terminal borders of these interaction domains were 
investigated using a progressive series of MBD4 C-terminal deletions (Figure 4.11). 
The previous yeast two-hybrid assay demonstrated that aa440-444 of MBD4 are 
required, but are not necessarily sufficient, to interact with ZSWIM3. This 
experiment shows that this region of MBD4 is not sufficient to interact with 
ZSWIM3, as ZSWIM3 did not interact with aal-455 of MBD4. Indeed, ZSWIM3 
did not interact with any of the five C-terminal deletions of MBD4 that were tested. 
Identical results were obtained using ZIP kinase as the prey protein, suggesting that 
the interaction domains of both ZSWIM3 and ZIP kinase extend to the extreme C-
term inus of MBD4. 
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Figure 4 11 Mapping of the C-terrnlnd norders of the ZSWIM3 anu ZIP kinase nteraction 
domains of MBD4. (A) The yeast two-hybrid assay was used to map the C-terminal borders 
of the ZSWIM3 and ZIP kinase interaction domains of MBD4. In addition to variants of the 
positive and negative controls described in the text, several co-transformations of MBD4 
deletion constructs and ZSWIM3 cxa7l-696 or ZIP kinase aci274-454 are shown. (B) 
Schematic of the MBD4 protein and the MBD4 deletion series that was used to map the 
ZSWIM3 and ZIP kinase interaction domain C-terminal borders. + or - indicates the presence 
or absence of an interaction between ZSWIM3 (1(171-696 or ZIP kinase czu274-454 and an 
MBD4 deletion construct. 
The ideal experiment to confirm that the MBD4 C-terminal deletions can be stably 
expressed within the co-transformed yeast cells would be to western blot yeast whole 
cell extracts with an anti-GAL4 DBD antibody. However, the expression of GAL4 
DBD fusion proteins from the pGBT9 plasmid is under the control of a truncated 
alcohol dehydrogenase 1 (ADHI) promoter, which results in a very low level of 
protein expression (Ruohonen et al., 1991; Ruohonen et al., 1995; Tornow and 
Santangelo, 1990). This low level of protein expression is generally sufficient to 
enable the detection of protein-protein interactions by the yeast two-hybrid assay, but 
is not sufficient to enable the detection of fusion proteins by western blotting 
(Clontech, 2000). As an alternative control experiment, MBD4 cial-555 and MLH 1 
were co-transformed. MLH1 was previously shown to interact with cta415-420 of 
MBD4 (Millar, 2002), and should therefore interact with MBD4 aul-555. As 
expected, the MBD4 cxctl-555/MLH1 co-transformant grew on QDO medium, 
confirming that the MBD4 aal-555 construct can be stably expressed within yeast 
cells. The deletion of only 24 amino acids from the C-terminus of MBD4 is therefore 
sufficient to disrupt the interaction of MBD4 with both ZSWIM3 and ZIP kinase. 
The ZSWIM3 and ZIP kinase interaction domains of MBD4 are shown in Figure 
4.12. ZSWIM3 interacts with amino acids 440 to 580 of MBD4, and ZIP kinase 
interacts with amino acids 435 to 580 of MBD4. These largely overlapping regions 
of MBD4 encompass and extend beyond the glycosylase domain of the protein and 
are highly conserved in MBD4 orthologs. 
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Chapter 4: An interaction between MBD4 and ZSWIM3 
4.55 Mapping the MBD4 interaction domain of ZSWIM3 
A yeast two-hybrid assay was also performed in an attempt to map the MBD4 
interaction domain of ZSWIM3 (Figure 4.13). In the assay that identified ZSWIM3 
as an interaction partner of MBD4, MBD4 interacted with aa7 1-696 of ZSWIM3 
(Millar, 2002). This interaction was also seen in this experiment, as was an 
interaction between MBD4 and full-length ZSWIM3. Three ZSWIM3 constructs, 
encoding the N-terminal region, the central region, and the C-terminal region of 
ZSWIM3 (which includes the SWIM domain) failed to give an interaction with 
MBD4. As this could be due to the MBD4 interaction domain overlapping the ends 
of two of the ZSWIM3 constructs, two additional constructs were made; one 
encoding the N-terminal half of the ZSWIM3 protein, and the other encoding the C-
terminal half of the protein. Again, no interaction with MBD4 was seen. Although 
these results are somewhat surprising, there are several possibilities that could 
explain why no interaction occurs between MBD4 and any of the five ZSWIM3 
deletion constructs; 1. The ZSWIM3 fusion proteins may not be stably expressed 
within the co-transformed yeast cells. 2. The MBD4 interaction domain of ZSWIM3 
may be composed of two or more regions of ZSWIM3 that are non-contiguous in the 
amino acid sequence of the protein. 3. The fused GAL4 AD may block the region of 
ZSWIM3 that would otherwise interact with MBD4. 4. The GAL4 AD-ZSWIM3 
fusion proteins may fold incorrectly due to the absence of the remainder of the 
ZSWIM3 protein and/or the presence of the GAL4 AD. and 5. The ZSWIM3 fusion 
proteins may not be localised to the yeast nucleus, and may therefore be unable to 
interact with the nuclear MBD4 fusion protein (this appears to be unlikely as full-
length ZSWIM3 and ZSWIM3 aa7l-696 can interact with MBD4, and can therefore 
localise to the nucleus correctly). 
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Figure 4.13: Mapping the MBD4 interaction domain of ZSWIM3. (A) The yeast two-hybrid 
assay was used in an attempt to delineate the MBD4 interaction domain of ZSWIM3. In 
addition to variants of the positive and negative controls described in the text, various MBD4 
and ZSWIM3 deletion construct co-transformations are shown. (B) Schematic of the 
ZSWIM3 protein and the ZSWIM3 deletion series that was used in this experiment. S = 
SWIM domain. + or - indicates the presence or absence of an interaction between MBD4 
and a ZSWIM3 deletion construct. 
The expression of the ZSWIM3 fusion proteins was investigated by western blotting 
yeast whole cell extracts prepared from MBD4/ZSWIM3 deletion protein co-
transformants using an anti-haemaglutinin (HA) epitope tag antibody (Figure 4.14; 
pACT2 contains an HA tag in frame with the GAL4 AD). As in the pGBT9 plasmid, 
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truncated ADH1 promoter; however, in pACT2 the promoter is adjacent to a region 
(pBR322 that acts a transcriptional enhancer in yeast (Tornow and Santangelo, 
1990), resulting in a level of fusion protein expression that is detectable by western 
bluitin (Clontech, 2000). 
The (jt\1_4 AD (aa768-881 of GAL4) has a predicted molecular weight of 12.4kD 
but runs with an apparent molecular weight of 25kD by SDS PAGE (approximately 
30 vector-encoded amino acids which include the HA epitope tag are also present). 
The GAL4 AD-ZSWM3 fusion proteins are expressed and run as expected 
according to the apparent molecular weight of the GAL4 AD by SDS PAGE and the 
predicted molecular weights of the ZSWIM3 deletion proteins (ZSWIM3 aczl-696: 
79.6kD, ZSWIM3 aa7l-696: 71.OkD, ZSWIM3 acd-232: 26.61cD, ZSWIM3 
acx233-464: 26.7kD, ZSWIM3 aa465-696: 26.2kD, ZSWIM3 aal-348: 40.OkD. 
and ZSWIM3 ct(049-696: 39.5kD), with the exception of the GAL4 AD-ZSWIM3 
uct465-696 fusion protein. The GAL4 AD-ZSWIM3 aa465-696 lane contains a 
band with an apparent molecular weight which is very similar to that of the GAL4 
AD alone. It would be useful to western blot yeast whole cell extracts isolated from a 
number of GAL4 AD-ZSWIM3 ctct465-696 transformed single colonies to determine 
whether a band of the expected molecular weight (approximately 50kD) is present in 
any of the extracts. Nonetheless, the GAL4 AD-ZSWIM3 ctct349-696 fusion protein, 
which encompasses amino acids 465 to 696 of the ZSWIM3 protein, is expressed as 
a fusion protein of the expected molecular weight, and does not interact with MBD4 
in the yeast two-hybrid assay. This suggests that the absence of an interaction 
between MBD4 and the ZSWIM3 deletion proteins  is not due to the absence of 
ZSWIM3 fusion protein expression within the co-transformed yeast cells. In this 
case, the most likely reason why MBD4 cannot interact with any of the ZSWIM3 
deletion proteins other than ZSWIM3 ua7l-696 is that the MBD4 interaction 
domain of ZSWIM3 is composed of two or more regions of ZSWIM3 that are non-
contiguous in the amino acid sequence of the protein, but that are adjacent in the 
tertiary structure of the protein. It would be interesting to mutate the zinc-chelating 
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Figure 4.14 Investigation of GAL4 AD-ZSWIM3 fusion protein expression. PJ694-a yeast 
was co-transformed with constructs encoding the fusion proteins indicated, and with GAL4 
DBD-MBD4. Yeast whole cell extracts were prepared, resolved by SIDS PAGE, and western 
blotted with an anti-HA antibody. A Coomassie Brilliant Blue R-250 stained gel is shown as a 
loading control. 
4.6 The intracellular distribution of ZSWIM3 
4.6.1 The distribution of ZSWIM3 in human cells 
A protein-protein interaction detected by the yeast two-hybrid assay may not 
necessarily occur in vivo because the proteins involved in the interaction may be 
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dcvelopment. Alternatively, the proteins may localise to different regions within the 
cell, or may be expressed in different cell types. In order to determine whether the 
intracellular distributions of MBD4 and ZSWIM3 overlap, MBD4 and ZSWIM3 
were over-expressed in human cells and the distributions of the proteins were 
visualised by immunocytochemistry. Ucla cells were transiently transfected with 
FLAG-tagged ZSWIM3 and either HA- or EGFP-tagged MBD4. MBD4 localised to 
the nucleus of the I-Ida cells, as has been seen previously (Figure 4.15) (Hendrich 
and Bird, 1998; Millar, 2002). In the majority of the cells, ZSWIM3 was distributed 
throughout the cell. In the remaining cells, ZSWIM3 was localised to either the 
nucleus or the cytoplasm. The variable localisation of ZSWTM3 in different cells 
could be due to changes in ZSWIM3 localisation at different stages of the cell cycle, 
or could simply be an artefact of ZSWIM3 over-expression. Nevertheless, it is clear 
that ZSWTM3 can be localised to the nucleus in human cells, and therefore that 
MBD4 and ZSWIM3 may interact in vivo. 
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Figure 4.15: The distribution of ZSWIM3 in Hela cells. ZSWIM3 can be distributed throughout 
the cell or can localise to either the nucleus or the cytoplasm in human cells. Hela cells were 
transiently transfected with FLAG-tagged ZSWIM3 and HA-tagged MBD4. FLAG-tagged 
ZSWIM3 was detected with an anti-FLAG antibody, and HA-tagged M13134 was detected with 
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an anti-HA antibody. DNA was visualised using 4-6-dtamidino-2-phenylindole (DAPI). FLAG-
tagged ZSWIM3 and EGFP-tagged MBD4 co-transfections gave identical results and are not 
shown. 
4.6.2 The distribution of Zswim3 in mouse cells 
In mouse cells, approximately half of the 5mcC present in the genome is located 
within the pericentromeric major satellite repeat (Miller el al., 1974), and when 
mouse cells are stained with DAPI these heterochromatic regions are visible as bright 
spots or 'DAPI bright spots' within the nuclei. When over-expressed in mouse cells. 
Mbd4 localises to the nucleus and to DAPI bright spots due to the presence of the 
MBD (Hendrich and Bird, 1998). It is therefore more informative to assess the co-
localisation of MBD4 and ZSWIM3 in mouse cells than in human cells. NIH3T3 
cells were transiently transfccted with FLAG-tagged Zswim3 and HA- or GFP-
tagged Mbd4. Mbd4 localised to the nucleus and to DAPI bright spots as expected 
(Figure 4.16). In the majority of the cells, Zswim3 was distributed throughout the 
cell but with some localisation to DAPI bright spots. In the remaining cells, Zswim3 
was either distributed throughout the cell with no DAPI bright spot localisation, or 
was localised to the cytoplasm. The co-localisation of Mbd4 and Zswim3 at DAPI 
bright spots in mouse cells is therefore consistent with the occurrence of an 
interaction between Mbd4 and Zswini3. 
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Figure 4.16: The distribution of Zswim3 in NIH3T3 cells. Zswim3 can be distributed 
throughout the cell either with or without some localisation to DAR bright spots, or can 
localise to the cytoplasm. NIH3T3 cells were transiently transfected with FLAG-tagged 
Zswim3 and HA-tagged Mbd4. FLAG-tagged Zswim3 was detected with an anti-FLAG 
antibody, and HA-tagged Mbd4 was detected with an anti-HA antibody. DNA and DAR 
bright spots were visualised using DAR. FLAG-tagged ZSWIM3 and GFP-tagged Mbd4 co-
transfections gave identical results and are not shown. 
The localisation of Zswim3 is dependent on Mbd4 
If the localisation of Zswim3 to DAPI bright spots in mouse cells is mediated by an 
interaction with Mbd4, this localisation should be dependent on the presence of both 
Mbd4 and DNA methylation. In order to test whether the localisation of Zswim3 to 
DAPI bright spots is dependent on the presence of Mbd4, an Mbd4 knockout mouse 
embryonic fibroblast cell line was transiently transfected with FLAG-tagged Zswim3 
and either HA-tagged Mbd4 or HA alone. The distribution of Zsw1m3 was examined 
in 50 cells and was categorised as either DAM bright spots + nucleus + cytoplasm 
(i.e. distributed throughout the cell but with some localisation to DAM bright spots), 
Nucleus + cytoplasm (i.e. distributed throughout the cell with no DAPI bright spot 
localisation), or Cytoplasm (i.e. localised to the cytoplasm) (Figure 4.17). Zswim3 
was localised to DAPI bright spots in 35 cells expressing HA-Mbd4, but in none of 
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L iiockout cell line after transient transfection with FLAG-tagged Zswim3 and either 
FP-tagged Mbd4 or GFP alone. In this experiment, Zsw1m3 was localised to DAPI 
bright spots in 28 cells expressing Mbd4-GFP, but in none of the cells expressing 
(IFP alone. The experiments in the Mbd4 knockout cell line therefore indicate that 
the localisation of Zswim3 to DAPI bright spots is dependent on the presence of 
\lbd4. 
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• cytoplasm 
i Figure 4.17: The localisation of Zswim3 s dependent on Mbd4. Mbd4 +1+  and Mbd4 1- cells 
were transiently co-transfected with FLAG-tagged Zswim3 and the constructs indicated. 
FLAG-tagged Zswim3 was detected with an anti-FLAG antibody, and HA-tagged Mbd4 was 
detected with an anti-HA antibody. DNA and DAR bright spots were visualised using DAPI. 
The distribution of Zswim3 was examined in 50 cells and was categorised as either DAR 
bright spots + nucleus + cytoplasm, Nucleus + cytoplasm, or Cytoplasm. 
These experiments were repeated in a wild type mouse embryonic fibroblast cell line 
in order to determine whether there is sufficient endogenous Mbd4 present to 
mediate the localisation of the over-expressed Zswim3 to DAPI bright spots (Figure 
4.17). Zswim3 was localised to DAPI bright spots in 40 cells expressing HA-Mbd4, 
but in none of the cells expressing HA alone. Similarly, Zswim3 was localised to 
DAPI bright spots in 28 cells expressing Mbd4-GFP, but in only one of the cells 
expressing GFP alone. These results suggest that, perhaps unsurprisingly, the level of 
141 
Clipte 	Aa tra tai btn tvlbD4 and ZS VV/t'id 
'11(101 	 IN ti a \\ ild ivpc tiiu 	iiibI\ uni 	1brobIat 	I1 linc 	tint 
cnerally sufficient to mediate the localisation of detectable levels of over-expressed 
Zswim3 to DAPI bright spots. 
The localisation of Zswim3 is dependent on DNA methylation 
In order to confirm that the localisation of Zswim3 to DAPI bright spots is also 
dependent on the presence of DNA methylation. the DNA methylation-deficient 
DnntJ p53 mouse embryonic fibroblast cell line was used (Jorgensen et al., 
2004). In this cell line, the major satellite repeat is only methylated at a very low 
level, although pericentromeric heterochromatin can still be visualised as DAPI 
bright spots. The absence of p53 is necessary to allow the survival of the Dnmtl-
deficient cells (Li etal., 1992: Jackson-Grusby etal., 2001). The Dnmt1"p53 cell 
line was transiently transfected with FLAG-tagged Zswim3 and either HA-tagged 
Mbd4 or HA alone. The distribution of Zswim3 was examined in 50 cells and was 
categorised as either DAPI bright spots + nucleus + cytoplasm, Nucleus + cytoplasm 
or Cytoplasm (Figure 4.18). Zswini3 was localised to DAPI bright spots in only three 
cells expressing HA-Mbd4, and in none of the cells expressing HA alone. Similarly, 
when the DNA methylation-deficient cell line was transiently transfected with 
FLAG-tagged Zswim3 and either GFP-tagged Mbd4 or GFP alone, Zsw1m3 was not 
localised to DAPI bright spots in any of the cells. These experiments were repeated 
in a Dnmti' p53 mouse embryonic fibroblast cell line, which contains normal 
levels of major satellite repeat methylation (Jorgensen et al., 2004), in order to verify 
that the absence of p53 does not affect the localisation of Zsw1m3 to DAPI bright 
spots (Figure 4.18). Zswim3 was localised to DAPI bright spots in 36 cells 
expressing HA-Mbd4, but in none of the cells expressing I-IA alone. Similarly, 
Zswini3 was localised to DAPI bright spots in 27 cells expressing Mbd4-GFP, but in 
none of the cells expressing GFP alone. This confirms that the absence of Zswirn3 
localisation to DAPI bright spots in the Dn,ntlnhmn  p53 cell line is due to the 
























Figure 4.18: The localisation of Zswim3 is dependent on DNA methylation. Dnmt1 p53 
and Dnmt1 1 p53 cells were transiently co-transfected with FLAG-tagged Zswim3 and the 
constructs indicated. FLAG-tagged Zswim3 was detected with an anti-FLAG antibody, and 
HA-tagged Mbd4 was detected with an anti-HA antibody. DNA and DAR bright spots were 
visualised using DAPI. The distribution of Zswim3 was examined in 50 cells and was 
categorised as either DAR bright spots + nucleus + cytoplasm, Nucleus + cytoplasm, or 
Cytoplasm. 
4.7 Conclusions 
MBD4 has been shown to interact with three proteins in yeast two-hybrid screens; 
the mismatch repair protein MLIIl, the pro-apoptotic kinase ZIP kinase, and an 
uncharacterised protein ZSWIM3 (Bellacosa et al., 1999; Millar, 2002). The 
interactions of MBD4 with different proteins are of interest as they may regulate the 
thyminc DNA glycosylase activity of MBD4 in vivo. Indeed, the DNA glycosylase 
activity of MBD4 appears to be inhibited by a protein component of nuclear extracts 
in an in vitro DNA glycosylase assay, although further experiments are required to 
confirm this observation. 
ZSWIM3 is a highly conserved protein that contains a zinc finger SWIM domain of 
unknown function. The ZSWIM3 interaction domain of MBD4 was investigated 
using the yeast two-hybrid assay, and ZSWIM3 was shown to interact with amino 
143 
Chapter 4: An interaction between MBD4 and ZSWIM3 
acids 440 to 580 of MBD4, a region of the protein that i highly conserved and that 
contains the DNA glycosylase domain. It is therefore likely that the thymine DNA 
glycosylase activity of MBD4 would be inhibited by an MBD4-ZSWIM3 interaction. 
Interestingly, ZIP kinase was shown to interact with, amino .acids 435 to 580 of 
MBD4, and may therefore compete with ZSWIM3 to bind to MBD4 in vivo. 
Alternatively, ZIP kinase may bind to MBD4 transiently and phosphorylate one or 
more residues, possibly changing the affinity of MBD4 for ZSWIM3, or altering the 
DNA binding or DNA glycosylase activity of MBD4. 
The MBD4 interaction domain of ZSWIM3 was also investigated using the yeast 
two-hybrid assay. The SWIM domain has been proposed to have diverse DNA-
binding or protein-protein interaction functions depending on the context of the 
protein in which the domain is present (Makarova et al., 2002), and may therefore 
mediate the interaction between MBD4 and ZSWIM3. However, amino acids 349 to 
696 of ZSWIM3 (which encompass the SWIM domain) failed to interact with 
MBD4. Indeed, none of the ZSWIM3 deletion proteins tested interacted with MBD4, 
with the exception of amino acids 71 to 696 of the protein (this is the MBD4-
interacting ZSWIM3 clone that was identified in the original yeast two-hybrid 
screen). It is therefore likely that the MBD4 interaction domain of ZSWIM3 is 
composed of two or more regions of ZSWIM3 that are separated within the amino 
acid sequence. The possibility that the SWIM domain of ZSWIM3 may mediate the 
MBD4-ZSWIM3 interaction could be investigated by mutation of the zinc-chelating 
cysteine or histidine residues within the SWIM domain, and then using the mutated 
ZSWTM3 protein in the yeast two-hybrid assay. 
MBD4 and ZSWIM3 were over-expressed in mouse and human cells in order to 
determine whether the intracellular distributions of the two proteins overlap, and 
therefore whether an MBD4-ZSWIM3 interaction could feasibly occur in vivo. 
ZSWIM3 showed variable intracellular distributions in both mOuse and human cells. 
In human cells, ZSWIM3 was distributed throughout the cell, or was either localised 
to the nucleus or to the cytoplasm Although the variable distribution of ZSWIM3 
may be an artefact caused by protein over-expression, it may reflect changes in the 
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localisation of ZSWIM3 at different stages of the cell cycle. This could be 
investigated by arresting cells at different stages of the cell cycle before visualising 
ZSWIM3 localisation. Zswim3 also showed variable intracellular distributions in 
mouse cells. In the majority of cells, Zswim3 was distributed throughout the cell but 
with some localisation to DAPI bright spots (DAPT bright spots contain highly 
methylated pericentromeric major satellite repeat sequences). In the remaining cells, 
Zswim3 was either distributed throughout the cell with no DAPI bright spot 
localisation, or was localised to the cytoplasm. As Mbd4 loéalises to DAPI bright 
spots via its MBD (Hendrich and Bird, 1998), the localisation of Zswim3 to DAPI 
bright spots in mouse cells is consistent with an Mbd4-Zswim3 interaction occurring 
in vivo, and suggests that Mbd4 can recruit Zswim3 to the highly methylated DNA 
sequences that constitute DAN bright spots. When this hypothesis was tested by the 
quantitation of Zswim3 localisation in mouse cells in the presence or absence of 
Mbd4, it was shown that Mbd4 was required to recruit Zswim3 to DAPI bright spots. 
Furthermore, the quantitation of Zswim3 localisation in mouse cells that contained 
normal or low levels of DNA methylation confirmed that the recruitment of Zsw1m3 
to DA-PI bright spots is dependent on the presence of normal levels of DNA 
methylation. 
The experiments presented in this chapter show that MBD4 can interact with 
ZSWIM3 in vivo, and suggest that this interaction may inhibit the DNA glycosylase 
activity of MBD4. Further experiments are required to confirm and extend these 
observations, e.g. the physical interaction between MBD4 and ZSWIM3 could be 
confirmed by an MBD4/ZSWIM3 co-immunoprecipitation experiment. It would 
also be useful to raise an antibody that can recognise the endogenous ZSWIM3 
protein to enable the interaction between endogenous MBD4 and ZSWIM3 to be 
investigated (a rabbit polyclonal antibody was raised against a ZSWIM3 peptide 
during the course of these experiments, but this antibody failed to recognise 
endogenous ZSWIM3).. Finally, it would be very interesting to determine whether 
ZSWIM3 can inhibit the thymine DNA glycosylase activity of MBD4 in the in vitro 
DNA glycosylase assay that was described in Section 4.2, using either recombinant 
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MBD4 and ZSWIM3, or nuclear extracts in which the level of ZSWIM3 has been 
knocked down by RNA-mediated interference. 
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Chapter 5 
The sumoylation of MBD4 
5.1 Introduction 
Sumoylation is the post-translational modification of a substrate protein by the 
covalent attachment of a small ubiquitin-related modifier (SUMO) protein (Johnson, 
2004). The linkage between SUMO and the substrate protein is an isopeptide bond 
between the C-terminal carboxyl group of SUMO and the 6-amino group of an 
acceptor lysine residue in the consensus sumoylation motif WKxE/D (where W is a 
large hydrophobic amino acid and x is any amino acid) within the substrate protein 
(Sampson et al., 2001; Rodriguez et al., 2001). Invertebrates have only a single 
SUMO gene, but vertebrates have three SUMO genes that are expressed (SUMO- 1, 2 
and 3). Human SUMO-1 is only approximately 50% identical to SUMO-2 and 3, 
which are approximately 95% identical to each other (Figure 5.1). Indeed, SUMO-2 
and 3 are regarded as functionally equivalent and are generally referred to as SUMO-
2/3. The majority of the SUMO-1 present within cells is conjugated to substrate 
proteins, but there is a large pool of unconjugated SUMO-2/3, which is only 
conjugated to substrate proteins when cells are exposed to environmental stress such 
as acute heat elevation or oxidative stress (Saitoh and Hinchey, 2000). As SUMO-2 
and 3 both contain a sumoylation motif, chains of poly-SUMO-2 or 3 can form in 
vitro and in vivo (Tatham et al., 2001), although the biological significance of these 
poly-SUMO chains is unknown. 
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Ubiquitin 1 ...................... MQIFKTLTKTITLEVEPSDTI 23 
SUMO-1 	1 SDQEA PSTEDLD1G . YKIS EIHVMTH 44 
SUMO-2 1 ADEK K.......VKTE 	 40 
SUMO -3 	1 	EEKPK.......VKTE 39 
50 	. 	60 	. 	70 	. 80 	. 	90 
Ubiquit.n 24 68 
SUMO-1 45 KKESQEVP 89 
SUMO-2 41 RQ]D DJ 85 
SUMO-3 40 _RQ I QP ION EPAQ*MED9 84 
Ubiquitin 69 LVLRLR 	76 
SUMO-1 90 YEQ'T 97 
SUMO-2 86 _ 93 
SUMO-3 85 QQ 92 
Figure 5.1 :'Amino acid alignment of human ubiquitin and SUMO-1 j 2 and 3. The processed 
forms of ubiquitin and SUMO-1, 2 and 3 are shown. The sumOylation motif present in 
SUMO-2 and 3 is indicated by a line below the alignment. Identical amino acids are shaded 
black, conserved amino acids are shaded dark grey, and similar amino acids are shaded 
light grey. 
Although the majority of sumoylated proteins that have been characterised to date 
are transcription factors, SUMO can be conjugated to proteins that are involved in a 
number of cellular processes other than transcriptional regulation, e.g. nuclear 
transport, signal transduction, DNA repair, and control of the cell cycle (Hay, 2005). 
In contrast to ubiquitin conjugation, which generally targets substrate proteins for 
26S proteasome-mediated degradation, the biological consequences of SUMO 
conjugation are highly variable and can include the prevention of ubiquitination 
(Desterro et al., 1998), and the alteration of interactions with Other proteins (Mahajan 
et al., 1997) or DNA. 
5.2 The SUMO conjugation pathway 
The SUMO conjugation pathway involves three enzymes; an El SUMO-activating 
enzyme, an E2 SUMO-conjugating enzyme and an E3 SUMO ligase (Johnson, 
2004). In vertebrates, the El SUMO-activating enzyme is a heterodimer composed of 
AOS1 and UBA2 (Johnson et al., 1997): The El enzyme catalyses the ATP-
dependent activation of the C-terminus of SUMO, and transfers activated SUMO to 
the E2 SUMO-conjugating enzyme. The E2 enzyme, UBC9, can bind to a 
sumoylation motif within a substrate protein and transfer SUMO to the substrate 
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protein (Okuma et al., 1999; Sampson et al., 2001). The transfer of SUMO from the 
E2 enzyme to the substrate protein occurs with significantly higher efficiency when 
an E3 SUMO ligase, which binds to both the E2 enzyme and the substrate protein, is 
also present. There are three known types of E3 SUMO ligases; the protein inhibitor 
of activated STAT (PIAS) family of proteins (Jackson, 2001; Kotaj a et al., 2002), the 
nuclear pore protein RanBP2 (Pichler .et al., 2002), and the Polycomb group protein 
Pc2 (Kagey et al., 2003). The E3 enzymes have relatively broad and partially 
overlapping substrate specificities, and often promote the sumoylation of proteins 
that have little apparent similarity to one another (Melchior et al., 2003). 
Sumoylation is a reversible and therefore potentially dynamic post-translational 
modification as SUMO can be deconjugated from substrate proteins by SUMO 
proteases (Melchior et al., 2003). In vertebrates, SUMO proteases belong to the 
sentrin-specific protease (SENP) family, and have a conserved C-terminal catalytic 
domain and a variable N-terminal region that targets the protease to a particular 
intracellular location, e.g. SENP 1, SENP3 and SENP6 are localised to the nucleus, 
the nucleolus and the cytoplasm respectively (Bailey and O'Hare, 2002; Nishida et 
al., 2000; Kim et al., 2000). In addition to the isopeptidase activity that deconjugates 
SUMO from substrate proteins, SUMO proteases also have a C-terminal hydrolase 
activity that processes SUMO precursor proteins to mature forms that can be 
conjugated to substrate proteins (Melchior et al., 2003). SUMO proteases are likely 
to mediate the selective deconjugation of SUMO from particular sumoylated proteins 
in vivo as a result of differences in SUMO paralog deconjugation activity and 
intracellular localisation. The steady-state level of a sumoylated substrate protein in 
vivo is therefore tightly regulated by a number of competing E3 SUMO ligase and 
SUMO protease activities. 
5.3 MBD4 may be sumoylated 
MBD4 was identified as a potential substrate of the SUMO-2 conjugation pathway in 
an experiment in which TAP-tagged SUMO-2 was over-expressed in Hela cells, and 
SUMO-2-conjugated proteins were TAP purified and identified by mass 
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spectrometry (Ron Hay, University of St Andrews, personal communication). The 
mouse and human MBD4 amino acid sequences contain a candidate sumoylation 
motif, consisting of the amino acid sequence LKPE, within the MBD. The LKPE 
motif is not conserved in any of the other MBD proteins, but is conserved in other 
MBD4 orthologs. Mouse Mbd4 also contains an additional candidate sumoylation 
motif (GKFD) within the MBD, but the acceptor lysine residue within this motif is 
not conserved in human MBD4, and is poorly conserved in other MBD4 orthologs. 
Similarly, human MBD4 contains an additional candidate sumoylation motif 
(LKED) between the MBD and the glycosylase domain, but this motif is not 
conserved in mouse Mbd4 and is relatively poorly conserved in other MBD4 
orthologs. An analysis of the mouse and human amino acid sequences of MBD4 
therefore suggests that the most likely site of SUMO conjugation to MBD4 is the 
conserved LKPE motif within the MBD of the protein. 
5.4 MBD4 can be sumoylated by SUMO-1 and 2 
The SUMO-1 conjugation pathway can be reconstituted in E. co/i by the co-
transformation of plasmids encoding the El SUMO-activating  enzyme, the E2 
SUMO-conjugating enzyme, SUMO-1 and a substrate protein (Mencia and de 
Lorenzo, 2004; Uchimura et al., 2004a). This system facilitates the preparation of 
large amounts of sumoylated recombinant proteins for biochemical or structural 
analyses, and the investigation of sites of SUMO-1 modification within substrate 
proteins. Inorder to determine whether SUMO- 1 can be conjugated to M13134 in this 
system, three plasmids were co-transformed into E. co/i;. 1. pBADE 12, which 
encodes HIS-tagged human AOS1 and UBA2 (AOS1 and UBA2 form the El 
SUMO-activating enzyme heterodimer) and mouse Ubc9 (UBC9 is the E2 SUMO-
conjugating enzyme). 2. pRSF Duet-1 HIS-SUMO-1, which encodes HIS-tagged 
human SUMO-1. and 3. pET6H mMbd4 or pET6H hMBD4, which encode HIS-
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Figure 5.2: MBD4 can be sumoylated in bacteria expressing SUMO-1 and components of 
the sumoylation pathway Bacteria were transformed with the constructs indicated (mMbd4 = 
mouse Mbd4, hMBD4 = human MBD4, SUMO-1 machinery = HIS-AOS1, UBA2, Ubc9 and 
HIS-SUMO-1), and protein expression was induced. Bacterial lysates were then prepared, 
resolved by SIDS PAGE, and western blotted with anti-MBD4, SUMO-1 and HIS antibodies 
as indicated. 
When the El SUMO-activating enzyme, the E2 SUMO-conjugating enzyme and 
SUMO-1 (i.e. the SUMO-1 machinery) are expressed in bacteria, several bands are 
present on an anti-SUMO-1 western blot of the bacterial lysate. This is probably 
caused by the conjugation of SUMO-1 to bacterial proteins that contain an exposed 
sumoylation motif by chance (the SUMO conjugation pathways are not usually 
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11S-tagged SUMO-I runs with an apparent molecular weight of approximately 
UkD by SDS PAGE (the HIS tag is only six amino acids long and is unlikely to 
Lontribute significantly to the apparent molecular weight of HIS-SUMO-l), and the 
conjugation of a single SUMO protein to a substrate protein adds approximately 
()kD to the apparent molecular weight of the substrate protein (Johnson, 2004). The 
cxprcssion of mouse or human MBD4 in bacteria results in a single major band on an 
anti-MB134 western blot of the bacterial lysate (the predicted molecular weights of 
mouse and human M13134 are 62.7 and 66.2kD respectively). However, when the 
SUMO-1 machinery is co-expressed with mouse or human MBD4, a higher 
molecular weight band is also present on the anti-MBD4 western blot of the bacterial 
lysate. The higher molecular weight band is only present when the SUMO-1 
machinery is co-expressed with mouse or human MBD4, therefore this band is likely 
to contain SUMO- 1-conjugated MBD4. The electrophoretic mobility of the higher 
molecular weight band is consistent with the band containing a single SUMO-1 
protein conjugated to MBD4, and the band is also detected on an anti-SUMO-1 
western blot. Furthermore, most or all of the higher molecular weight band 
disappears when the bacterial lysate is incubated with either of two SUMO proteases, 
yeast ubiquitin-like protease 1 (UlpI) or human SENPI (Figure 5.3). The identity of 
the higher molecular weight band as SUMO-1-conjugated MBD4 is therefore 
supported by the recognition of the band by both anti-MBD4 and SUMO-1 
antibodies, and by the sensitivity of the band to SUMO proteases. 
rnMbd4 	hMBD4 
-SUMO-1 -SUMO-1 
- 	+ 	- 	- 	+ 	- HIS-Ulpi 






Figure 5.3: SUMO-1-modified mouse and human MBD4 can be de-sumoylated by SUMO 
proteases. Bacterial lysates containing SUMO-1-modified mouse or human MBD4 were 
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nurnan SENP1 (HIS-SENP1CD), resolved by SIDS PAGE, then western blotted with an anti-
1131D4 antibody. 
I lie experiment shown in Figure 5.2 suggests that more than one SUMO-1 protein 
may be conjugated to mouse and human MBD4. At least one additional higher 
molecular weight band is faintly visible on the anti-MBD4 western blot of the 
bacterial lysate that contains human MBD4 and the SUMO-1 machinery (this band is 
absent from the lane that contains the bacterial lysate that only expresses human 
M13134). The additional higher molecular weight band is also visible on the anti-
SUMO-1 western blot of the bacterial lysate that contains human MBD4 and the 
SUMO-1 machinery, and appears to be absent from the lane that contains the 
bacterial lysate that only expresses the SUMO-1 machinery. SUMO-1 does not 
contain a sumoylation motif, therefore the conjugation of more than one SUMO-1 
protein to MBD4 in this experiment would probably be due to the conjugation of 
single SUMO-1 proteins to two or more different positions of the MBD4 protein, 
rather than to the formation of a poly-SUMO-I chain at a single position of the 
MBD4 protein. Indeed, the SUMO- I-conjugated mouse Mbd4 band on both the anti-
MBD4 and SUMO-1 western blots appears to be composed of a small number of 
closely spaced bands. The presence of these distinct bands may be due to the 
conjugation of a single SUMO-1 protein to different positions of the Mbd4 protein, 
resulting in small differences in the apparent molecular weights of the modified 
Mbd4 proteins. 
The SUMO-1 conjugation system described above can be converted to a SUMO-2 
conjugation system by replacement of the SUMO-l-encoding plasmid with a 
SUMO-2-encoding plasmid (Uchimura et al., 2004b). In order to determine whether 
SUMO-2 can be conjugated to MBD4 in this system, three plasmids were co-
transformed into E. co/i; pBADE12, pRSF Duct-I HIS-SUMO-2 (which encodes 





























Figure 5.4: MBD4 can be sumoylated in bacteria expressing SUMO-2 and components of 
the sumoylation pathway. Bacteria were transformed with the constructs indicated (mMbd4 = 
mouse Mbd4, hMBD4 = human MBD4, SUMO-2 machinery = HIS-AOS1, UBA2, Ubc9 and 
HIS-SUMO-2), and protein expression was induced. Bacterial lysates were then prepared, 
resolved by SIDS PAGE, and western blotted with anti-MBD4, SUMO-2/3 and HIS antibodies 
as indicated. A Coomassie Brilliant Blue R-250 stained gel is shown as a loading control. 
When the El SUMO-activating enzyme, the E2 SUMO-conjugating enzyme and 
SUMO-2 (i.e. the SUMO-2 machinery) are expressed in bacteria, several bands are 
visible on an anti-SUMO-2/3 western blot of the bacterial lysate. As SUMO-2 
contains a sumoylation motif and can form chains of poly-SUMO-2 in vitro and in 
vivo (Tatham ci al., 2001), these bands may consist of either single or poly-SUMO-
2-conjugated bacterial proteins, or chains of poly-SUMO-2 alone. Although SUMO- 
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pparent molecular weight of 20kD by SDS PAGE. As in the previous experiment, 
lie expression of mouse or human M13134 in bacteria results in a single major band 
on an anti-MBD4 western blot of the bacterial lysate. When the SUMO-2 machinery 
co-expressed with mouse or human M13134, a higher molecular weight band is also 
present on the anti-MBD4 western blot of the human M13134-containing bacterial 
lvsatc, and a higher molecular weight doublet is present on the anti-MBD4 western 
blot of the mouse Mbd4-containing bacterial lysate. These bands are only present 
when the SUMO-2 machinery is co-expressed with mouse or human M13134, and are 
therefore likely to contain SUMO-2-conjugated MBD4. The electrophoretic 
mobilities of these bands are consistent with the bands containing a single SUMO-2 
protein conjugated to M13134 (the SUMO-2-conjugated mouse Mbd4 doublet is likely 
to contain mouse Mbd4 that has been modified by the conjugation of a single 
SUMO-2 protein to two different positions of the Mbd4 protein). The higher 
molecular weight bands are also detected on an anti-SUMO-2/3 western blot, and 
these bands disappear when the bacterial lysates are incubated with Ulpi or SENPI 
SUMO proteases (Figure 5.5). The recognition of the higher molecular weight bands 
by both anti-MBD4 and SUMO-2/3 antibodies, and the sensitivity of these bands to 
SUMO proteases, supports the hypothesis that the bands contain SUMO-2-
conjugated M13134. It is interesting to note that although SUMO-2 contains a 
sumoylation motif, there is no evidence of the formation of poly-SUMO-2-
conjugated M13134 in this experiment (this may be due to low efficiency SUMO-2 
conjugation as a result of the absence of an E3 SUM ligase in this experiment). 
mMbd4 	hMBD4 
-SUMO-2 -SUMO-2 
- 	+ 	- 	- 	+ 	- HIS-Ulpi 








Figure 5.5: SUMO-2-modified mouse and human MBD4 can be de-sumoylated by SUMO 
proteases. Bacterial lysates containing SUMO-2-modified mouse or human MBD4 were 
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incubated with HIS-tagged yeast Ulpi (HIS-UIpl) or the HIS-tagged catalytic domain of 
human SENP1 (HIS-SENP1c0) resolved by SIDS PAGE, then western blotted with an anti- 
MBD4 antibody. 
The conjugation of SUMO-1 and 2 to mouse and human MBD4 in these experiments 
suggests that MBD4 contains sumoylation motifs that are accessible to the E2 
SUMO-conjugating enzyme UBC9. As discussed in Section 5.3, the amino acid 
sequence of human MBD4 contains two candidate sunioylation motifs; one of these 
motifs is within the MBD of MBD4 and is highly conserved in various MBD4 
orthologs, and the other is located between the MBD and the glycosylase domain and 
is relatively poorly conserved (Figure 5.6). 
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In an attempt to determine whether SUMO-1 is conjugated to these candidate 
sumoylation motifs in human MBD4, the putative acceptor lysine residues were 
mutated to alanine residues, and the mutated versions of human MBD4 (MBD4 
K137A and MBD4 K215A) were co-expressed with the SUMO-1 machinery (Figure 
5.7). Somewhat surprisingly, anti-MBD4 and SUMO-1 western blots of the bacterial 
lysates show that SUMO-1 can be conjugated to both MBD4 K137A and MBD4 
K2 1 5A, which could suggest that SUMO-1 is not conjugated to either lysine 137 or 
lysine 215 of human MBD4 in this experiment. However, it should be borne in mind 
that SUMO-1 may be conjugated to two or more different positions of human MBD4 
(as suggested by the experiment shown in Figure 5.2). If this is the case, and if 
SUMO-1 can be conjugated to both lysine 137 and lysine 215 of human MBD4, the 
outcome would resemble the result shown in Figure 5.7. This hypothesis could be 
tested by the mutation of both putative acceptor lysine residues, followed by the co-
expression of MBD4 K137A/K215A and the SUMO-1 conjugation pathway in 
bacteria. An alternative explanation that could account for this result is that SUMO-1 
may be conjugated non-specifically to lysine residues of MBD4 that are not within a 
consensus sumoylation motif, due to high levels of the El SUMO-activating and E2 
SUMO-conjugating enzymes. Indeed, non-specific sumoylation can occur ,  during 
SUMO conjugation reactions performed in vitro if the concentration of the E2 
enzyme UBC9 is too high (Ronald Hay, University of Dundee, personal 
communication). The SUMO-1 conjugation sites of M1304 could therefore be 
mapped by SUMO conjugation reactions performed in vitro, where the concentration 
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Figure 5,7: Human MBD4 K137A and K215A can be sumoylated in bacteria expressing 
SUMO-1 and components of the sumoytation pathway. Bacteria were transformed with the 
constructs indicated (hMBD4 = human MBD4, SUMO-1 machinery = HIS-AOS1, UBA2, 
Ubc9 and HIS-SUMO-1) and protein expression was induced. Bacterial lysates were then 
prepared, resolved by SIDS PAGE, and western blotted with anti-MBD4, SUMO-1 and HIS 
antibodies as indicated. 
5.5 Is M13D4 sumoylated in vivo? 
The most challenging aspect of studying the sumoylation of a protein of interest in 
vivo is that only a very small proportion (often less than 1%) of a SUMO substrate 
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01 an antibody that recognises the protein of interest with high sensitivity and 
specificity is therefore critical to the investigation of protein sumoylation (Jaffray 
and Hay, 2006). An additional problem encountered when studying protein 
sumoylation is that SUMO protcases rapidly deconjugate SUMO from modified 
substrate proteins during the isolation of protein extracts for analysis. In an attempt 
to detect endogenous MBD4 that had been sumoylated in vivo, a number of different 
protein extracts (a whole cell extract, a cytoplasmic extract, a whole nuclear extract, 
a nuclear extract and a nuclear pellet extract) were isolated from Ucla cells in the 
presence of N-ethylmaleimide (NEM; NEM inhibits SUMO proteases by irreversibly 
reacting with the thiol group of the active site cysteine residue to form a thioether). If 
endogenous MBD4 is sumoylated in vivo, one or more bands with a higher molecular 
weight than unmodified MBD4 may be visible on an anti-MBD4 western blot of the 
NEM-containing protein extracts. The various Ucla cell protein extracts were 
resolved by SDS PAGE and were western blotted with two different antibodies that 
recognise endogenous human MBD4 (Figure 5.8). Anti-MBD4 M9817 was raised 
against a short peptide corresponding to the C-terminus of MBD4, and anti-MBD4 
417-3 was raised against full-length human MBD4; these antibodies are therefore 
likely to react with different epitopes of the human MBD4 protein, and are unlikely 
to cross-react with the same non-MBD4 proteins, thereby reducing the possibility of 
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Figure 5.8: Endogenous sumoylated MBD4 is not detected in various protein extracts 
isolated from mammalian cells. A whole cell extract, cytoplasmic extract, whole nuclear 
extract, nuclear extract and nuclear pellet extract were isolated from Hela cells in the 
presence of the SUMO protease inhibitor NEM. The protein extracts were resolved by SIDS 
PAGE, then western blotted with anti-MBD4 M9817 and anti-MBD4 417-3 antibodies as 
indicated. Coomassie Brilliant Blue R-250 stained SIDS PAGE 8% and 15% gels are shown 
as protein loading controls. 
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corresponding to unmodified MBD4 on western blots of the whole cell extract, the 
hole nuclear extract, the nuclear extract and the nuclear pellet extract (as expected, 
little or no MBD4 is detected in the cytoplasmic extracts). Somewhat 
disappointingly, there are no higher molecular weight bands that appear to 
)rrespond to SUMO-conjugated MBD4 on the anti-MBD4 M9817 and anti-MBD4 
417-3 western blots. This experiment may therefore indicate that MBD4 is not 
sumoylated in vivo. Alternatively, the absence of detectable SUMO-conjugated 
MBD4 may simply reflect the difficulty of detecting sumoylated proteins that are 
generally present at low steady-state levels, or that may only be present under certain 
conditions. As MBD4 was identified as a potential substrate of SUMO-2 
modification (Ronald Hay, personal communication), and the conjugation of SUMO-
2/3 to substrate proteins is induced by heat-shock (Saitoh and Hinchey, 2000), it 
would be interesting to try to detect sumoylated MBD4 in protein extracts isolated 
from heat-shocked cells. 
5.6 MBD4 sumoylation can be promoted by over-
expressed PIASI and PIAS3 
In order to determine whether endogenous MBD4 is sumoylated when an E3 SUMO 
ligase is over-expressed in mammalian cells, PIAS1 was over-expressed in Hcla cells 
and nuclear extracts were isolated in the presence of NEM (Figure 5.9). A single 
major band of endogenous MBD4 is present on an anti-MBD4 western blot of a 
nuclear extract isolated from mock transfected Ucla cells, but when PIAS1 is over-
expressed, a higher molecular weight doublet is also present on the anti-MBD4 
western blot of the nuclear extract. This doublet is likely to contain SUMO-
conjugated MBD4 as it is only present when the E3 SUMO ligase PIAS1 is over-
expressed, and the apparent molecular weight of the doublet is consistent with the 
conjugation of a single SUMO protein. The presence of two closely spaced bands 
that contain SUMO-conjugated MBD4 suggests that a single SUMO protein has been 
conjugated to two different positions of the MBD4 protein resulting in small 
differences in the electrophoretic mobilities of the modified proteins. It is interesting 
162 
Chptt .5 1 he.iinoyIation of A45D4 
noIc thol lo 	 in 	',l. \1( )-I 	 ihI OtU,C the ippc:ironcc 0! 
SUMO-conjugated MBD4, and the over-expression of SUMO-1 and PIAS I does not 
cause an increase in the amount of SUMO-conjugated MBD4 relative to the over-


















Figure 5.9: Endogenous MBD4 is sumoylated when PIAS1 is over-expressed within 
mammalian cells. Hela cells were transiently transfected with the constructs indicated. PIAS3 
C299S/H301A contains a non-functional SP-RING domain and lacks E3 SUMO ligase 
activity. Nuclear extracts were prepared from the transfected cells in the presence of the 
SUMO protease inhibitor NEM. The nuclear extracts were resolved by SIDS PAGE, then 
western blotted with anti-MBD4, PIAS1 and SUMO-1 antibodies. A Coomassie Brilliant Blue 
R-250 stained SIDS PAGE gel is shown to demonstrate equal loading. 
PIAS3 was also tested for MBD4-specific E3 SUMO ligase activity by over- 
expression in Ucla cells (Figure 5.10). As in the previous experiment, an anti-MBD4 
western blot of a nuclear extract isolated from mock transfected Hela cells has a 
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molecular weight band (which is visible against a background of faint bands that are 
present in all lanes of the western blot) is also present when wild type PIAS3 is over-
L\pressed. This band is likely to contain sumoylated MBD4 as it is present when 
wild type PIAS3 is over-expressed, but absent when PIAS3 with a mutated SP-RING 
domain is over-expressed (the SP-RING domain is homologous to the RING domain 
of E3 ubiquitin ligases and is essential for E3 SUMO ligase activity). Furthermore, 
the clectrophoretic mobility of the higher molecular weight band is consistent with 
the band containing MBD4 that has been modified by the conjugation of a single 
SUMO protein. Once again, the over-expression of SUMO- I alone does not cause 
the appearance of SUMO-conjugated MBD4, and the over-expression of SUMO- I 
and PIAS3 does not cause an increase in the amount of sumoylated MBD4 relative to 
the over-expression of PIAS3 alone. This could either suggest that PIAS land PIAS3 
promote the conjugation of SUMO-2/3 rather than SUMO-1 to MBD4, or (if PIAS I 
and PIAS3 promote the conjugation of SUMO-1 to MBD4) that SUMO-1 is not the 
limiting factor in this reaction. Nevertheless, irrespective of whether MBD4 is being 
modified by the conjugation of either SUMO-1 or SUMO-2/3, these experiments 
clearly show that over-expressed PIAS I and PIAS3 can act as M13134-specific E3 
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Figure 5.10: Endogenous MBD4 is sumoylated when PIAS3 is over-expressed within 
mammalian cells. Hela cells were transiently transfected with the constructs indicated. 
Nuclear extracts were prepared from the transfected cells in the presence of the SUMO 
protease inhibitor NEM. The nuclear extracts were resolved by SIDS PAGE, then western 
blotted with anti-MBD4, GFP and SUMO-1 antibodies. A Coomassie Brilliant Blue R-250 
stained SDS PAGE gel is shown to demonstrate equal loading. 
5.7 Conclusions 
Human MBD4 was identified as a potential substrate of the SUMO-2 conjugation 
pathway (Ronald Hay, personal communication), and contains a conserved candidate 
sumoylation motif (LKPE) within the MBD of the protein. The sumoylation of 
MBD4 at this position would be highly likely to disrupt DNA binding activity and 
may also affect DNA glycosylase activity of the protein, therefore the likelihood of 
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MBD4 being a bona fide substrate of the SUMO conjugation pathways was 
investigated in a series of in vitro and in vivo experiments. 
The SUMO-1 and 2 conjugation pathways were reconstituted in E. coli by the co-
expression of the El SUMO-activating enzyme (AOS1-UBA2), the E2 SUMO-
conjugating enzyme (Ubc9) and either SUMO-1 or 2. It should be borne in mind that 
SUMO-1 and SUMO-213 are not differentially conjugated to substrate proteins in the 
absence of an E3 SUMO ligase (Tatham et al., 2001; Tatham et al., 2003), therefore 
this system cannot be used to investigate SUMO paralog-specific modification. 
Nevertheless, when mouse or human MBD4 was co-expressed in bacteria with either 
of the conjugation pathways, SUMO conjugation occurred confirming that these 
proteins both contain at least one exposed sumoylation motif. Indeed, sumoylation 
appeared to occur at more than one position of mouse and human MBD4, although it 
is possible that non-specific sumoylation may occur in this system due to high 
expression levels of the El SUMO-activating and E2 SUMO-conjugating enzymes. 
It would be interesting to map the SUMO conjugation site(s) of mouse and human 
MBD4 in vitro, where the concentrations of the El and E2 enzymes can be titrated to 
minimise the possibility of non-specific sumoylation. 
In an attempt to determine whether MBD4 is sumoylated in vivo, various protein 
extracts were prepared from Hela cells in the presence of the SUMO protease 
inhibitor NEM, but when the protein extracts were western blotted with two different 
anti-MBD4 antibodies, bands corresponding to sumoylated MBD4 were not detected. 
Although this could be due to the absetice of sumoylated MBD4 in vivo, it is also 
possible that a low but undetectable level of sumoylated MBD4 is present. As MBD4 
was identified as a potential substrate of SUMO-2 conjugation, and SUMO-2 
conjugation is induced in response to environmental stress such as heat-shock (Saitoh 
and Hinchey, 2000), the level of sumoylated MBD4 may be increased to a detectable 
level by heat-shocking cells prior to the isolation of protein extracts. Further 
experiments are required in order to investigate this possibility. 
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The transfer of SUMO from the E2 SUMO-conjugating enzyme to a substrate 
protein is promoted by an E3 SUMO ligase in vivo, and three different types of E3 
enzyme have been characterised; the PIAS family of proteins (Jackson, 2001; Kotaja 
et al., 2002), which consists of PIAS 1, PIAS3, PIASx and PIASy; the nuclear pore 
protein RanBP2 (Pichler et al., 2002); and the Polycomb group protein Pc2 (Kagey et 
al., 2003). A candidate approach was adopted to identify E3 enzymes that may have 
MBD4-specific E3 SUMO ligase activity in vivo. PIAS 1 and PIAS3 were over-
expressed in Hela cells and NEM-containing nuclear extracts were isolated. Anti-
MBD4 western blots of these extracts show that MBD4 can be sumoylated when 
either PIAS 1 or PIAS3 are over-expressed. The PIAS proteins are already known to 
have partially overlapping substrate specificities, e.g. both PIAS1 and PIASx3 (an 
alternatively spliced isoform of PIASx) can promote the sumoylation of p53 (Kahyo 
et al., 2001; Schmidt and Muller, 2002), and it would be interesting to investigate 
whether the PIASx isoforms and PIASy (and indeed, RanBP2 and Pc2) also display 
MBD4-specific E3 SUMO ligase activity. Interestingly, the pattern of MBD4 
sumoylation differs depending on which PIAS protein is over-expressed; if PIAS 1 is 
over-expressed, a single SUMO protein is conjugated to two different positions of 
MBD4, but if PIAS3 is over-expressed, a single SUMO protein is conjugated to a 
single position of MBD4. In the experiments in which the SUMO-1 and 2 pathways 
were reconstituted in E. co/i, sumoylation appeared to occur at two, or more positions 
of human MBD4, and in addition to the conserved candidate sumoylation motif 
within the MBD, human MBD4 also contains a less well conserved candidate 
sumoylation motif between the MBD and the glycosylase domain. The utilisation of 
these sumoylation sites could be investigated using PIAS 1 and PIAS3-containing in 
vitro SUMO conjugation reactions. 
The experiments presented in this chapter support the hypothesis that MBD4 is a 
bonafide substrate of the SUMO conjugation pathways, as they show that mouse and 
human MBD4 contain exposed SUMO conjugation motifs, and that he over-
expression of the E3 SUMO ligases PIAS 1 and PIAS3 promotes SUMO conjugation 
to human MBD4. Further experiments are 'required to confirm that endogenous 
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MBD4 is sumoylated in vivo, to map the SUMO modification sites of MBD4 and, 
ultimately, to determine the effect that this versatile and dynamic modification has on 
the activity of MBD4 within the cell. 
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Chapter 6 
Discussion 
The ultimate aim of the research presented in this thesis was to characterise the 
activity of the thymine DNA glycosylase MBD4 within the cellular environment. 
Three principal areas of research were investigated; 1. The in vivo substrate 
specificities of MBD4 and TDG. 2. The interaction between M13134 and the 
uncharacterised protein ZSWTM3. and 3. The potential post-translational 
modification of MBD4 by sumoylation. 
The in vivo substrate specificities of MBD4 and TDG were investigated by the in 
vivo Big Blue cli mutation assay (Chapter 3), and M13134 was shown to repair 5meC 
deamination-induced TpG/5rneCpG mismatches in vivo. This was subsequently 
confirmed in an independent study, in which a second line of Mbd4 knockout mice 
was generated, and the frequency and spectrum of mutations in spleen and small 
intestine epithelium was determined using the in vivo Big Blue lacI mutation assay 
(Wong et al., 2002). The two independently generated lines of Mbd4 knockout mice 
were also crossed onto tumour-prone genetic backgrounds, in which one allele of the 
adenomatous polyposis coli (Apc) tumour suppressor gene is inactivated by mutation 
(Millar et al., 2002; Wong et al., 2002). Although Apc mice usually develop 
adenomatous polyps in the small intestine after deletion of the wild type Apc allele, 
tumours can also form when this allele is inactivated by mutation (Luongo et al., 
1994; Smits et al., 1997). In the study by Millar et al. (2002), Mbd4 knockout mice 
were crossed with ApcMh1  mice (the Apc' allele contains a truncation mutation at 
codon 850), and were euthanised upon the development of symptoms of intestinal 
neoplasia. Mbd4 ApcM1  mice had significantly reduced survival relative to 
Mbd4 ApcMI+  mice, and had a two-fold increase in intestinal adenoma burden at 
the time of death. Furthermore, although all of the Mbd4 ApcM  tumours had lost 
the wild type Apc allele by deletion, 38% of the Mbd4 Apc' tumours retained 
both Apc alleles, and several C:G to T:A transition mutations at CpG sites were 
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identified in the Apc allele. Similar results were observed in the study by Wong et 
al. (2002). In this study, Mbd4 knockout mice were crossed with Apc
1638N/+ mice (the 
ApcloisN allele contains a truncation mutation at codon 1638), and were euthanised at 
10 months of age. Mbd4 Apc' 638 mice had significantly more tumours in the 
jejunum and ileum than Mbd4 Apc' 638 mice, and C:G to TA transition 
mutations at CpG sites occurred at a higher frequency in the Apc allele of Mbd4' 
Apc l 63sN mice than in the Apc allele of Iv1bd4 Apc 1638 mice. These studies 
therefore confirm that MBD4 can repair 5meC deammation-induced TpG/5meCpG 
mismatches in an endogenous gene in vivo. It would be very interesting to introduce 
a targeted mutation into the MBD of mouse Mbd4, and to cross these mice onto both 
the Big Blue genetic background and a tumour prone Apc genetic background in 
order to determine whether the MBD of Mbd4 is involved in the repair of 
TpG/5meCpG mismatches in vivo. 
The absence of Tdg results in mouse embryonic lethality between E10.5. and  E11.5, 
therefore the in vivo substrate specificity of Tdg was investigated by the isolation of 
Mbd4 Tdg, Mbd4 Tdg, Mbd4' Tdg and Mbd'f' Tdg mouse 
embryonic cell lines, followed by the determination of the frequency and spectrum of 
mutations in the cell lines by the Big Blue assay. Unfortunately, the presence of a 
high level of mutational noise in the mutational spectra of each of the cell lines 
prevents the formation of any conclusions with regard to the substrate specificity of 
Tdg in vivo. The hypothesis that TDG contributes to the repair of 5meC deamination-
induced T:G mismatches in vivo would ideally be tested by the generation of a 
conditional Tdg mouse knockout, and the determination of the frequency and 
spectrum of mutations in Tdg-deficient tissues. 
The interaction between MBD4 and the uncharacterised protein ZSWIM3 was 
investigated by a series of yeast two-hybrid assays and intracellular localisation 
experiments (Chapter 4), ZSWIM3 interacts with amino acids 440 to 580 of MBD4, 
a highly conserved region of the protein that contains the glycosylase domain. It is 
therefore possible that the interaction between MBD4 and ZSWIM3 could inhibit the 
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DNA glycosylase activity of MBD4 in vivo, and it is hoped that future experiments 
will address this interesting possibility. 
The potential post-translational modification of MBD4 by sumoylation was 
investigated by experiments in which the SUMO-1 and 2 conjugation pathways were 
reconstituted in E. coli, and E3 -SUMO ligases were over-expressed in mammalian 
cells (Chapter 5). These experiments support the hypothesis that MBD4 can be 
sumoylated in vivo, although experimental evidence that confirms that MBD4 is 
sumoylated in the absence of an over-expressed E3 SUMO ligase is still required. 
The interaction between MBD4 and ZSWIM3 is interesting with respect to the 
potential sumoylation of MBD4, as the SWIM domain of MEK kinase- 1 has been 
proposed to have E3 ubiquitin ligase activity (Nishito et al., 2006). Experiments to 
determine whether the SWIM domain of ZSWIM3 can promote the conjugation of 
ubiquitin or SUMO to MBD4 are currently underway. The characterisation of the 
interaction of MBD4 with protein partners such as ZSWIM3, and the post-
translational modification of MBD4, may elucidate a mechanism by which the DNA 
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